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Research Goals 
The main goal of this thesis was to create a framework for the detection of imprinting 
in health and disease, which was later extended to allele-specific expression in 
general. Imprinting is the parent-of-origin, monoallelic expression of genes. For 
autosomal genes, humans inherit a copy from each of their parents, with a paternal 
and a maternal version present in somatic human cells. Both copies, called alleles, 
are usually active and expressed at similar levels. However, for a subset of genes, 
one allele is expressed more than the other, called allele-specific expression. Many 
different types of allele-specific expression exist and imprinting is the remarkable case 
where one allele is (typically) completely silenced depending on its parental origin. 
For imprinted genes, the two parental copies are differentially regulated by 
epigenetics, whereas for most other genes the epigenetic marks present on the DNA 
are the same for both copies. To date, no genome-wide and affordable methodologies 
exist for the identification of imprinted loci. In mice, imprinting is typically detected 
through crossing experiments of inbred strains, which is both impossible and 
unethical in humans. As common alternative, DNA data is combined with RNA data 
to identify genes for which heterozygous individuals differentially express both alleles. 
Yet combining two data types is expensive. Studying single epigenetic marks, 
typically DNA methylation, in the genome is another alternative, however, also other 
epigenetic marks regulate expression, leading to a limited view of imprinting. 
Therefore, the first goal of this thesis was to develop a methodology to identify 
genome-wide imprinting, solely using RNA data. 
Imprinted genes are important for normal development and growth. Their frequent 
deregulation is known to cause a myriad of imprinting disorders. All those diseases 
have imprinting deregulation in common with symptoms associated with deregulated 
growth. Not surprisingly, disruption of imprinting is also frequently found in cancer, 
offering tumours a growth advantage over healthy cells. However, deregulated 
imprinting in cancer has only been studied at single loci and a clear evaluation of its 
role in cancer development and progression is still lacking. The second objective was 
thus to develop a method to obtain a complete overview of imprinting deregulation in 
cancer. 
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As stated in the first paragraph, imprinting is only one example of allele-specific 
expression. Many other types exist and are relevant for (de)regulation of the cell in 
health and disease. Therefore, lastly, we also aimed at extending our developed 
framework to enable detection of other genes with allele-specific expression and their 
deregulation in cancer, such as cis-eQTLs (expression quantitative trait loci) and 
induced allelic imbalance, respectively. cis-eQTLs correspond to those loci for which 
expression is (in part) determined by one or more genetic variant(s) present at the 
same locus, independent of the parental origin or disease status. Induced allelic 
imbalance refers to the genes for which both alleles are expressed to the same extent 
in healthy samples, but not in diseased samples. Consistent induced allelic imbalance 
suggests a central role of the locus in the disease process. The third objective was 
therefore to also enable the RNA-based study of other allele-specific mechanisms in 
health and disease. 
 




In four parts, this thesis elaborates on how the research goals stated in the previous 
section were reached. Part 1 describes the necessary biological and molecular 
background. It is presented in two major sections, starting with the biology of healthy 
tissue, to continue with how the same biological mechanisms are deregulated in 
disease. Basic genetics are shortly explained first, after which the main focus lies on 
epigenetics. The latter is an essential regulator of imprinting and other allele-specific 
expression phenomena, the central scope of this thesis. In the second subsection, 
we particularly focus on their deregulation, both regarding mechanisms and general 
importance. 
In part 2, a concise overview is provided on the use of sequencing technologies to 
study genetics and epigenetics. First, several sequencing techniques are described, 
such as Sanger sequencing and next-generation Illumina sequencing (including RNA 
sequencing). The second subsection of part 2 focusses on how these sequencing 
data can be analysed with regard to the objectives of the research. This is a very 
broad topic and only the methods necessary to comprehend the subsequent analyses 
are detailed. A last subsection sketches the state-of-the-art in the field of allele-
specific expression detection. Existing methods are introduced and their specific 
benefits and shortcomings are discussed. 
The experimental work is carefully described in part 3. Here, it is explained how we 
were able to achieve the research goals. In the first subsection, the developed 
methodology for genome-wide detection of imprinting and its deregulation in cancer, 
the two main goals of this thesis, is described. The methodology was applied on 
healthy breast tissue and breast cancer in a first study. A further improved 
methodology is subsequently outlined in the last subsection of part 3. Moreover, this 
subsection introduces the extended framework to also allow detection of other allele-
specific features, namely cis-eQTLs and induced allelic imbalance, achieving the final 
goal. As case study, the set of methods was used to study allele-specific effects in 
healthy renal tissue as well as clear cell renal cell carcinoma. 
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The final part, part 4, ends the doctoral thesis with a conclusion and discussion and 
also hints at further research possibilities. 
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1  Epigenetics in healthy tissue 
1.1. The human genome and the central dogma of molecular biology 
Humans are diploid organisms, meaning that their genetic information is contained in 
two sets of chromosomes. Each normal somatic cell in the human body contains 23 
pairs of chromosomes, with from each pair one chromosome inherited from the father 
and a very similar copy inherited from the mother. The element of a chromosome that 
contains the genetic information is a deoxyribonucleic acid (DNA) molecule that is 
composed of different genes, which are sequences of nucleotides coding for 
functional molecules in the cell. The genetic information in DNA is encoded as four 
nucleotides, namely adenine (A), thymine (T), cytosine (C) and guanine (G), with 
about 3 billion of those bases in the human genome (per set of chromosomes). The 
main functional units in cells are, however, not DNA, but are sequences of amino 
acids folded in a three-dimensional structure, called proteins. The central dogma, first 
described by Crick, explains how DNA is converted into proteins: DNA makes 
ribonucleic acid (RNA) which makes proteins (Figure 1).1 DNA is either replicated by 
Figure 1 The central dogma of molecular 
biology. DNA is replicated by DNA polymerase 
or is transcribed into RNA by RNA polymerase. 
RNA molecules are afterwards translated into 
functional proteins by ribosomes.2 
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DNA polymerase or it is transcribed into RNA by RNA polymerase. RNA is then 
translated into functional proteins or can have a function by itself (non-coding RNA).2 
1.2. Epigenetics 
All cells carry essentially the same genetic information, yet their physical appearances 
(i.e. phenotypes) may differ vastly. A blood cell, for example, is very different from a 
lung epithelial cell, though both may have exactly the same DNA. This is regulated by 
a set of mechanisms jointly called epigenetics that controls which parts of the DNA 
are (in)active in various cells and tissues.3 Another example of epigenetic regulation 
can be seen in monozygotic twins. They share the same DNA, but their phenotype is 
not identical. Again epigenetics plays an important role in these phenotypic 
differences.4 Waddington was the first to describe epigenetics in 1942 as the “the 
branch of biology which studies the causal interactions between genes and their 
products, which bring the phenotype into being”.5 Epigenetics, literally on top of 
genetics, represents an extra, heritable, layer on DNA that determines if genes are 
switched on or off, without changing the DNA itself. Mostly, chemical modifications of 
DNA and the DNA structure itself control the (in)activation of genes and give cells 
their specific function and phenotype. Three main classes of epigenetic mechanisms 
are known: DNA methylation, histone modifications and non-coding RNA.6 
1.2.1. DNA methylation 
The epigenetic methylation mark in humans is the addition of a methyl-group on the 
fifth carbon of a cytosine, creating 5-methylcytosine (5mC). In bacteria, also adenine 
methylation is observed, but this is far less common in mammals.7 Mostly, methylation 
occurs in a CpG dinucleotide context and is associated with transcriptional gene 
silencing, particularly when present in the gene promoter region. The same holds true 
for repetitive sequences and transposons, which are featured by high densities of 
CpGs. Heavy methylation of, for example, transposons suppresses their expression 
and thus protects the genome from instability due to transposition events.8,9 CpGs in 
gene bodies, on the other hand, are often featured by heavy methylation, but are 
associated with highly expressed genes. Here, methylation correlates with gene 
expression, with more methylation in exons and less in introns. Methylation 
differences between the latter two are also important for the regulation of alternative 
splicing.8,10 
The genome, however, is depleted from CpGs, with a frequency of about 1% (instead 
of an expected frequency of about 4%), due to the more frequent unsuccessful DNA 
repair when a methylated cytosine deaminates into thymine. It has been estimated 
that about 70% of all CpGs spread across the genome are heavily methylated.11,12 
The other, less frequently methylated CpGs are typically present in CpG islands, sites 
with a high frequency of CpGs. As these are generally unmethylated in the germ line, 
the islands are more resistant to mutations of cytosine to thymine throughout 
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evolution. CpG islands are frequently found near start sites of genes, about 70% of 
gene promoters are associated with CpG islands.13 In CpG islands, methylation of the 
CpGs results in repression of the expression. Accordingly unmethylated CpG islands 
are often associated with housekeeping genes, resulting in their active expression.8 
Furthermore, methylation differences between tissues predominantly occur on CpGs 
outside of CpG islands.14. 
One of the main topics of this thesis is imprinting (see 1.3.1), which requires a specific 
form of regulation. It is therefore important to shortly focus on the creation and erasure 
of methylation patterns during development. DNA methylation is indeed not constant, 
but rather shows dynamic variation during development. DNA reprogramming 
happens in two main de- and remethylation events, one during gametogenesis and 
one during early embryogenesis (Figure 2).10 In the former, pluripotent cells have to 
be created that can differentiate to germ cells. Global methylation is therefore erased 
and sex-specific methylation patterns are subsequently created to develop either 
sperm cells or oocytes. In this step, methylation of imprinted genes is established, 
which is different in both germ cells.10,15 After fertilisation, methylation is again 
generally erased in the zygote and the embryonic methylation patterns are formed. 
Here, however, demethylation is not complete as methylation of imprinted genes is 
maintained.15 
As methylation has to be stably transmitted during DNA replication, yet also de novo 
methylation is essential (for example during embryogenesis), several DNA 
methylation mechanisms are present in the cell. The process is catalysed by DNA 
methyltransferases (DNMTs) which transfer a methyl-group from S-adenosyl 
methionine (SAM) to DNA. Three main enzymes exist in humans: DNMT1, DNMT3A 
Figure 2 During gametogenesis, methylation marks are erased in primordial germ cells 
(PGCs) to obtain pluripotent cells. Sex-specific methylation marks are then established in 
sperm cells and oocytes, these include methylation regulating imprinted genes. After 
fertilisation, all DNA methylation is again erased in the zygote during embryogenesis, 
however, methylation at imprinted loci is protected and stably maintained in the embryo. Other 
methylation marks are again established after implantation.10 
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and DNMT3B.16 The first, DNMT1, is the maintenance methyltransferase, which is 
important during mitosis or cell division. It binds to hemimethylated DNA, with one 
methylated DNA strand and one unmethylated strand, and methylates the 
unmethylated one (Figure 3).17 As it is necessary for DNA replication, it is highly 
expressed in proliferating cells.9,10 The two DNMT3s, on the other hand, perform de 
novo methylation and are thus mainly important during gametogenesis (Figure 3).17 
They have a high affinity for unmethylated CpGs.18 DNMT3B will, however, especially 
methylate CpGs in sequences with a high CpG content, while DNMT3A mainly 
methylates CpGs at single loci.8,12 DNMT3A is thus highly expressed in germ cells to 
establish the sex-specific methylation patterns such as imprinting. However, this clear 
division of function between the DNMTs is slightly outdated and their functions 
overlap to a larger extent than originally thought.18 
As stated before, DNA methylation is a dynamic process, with waves of de- and 
remethylation.10 Besides methylation processes, also demethylation mechanisms are 
required in cells. It was long thought that only passive demethylation was possible, 
because DNA methylation is a very stable modification.19,20 Passive demethylation 
occurs during DNA replication in which not all replicated 5mC are methylated leading 
to dilution of methylation (Figure 3).20 However, also an active demethylation pathway 
has been discovered. Here, ten-eleven translocation (TET) enzymes convert a 
methylated cytosine to an unmethylated one (Figure 3).19 In the process also 
Figure 3 Methylation of CpG sites in DNA is established by DNA 
methyltransferases (DNMTs). De novo methylation of unmethylated sites 
is done by DNMT3A and DNMT3B, while maintenance of hemimethylated 
DNA sites to fully methylated CpGs is accomplished by DNMT1. DNA 
demethylation occurs either passively during DNA replication or actively 
by ten-eleven translocations (TET) enzymes.17 
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hydroxymethylation is created, which may not solely act as an intermediate but also 
as a genuine functional epigenetic mark.21 Nevertheless, we do not further elaborate 
on hydroxymethylation given the low relevance for this work. 
1.2.2. Histone modifications 
Since DNA would not fit in the cell without condensation, DNA is packaged together 
as chromatin.22 Histones are small, negatively charged proteins that help DNA 
achieve this chromatin structure. Their negative charge ensures a tight bond to the 
positive DNA molecule. DNA wraps around eight of these histones, called a histone 
octamer, to form nucleosomes, which are tightly packed to build chromatin (Figure 4). 
The main function of histones is packaging of DNA, yet they sustain more 
functionalities in the cell such as regulation of transcription.23 
(a) 
(b) 
Figure 4 (a) Representation of the nucleosome structure. The core histones 
(H2A, H2B, H3 and H4), with visualised tails, form the histone octamer around 
which DNA is wrapped. The linker histone H1 holds the DNA in place.22 (b) 
Overview of the chromatin structure. Depending on the specific histone tail 
modifications, such as acetylation (Ac), Methylation (Me) and Phosphorylation 
(P), the nucleosomes are positioned in an open, accessible chromatin 
structure, called euchromatin (left), or a closed, inaccessible one, called 
heterochromatin (right).34 
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Histone octamers are built from two copies of each of the core histones (H2A, H2B, 
H3 and H4). Different nucleosomes are separated from each other by stretches of 
DNA, called linker DNA. Another histone, H1, binds this linker DNA to ensure that the 
DNA remains correctly wrapped around the octamer (Figure 4(a)).23,24 Histones are 
globular proteins with N-terminal tails that can easily be modified to change the 
chromatin structure and attract diverse proteins, such as transcription factors.25 This 
way, histone modifications are identified as epigenetic marks that can regulate 
expression. Various post-transcriptional modifications (PTMs) occur on the histone 
tails, though it was discovered that also the globular domains can be modified.26 The 
most well-known PTMs are methylation and acetylation, but also phosphorylation, 
ubiquitylation, and sumoylation are often observed. Acetylation of lysine residues in 
the tail neutralises the charge of the histone, making the DNA more accessible as the 
bond becomes less tight. Furthermore, it attracts various transcription activators as 
well as inhibitors.27 While acetylation always happens on lysine residues, methylation 
can occur on distinct amino acids and one, two or three methyl-groups can be added. 
Here, the number of methyl-groups as well as the specific amino acid change the 
effect of the PTM.28 For example, H3 methylated at lysine 9 silences expression and 
is thus found at tightly packed chromatin regions. H3 methylation at the 4th lysine, on 
the other hand, results in gene activation and is enriched in promoter regions.29,30 
Contrasting the earlier idea that PTMs only occur on core histones, also H1 
modifications have been found.31 
Each of the histones is generally modified by several PTMs at various amino acids 
and the combination of all these modifications, called the “histone code”, in fact 
determines the overall transcriptional effect. This is associated with attracting various 
proteins important in, for example, replication and in changing the chromatin state.32 
Here, also cross-talk between DNA methylation and the histone code helps to shape 
gene expression patterns.33 The histone code thereby results in roughly two different 
states of chromatin, euchromatin and heterochromatin, each featured by a specific 
set of PTMs and methylated DNA sites (Figure 4(b)).34 The tightly packed, inactive 
heterochromatin is associated with hypoacetylation (low numbers of acetylated lysine 
residues), mono- and dimethylation and DNA methylation. The open, accessible 
euchromatin, on the other hand, is devoid of DNA methylation and is enriched for 
acetylated and trimethylated lysine residues.32,35 The open or closed state of 
chromatin for eu- or heterochromatin, respectively, as well as the different proteins 
the PTMs attract, determine if the region is expressed or not. 
1.2.3. Non-coding RNA and other mechanisms 
The largest part of our genome is non-coding and is thus not translated over an RNA 
intermediate into functional proteins. Though it was long thought that this part was 
largely non-functional, studies identified non-coding RNA (ncRNA) to be an important 
regulator of transcription and translation. ncRNAs are divided in two classes: short 
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ncRNAs and long ncRNAs (lncRNAs). The former are shorter than 200 nucleotides 
and also consist of several classes, with microRNA (miRNA) and short-interfering 
(siRNA) as the best-known ones.36 siRNA and miRNA regulate expression through 
homology to their target messenger RNA (mRNA): to the complete mRNA or to 
untranslated regions (UTR), respectively. miRNA will repress expression by inhibiting 
translation, while siRNA will degrade the mRNA itself. Other short ncRNAs exist, with 
additional ways of transcription regulation.37 ncRNAs also interfere with other 
epigenetic modifications to regulate expression, they have been linked to 
downregulation of DNA methylation and to histone modifications.38 Furthermore, 
different ncRNAs can attract methyltransferases and other protein complexes, such 
as chromatin-modifying proteins, and are involved in alternative splicing.36 
Recently, also other epigenetics mechanisms have been described, including the 
relevance of nucleosome positioning. As described in section 1.2.2, chromatin is a 
flexible and dynamic state that varies between cells and tissues. Nucleosomes thus 
have to be formed and removed in cells and their position in and on the DNA has an 
important role in gene expression. Several factors affect the positioning of 
nucleosomes, such as DNA sequence, transcription factors, nucleosome remodelers 
and RNA polymerase.39–41 These factors combined lead to specific positioning of 
nucleosomes in, for example, promoters and enhancers, that differs between cells 
and genes. Additionally, they interact with other epigenetic marks to stabilise the 
nucleosome patterns.39 Also other features have been described as epigenetic, such 
as telomere length, as here the length and not the DNA sequence itself is of 
importance.42 As these are not relevant for this thesis, they are not further elaborated 
here. 
1.3. Allele-specific and monoallelic expression 
In section 1.1 it was already described that diploid organisms, such as humans, have 
two pairs of each chromosome. All genes are thus present in two copies, called 
alleles, one inherited from the father and one from the mother. Most of the genes on 
chromosomes are expressed from both alleles at basically equal levels. However, a 
few exceptions exist where one allele is expressed to a higher extent than the other, 
called allele-specific expression (ASE), or where only a single allele is active and the 
other is silenced, called monoallelic expression. The origin of monoallelic expression 
can be parentally determined, which occurs in imprinting, or random, which happens 
in X chromosome inactivation or autosomal random monoallelic expression.43 
1.3.1. Imprinting 
Imprinting is the monoallelic expression of genes depending on their parental origin, 
i.e. either the paternal or the maternal allele is expressed. Imprinting was discovered 
in mice when no viable mice could be obtained from gynogenetic or androgenetic 
embryos (embryos with either two maternal or two paternal chromosomes, 
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respectively). It became clear that both parental chromosomes are necessary for 
normal development. Furthermore, as gynogenetic and androgenetic embryos were 
underdeveloped due to lack of embryonic and extraembryonic tissue, respectively, 
the parental chromosomes can be attributed different roles in embryogenesis.44,45 
About 100 imprinted genes have since been detected in humans.46 As explained in 
section 1.2.1 and Figure 2, imprinting is mainly regulated by DNA methylation and is 
established in the germ cells, called primary imprinting.10 As several imprinted genes 
are only involved in foetal development, many of the imprinting marks are erased, 
overall or in specific tissues, after embryogenesis. Imprinting thus becomes tissue-
specific, with reportedly more imprinting in for example brain tissue.45 Contrarily, 
some genes only become imprinted after embryogenesis, called secondary 
imprinting. 
As described in the previous paragraph, imprinting has an important foetal and 
placental role. For example, one of the first discovered imprinted genes, insulin-like 
growth factor 2 (IGF2), is expressed paternally and promotes growth, especially in 
foetuses. In mice, the Igf2 receptor (Igf2r) is maternally expressed and counteracts 
the growth effect of Igf2, while in humans this is mainly regulated by H19. Indeed, 
biallelic expression of Igf2 or mutations in Igf2r or H19 result in overgrowth and 
inviable embryos.47 In humans, imprinting of IGF2R almost solely occurs in the 
placenta, while IGF2/H19 imprinting is conserved in various tissues.48 In general, the 
growth-promoting or -repressing role of maternally or paternally imprinted genes, 
respectively, can be extended to most imprinted genes, with functions in normal 
growth and development. Indeed, imprinting is also involved in normal functioning of 
the brain.45 The distinct function of paternally and maternally expressed genes might 
explain the evolutionary origin of imprinting. Females want to share their resources 
over all of their offspring, which can be from different fathers, to increase overall 
fitness. Males, on the other hand, can mate with multiple females, aiming for maximal 
fitness of all of their offspring, even if this is disadvantageous for the female. 
Paternally expressed genes thus typically promote growth, while maternally 
expressed genes repress and counteract this growth. This kinship theory of 
imprinting, is the most widely accepted hypothesis explaining the origin of 
imprinting.49 Multiple theories exist, however, and imprinting most likely arose due to 
a combination of those hypotheses.50 The kinship theory, for example, does not 
explain all imprinted genes and does not clarify why most imprinted genes are 
maternally expressed. Two other well-known theories are the maternal coadaptation 
theory and the sexual antagonism theory. The former states that solely expressing 
the maternal allele increases fitness of the offspring and is thus favoured by natural 
selection.51 Fitness of a genotype is indeed also determined by interactions between 
different, genetically similar individuals. Imprinting may thus improve both offspring 
development and maternal provisioning.52 The kinship theory also assumes maternal 
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provisioning and asymmetric relatedness between parental alleles. The sexual 
antagonisms theory, on the other hand, does not require asymmetric relatedness and 
states that some alleles may be differentially favoured by selection in males and 
females53. Imprinting may then provide an evolutionary mechanism to address this.49 
Imprinted genes are generally clustered together and controlled by an imprinted 
control region (ICR), though single imprinted genes are also observed. Many different 
regulation mechanisms of imprinting exist of which two well-known ones will be 
described here: the insulator model and the ncRNA model, with IGF2/H19 and 
KCNQ1/KCNQ1OT1, respectively, as key examples (Figure 5).47,54 
In the insulator model, the ICR, which contains a differentially methylated region 
(DMR), is located between IGF2 and H19. On the maternal strand, the DMR is 
unmethylated and hence a CCCTC binding factor (CTCF) may bind the DMR. CTCF 
here acts as an insulator, preventing the downstream enhancer, shared by IGF2 and 
H19, to activate IGF2. The enhancer instead activates the H19 promoter. The DMR 
is methylated paternally, preventing the insulator to bind it. As the enhancer can now 
access the IGF2 promoter, IGF2 is actively transcribed from the paternal strand 
(Figure 5(a)).54 KCNQ1/KCNQ1OT1 is regulated differently by a ncRNA. The DMR is 
located in the promoter of KCNQ1OT1, an antisense lncRNA. Paternally, the ICR is 
unmethylated and KCNQ1OT1 is hence expressed, which silences the expression of 
neighbouring genes, such as KCNQ1. On the maternal allele, on the other hand, the 
ICR is methylated, preventing activation from KCNQ1OT1 and allowing expression of 
the other genes (Figure 5(b)).55 Here, only DNA methylation and ncRNA are 
described as regulators of imprinting, yet also histone modifications, such as 
acetylation (including H3 lysine 27 acetylation), and chromatin structure play an 
important role.56 For example, paternally IGF2 is located in an open chromatin region 
and H19 in a more tightly packed region, while on the maternal allele this is 
reversed.57 In 2006, studies discovered that an imprinted gene network (IGN), in 
which imprinted genes are co-regulated, exists in mice. The known imprinted genes 
Zac1 (with its human ortholog PLAGL1) and H19 were detected as crucial regulators 
of this network.58,59 Subsequently, the same IGN was discovered to be deregulated 
in prostate cancer, hinting at the presence of an IGN in human tissue as well.60 
1.3.2. X chromosome inactivation 
Females inherit two X chromosomes, while males inherit an X and a Y chromosome. 
To compensate for the dosage effect of two X chromosomes in females, one X 
chromosome is silenced, called X chromosome inactivation (XCI). The inactivation 
does not depend on parental origin, as in imprinting, but rather occurs randomly. XCI 
takes place in the embryo early in development and hence all subsequent cells will 
stably silence the same X chromosome.43,61 An important regulator of XCI is the 
lncRNA X inactive-specific transcript (XIST), located in the X chromosome 
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inactivation centre (XIC). XIST is only expressed from the inactive X chromosome 
and silences that specific X chromosome by coating it. Afterwards, many epigenetics 
modifications further ensure stable silencing. The inactive X chromosome is, for 
example, featured by low levels of acetylation and high levels of histone as well as 
DNA methylation, resulting in a heterochromatin state.61 The antisense transcript of 
XIST (TSIX) is only expressed from the active chromosome and represses 
transcription of XIST, which ensures expression of genes on the corresponding, 
active X chromosome.62 
Figure 5 Examples of two regulation mechanisms of imprinting: (a) the 
insulator model and (b) the non-coding RNA (ncRNA) model. (a) On 
the maternal strand, a CCCTC binding factor (CTCF) binds to the 
unmethylated imprinting control region (ICR), inhibiting the enhancer 
to activate Igf2 and activating H19 instead. The methylated paternal 
ICR, on the hand, prevents CTCF from binding. Here, the enhancer 
can thus activate Igf2. (b) Paternally, the ICR, which is located in 
promoter of Kcnq1ot1, is unmethylated and hence transcribed. 
Kcnq1ot1 is an antisense ncRNA that after expression, silences 
neighbouring genes. The ICR is methylated on the maternal strand, 
inhibiting Kcnq1ot1 expression. As Kcnq1ot1 is not expressed it 
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1.3.3. Autosomal random monoallelic expression 
More recently, it was discovered that also some autosomal genes are monoallelically 
expressed. Contrasting imprinting there is no parental influence, whereas compared 
to XCI, the monoallelic pattern is not always conserved between cells. Furthermore, 
XCI silences a whole chromosome, while autosomal random monoallelically 
expressed genes are spread over various chromosomes.63 As monoallelic regulation 
is largely established in the embryo, not all cells in an organism show the same 
monoallelic expression pattern: some cells will express the maternal allele and other 
cells the paternal one. The first identified autosomal genes were immunoglobulins 
and T-cell receptors and later on also odorant receptor genes were discovered to be 
regulated by random monoallelic expression.43 Recent studies discovered that up to 
5% of the autosomal genes show random monoallelic expression.64,65 Again, 
regulation of these genes was linked to epigenetic marks, such as histone 
modifications and ncRNAs.66 
1.3.4. cis-eQTL 
In the genome, the expression levels of some genes are influenced by genetic 
variation, called expression quantitative trait loci (eQTL). Variation, typically single 
nucleotide polymorphisms (SNPs), is located in regulatory regions, where it may 
determine the amount of mRNA and protein produced.67 eQTLs can regulate genes 
in close proximity to the variant itself, called cis-eQTLs, or genes located further away 
(even on different chromosomes), called trans-eQTLs, for example when the genetic 
variant affects transcription factor expression and/or function. Depending on the 
eQTL, one allele will thus be expressed to a higher extent than the other, i.e. ASE will 
be observed.68 Contrary to imprinting, ASE is determined by the variant itself and not 
by the parental origin. The specific allele will determine the expression level 
independent of its paternal or maternal origin. For an A/T SNP, for example, A may 
lead to higher expression of a gene on both parental chromosomes, while T results 
in lower gene expression.69 
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2  Epigenetics in human diseases 
2.1. Epigenetic deregulation in cancer 
Since the discovery of epigenetics, the major role of epigenetic deregulation in 
cancer, aside from genetic mutations, has become clear. Epigenetic changes have 
been discovered in all types of cancer. Generally, however, the disruption of both 
normal genetics and epigenetics is required to lead to the phenotype of cancer cells. 
Genetic mutations, for example, often occur in genes that regulate epigenetic 
mechanism, thus disturbing normal epigenetic patterns. The chromatin state, in turn, 
affects mutation frequencies with less mutations in open chromatin.70 
General hypomethylation of the genome is observed in most cancer cells. While 70% 
of CpGs are methylated in normal cells, only about 50% show methylation in cancer 
cells. Hypomethylation activates normally silenced repeats and transposon, resulting 
in instability of the genome.71 Furthermore, a special set of genes, called oncogenes, 
are featured by reduced methylation as well. Oncogenes promote cell growth and 
proliferation and also prevent cells from going into apoptosis. Increased expression 
of these oncogenes due to changed epigenetics thus results in cells that grow faster 
and have a higher survival rate.72 However, also increased (local) de novo 
methylation is observed, for example of gene promoters.73 Here, the higher 
methylation levels often result in silencing of genes and disruption of the 
corresponding pathways. Yet gene promoters can also be silenced by histone 
modifications, such as deacetylation, after which chromatin remodelers attract DNA 
methylation to ensure stable silencing of the gene, i.e. promoter hypermethylation is 
not necessarily the underlying cause of gene silencing. Additionally, it should be noted 
that not all CpGs are equally important and methylation of only some CpGs rather 
than the whole promoter region is necessary for gene silencing.74 This may lead to 
gradual DNA methylation, where not all CpGs are simultaneously methylated.75 
Finally, the complexity is further emphasised by the observation that for some genes, 
such as TERT, promoter methylation was found necessary for gene activation.76 
Independent of the exact mechanism, typically tumour suppressor genes (TSG) are 
epigenetically silenced in cancer. They regulate cell growth, DNA repair and cell 
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death, all important for a cell’s normal functioning. By epigenetic silencing of TSGs, 
cells will be more prone to cancer progression.77 In colorectal cancer, a CpG island 
methylator phenotype (CIMP) was found for a subset of samples.78 In CIMP cancers, 
a specific set of CpG islands, which are normally unmethylated, become 
hypermethylated and the corresponding TSGs are inactivated. After its discovery in 
colorectal cancer, it was also found in a broad range of cancer, such as gliomas and 
breast cancer.79 The specific set of deregulated CpG islands and the degree of 
hypermethylation differ per cancer type, making it an interesting phenotype for cancer 
classification.80 However, it is important to note that the presence of CIMP depends 
on the definition used to describe CIMP and that a consensus definition is still lacking. 
To date, it remains unsure whether CIMP is cancer-specific or universal. Distinction 
between cancer types and even cancer subtypes might be necessary in further 
research.79 
In addition to deregulation of DNA methylation, also aberrant histone modifications 
are key regulators in cancer development. A global loss of acetylated lysine residues 
is often observed, which concurs with repression of gene expression. This is 
accompanied by loss of lysine trimethylation and gain of monomethylation, two other 
silencing marks. The combination of these PTMs leads to repression of TSGs.81 
These are only a few examples of PTM deregulation, however, a myriad of changes 
has already been described. Also specific PTM enzymes are often mutated, 
epigenetically silenced or overexpressed, inhibiting the preservation of normal 
PTMs.72 The altered combination of PTMs, DNA methylation and mutations in cancer 
also results in expression of distinct ncRNAs. Some miRNAs associated with 
apoptosis have been found to be downregulated, for example, while oncogenic 
miRNAs and lncRNAs become upregulated.37 
2.2. Imprinting disorders 
The main functions of imprinted genes are associated with development and growth. 
It is thus not surprising that disruption of imprinting causes a variety of diseases. The 
Prader-Willi syndrome (PWS), Angelman syndrome (AS), Silver-Russell syndrome 
(SRS) and Beckwith-Wiedemann syndrome (BWS) are only a few examples of 
imprinting disorders.82 Chromosomal deletions, uniparental disomy (inheritance of 
(part of) a chromosome from only one parent), imprinting defects and genetic 
mutations are involved in the establishment of imprinting disorders.83 
PWS and AS both originate from a disrupted expression of imprinted genes on 
chromosome 15. Although both syndromes are caused by (epi)genetic changes in 
the same region, their specific phenotypes are very different.84 For PWS and AS, 
deletions of the paternally and maternally expressed imprinted genes, respectively, 
determine the corresponding clinical symptoms. The main cause of PWS is a deletion 
or maternal uniparental disomy of a region containing a maternally imprinted cluster, 
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including SNORD116.85 AS, on the other hand, is mostly caused by mutations of the 
maternally expressed UBE3A. PWS patients are characterised by an insatiable 
appetite, resulting in obesity, and typical facial features, as well as many other 
complications. AS patients are mentally retarded (including speech problems) and 
laugh excessively.86 
In BWS, genetic and epigenetic changes occur on chromosome 11 where the 
IGF2/H19 and KCNQ1 imprinted clusters are located. Alterations to these clusters 
result in biallelic expression of paternally expressed IGF2, a growth factor, or reduced 
expression of the paternally imprinted CDKN1C, an inhibitor of cell growth.87 
Overgrowth is thus stimulated and is also the main symptom of BWS. Abnormal 
growth also causes other symptoms such as speech and feeding difficulties.88 
Another growth disorder is SRS, where, contrasting BWS, growth restriction is the 
main cause. Disruption of imprinted genes on chromosome 7 and 11 are often found 
in SRS. Contrasting BWS, for chromosome 11, IGF2 expression is reduced and H19 
is overexpressed. In other SRS patients, modification of GRB10, a growth factor, on 
chromosome 7 is believed to be the key disruption involved.89 
2.3. Loss of imprinting in cancer 
The growth regulating and developmental functions of imprinted genes combined with 
a complex regulation pattern make them weak spots for cancer development. Indeed, 
deregulated imprinting is observed in various cancers, as imbalanced dosage effects 
of imprinted genes offer a great advantage to tumour progression by activation of 
growth-promoting genes and silencing of growth-repressing ones.90 It was even found 
that loss of imprinting (LOI) is one of the first occurring alterations in cancer.91 LOI 
either results in re-expression of the silenced allele, leading to biallelic expression, or 
silencing of the active allele. To enable easier distinction between both types, only 
the former is called LOI later in this thesis, whereas general deregulation is termed 
differential imprinting (DI). 
As for imprinting in general, IGF2 is the best studied example of LOI. Its upregulation 
has, for example, been detected in renal and colon cancer, resulting in cell 
overproliferation.91 This appears to be the obvious route for aberrant IGF2 expression, 
though the opposite, where IGF2 is downregulated, has been found as well.92,93 
Various mechanisms that induce IGF2 LOI have already been discovered. For 
example, IGF2 expression is regulated by various promoters and a switch of promoter 
usage in specific tissues can lead to LOI. The DMR regulating IGF2 and H19 
expression can be epigenetically changed as well. Both paternal hypermethylation, 
resulting in H19 overexpression, and maternal hypomethylation will cause LOI.94 
Aside from tumour-specific LOI of IGF2, it was found in surrounding tissue of 
colorectal and Wilms’ tumours. This might indicate that deregulation of imprinting 
occurs before tumours develop, though causality remains uncertain. These findings 
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show that aberrant imprinting of IGF2 could be an interesting diagnostic as well as 
prognostic target for several cancer types.91,95 
Deregulation of other imprinted genes has since been detected in many other types 
of cancer. Disrupted methylation at the CDKN1C promoter occurs in gastric, 
pancreatic and breast cancer, while deregulation of an imprinted gene in the same 
cluster, PHLDA2, was found in Wilms’ tumour an osteosarcoma.94,96 A recent study 
discovered differential expression (DE) of many imprinted genes in a wide variety of 
cancer types, though here mainly downregulation, also for IGF2, was observed.97 This 
downregulation was, for example, also correlated with MEG3 LOI in neuroblastoma.94 
Deregulation of imprinting is thus not as straightforward as previously thought and 
more studies are necessary to understand the exact role of imprinting deregulation in 
cancer. The various studies that already discovered disrupted imprinting expression, 
however, show that it is indeed an interesting field to study and that not only LOI of 
IGF2 could be used as prognostic or diagnostic marker. 
2.4. Induced allelic imbalance 
The examples introduced higher illustrate that a multitude of genetic and epigenetic 
effects may lead to expression deregulation of specific loci, which in their turn may be 
causally involved in disease initiation and progression. Such loci will typically be 
consistently deregulated in the disease under study, but will also demonstrate 
induced allele-specific expression, given that the different aberrations will affect both 
alleles differently (in cis).93 This contrasts the downstream impact, where both alleles 
will show similar increase or decrease of expression, typically due to trans effects (for 
example, due to feedback mechanisms or disturbed transcription factors). Allelic 
imbalance leads to abnormal ASE and can be caused by various alterations, such as 
copy number alterations (CNAs) or loss of heterozygosity (LOH), promoter mutations 
and aberrant methylation. Here we term this type of aberrant ASE induced allelic 
imbalance (iAI). If, for example, one allele of a tumour suppressor gene is mutated 
and the second allele is lost, the TSG loses its function and cannot protect the cell 
against tumourigenesis.98 In LOH, one parental copy of a gene is completely lost, 
which leads to expression of a single allele. LOH was already observed in colorectal 
cancers and triple negative breast cancer.99,100 In ovarian cancer, for example, allelic 
imbalance at chromosome 6 and 10 has been found.101,102 On chromosome 10, a 
TSG, namely PTEN, is located which is involved in cancer development. Allelic 
imbalance of PTEN was discovered in various cancers, such as breast and prostate 
cancer, where it is often lost and mutated.102 In prostate cancer, also imbalance of 
chromosome 8 has shown importance, where loss of the short arm was associated 
with higher tumour grade.103 These are only a few examples of iAI in cancer, yet 
numerous aberrations have already been described. Furthermore, other studies 
found methylation differences in cancer compared to healthy tissue causing iAI.100 
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3  Sequencing the (epi)genome 
3.1. Sanger sequencing 
Much of our knowledge about DNA and its regulation in the cell has been obtained 
after the invention of DNA sequencing techniques. Sequencing is the process in 
which the order of nucleotides (A, T, C, G) in a DNA sequence is determined. The 
first commercially viable method, called Sanger sequencing after its inventor Frederik 
Sanger, was developed in 1977 and is now also known as first-generation 
sequencing.104 The development of sequencing led to the foundation of the Human 
Genome project in 1990 by which the first complete, human genome was sequenced 
in 2001.105,106 
The Sanger sequencing method, also called the chain-terminating method, involves 
inhibitors of the DNA elongation process, namely dideoxynucleotides (ddNTPs). 
ddNTPs lack the 3'-hydroxyl group necessary for normal elongation of the DNA strand 
by DNA polymerase. If, instead of a normal nucleotide, a ddNTP is incorporated in a 
developing DNA strand, elongation will be terminated at that position (Figure 6).107 
When normal nucleotides as well as ddNTPs are added to a reaction, ddNTPs are 
integrated only at random positions and DNA strands of various lengths are obtained. 
Four reactions are performed simultaneously with a specific ddNTP in each reaction. 
Figure 6 Overview of Sanger sequencing. In a repetitive cycle, nucleotides are added to the 
sequencing reaction together with labelled dideoxynucleotides (ddNTPs) and polymerase. 
ddNTPs stop elongation when incorporated and DNA strands of different lengths are obtained. 
These strands can be separated on size. The fluorescent signals correspond to the 
incorporated nucleotides and these can be measured to determine the sequence.107 
3 Sequencing the (epi)genome 22 
 
Afterwards, the resulting DNA strands from all four reactions can be separated on 
size and the DNA sequence can be determined (Figure 6).104 Improvements with, for 
example, fluorescently or radioactively labelled ddNTPs, were developed later to 
reduce the number of reactions to only one.108 
3.2. Next-generation sequencing 
The need for faster and cheaper sequencing led to the beginning of next-generation 
sequencing (NGS) in 2005 with the invention of the 454 pyrosequencing method. 
NGS, also called massive parallel sequencing, sequences DNA in high-throughput by 
performing thousands of reactions simultaneously.109 Many different NGS techniques 
exist, though they are typically based on the same steps: library preparation, 
sequencing and imaging.110 The reduced cost and higher throughput compared to 
Sanger sequencing compensate for the shorter read-lengths and higher error rates 
obtained with NGS.111 
One of the most widely used NGS methods to date is Illumina sequencing (Figure 7). 
It is based on a sequencing-by-synthesis principle and involves four main steps: 
library preparation, amplification, sequencing and data analysis. In the first step, DNA 
is fragmented into smaller sequences and adapters are ligated. The latter are 
necessary for the subsequent amplification step. Amplification is performed by bridge 
polymerase chain reaction (PCR, Figure 7(a)). Forward and reverse PCR primers, 
complementary to the adapter sequences, are attached to the surface of a flow cell 
to which the DNA fragments can bind and form a complementary DNA strand. After 
denaturation of the DNA and removal of the original DNA fragments, immobilised 
copies of the fragments are present on the surface of the flow cell. The free end of 
DNA fragments can form a bridge by hybridising to free primers attached on the flow 
cell, which can be used to initiate DNA elongation. This process, called bridge PCR, 
can be repeated until dense clusters of DNA copies immobilised to the cell surface 
are formed. These clusters can subsequently be sequenced simultaneously by 
sequencing-by-synthesis, also known as cyclic reversible termination sequencing 
(Figure 7(b)). Here, fluorescently-labelled, reversible terminators together with DNA 
polymerase are added, imaged and cleaved in a repeated cycle. In each cycle, one 
nucleotide is incorporated by the polymerase and the corresponding fluorescent label 
is imaged. Again, the 3’-hydroxyl is modified to ensure single-base elongation of the 
DNA, though here the modification is cleavable. After incorporation of a single 
nucleotide, the other nucleotides are washed away, the nucleotide is imaged, the 
modification is cleaved and the process can be repeated. This happens for all clusters 
simultaneously, resulting in the parallel sequencing of all DNA fragments. Visualising 
clusters containing about 1,000 DNA copies each results in an increased signal for 
each DNA fragment during sequencing and hence less sequencing errors.107,112–114 
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Other NGS techniques, such as 454 pyrosequencing are based on emulsion PCR. 
Here, the DNA is amplified on beads which are afterwards immobilised on a 
polyacrylamide gel. Sequencing is done by pyrosequencing in which a light is emitted 
when a nucleotide is incorporated. Ion Torrent’s semiconductor sequencing also uses 
sequencing-by-synthesis, here however the hydrogen ion released when a nucleotide 
is incorporated in a DNA strand is measured. The main advantage of this 
methodology is that no time-consuming imaging is required, yielding sequences in a 
far faster manner (but at increased cost). More techniques exist, all with their own 
advantages and disadvantages.109,114 
3.3. Third-generation sequencing 
The fast development and improvement of sequencing techniques resulted in third-
generation sequencing (TGS). The most important change is the elimination of the 
amplification step, hence enabling sequencing of single molecules.115 Furthermore, 
sequencing happens in real-time and no cyclic addition, imaging and washing of 
chemically modified nucleotides occurs. This leads to easier sample preparation, 
faster sequencing and longer read-lengths. The major downsides of third-generation 
sequencing to date are high error rates, though most techniques are still undergoing 
improvements, and the higher cost compared to NGS. The two best-known 
techniques that will be described here are single molecule real-time (SMRT) 
sequencing developed by Pacific Bioscience and nanopore sequencing by Oxford 
Nanopore.116 
SMRT sequencing uses DNA polymerase attached to zero-mode waveguides (ZMW), 
small nanoholes that can bind one single polymerase.116 As the DNA polymerase 
(a) (b) 
Figure 7 Two steps from the Illumina sequencing process: (a) cluster generation and (b) 
sequencing-by-synthesis. Adapted from 110 
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incorporates fluorescently-labelled nucleotides, the emission signal can be imaged in 
real-time. Cleavage of the label is done by normal polymerase activity. A SMRT-cell 
contains about 150,000 ZMWs. In SMRT sequencing, the DNA polymerase actually 
functions as the sequencer and the process is quite fast, but high error rates are 
obtained.117 Oxford Nanopore developed a methodology that uses nanopores for 
DNA sequencing and can even be incorporated in a small, portable device. An ionic 
gradient is generated in nanopores, small holes in a phospholipid bilayer. Negatively 
charged DNA is forced through a nanopore and for each nucleotide that passes the 
pore, the current changes in a nucleotide-dependent manner and can be measured 
to sequence the DNA strand.118 The process is very fast and cheap, mainly because 
unlabelled DNA can be used.119 A downside of nanopore sequencing is that multiple 
nucleotides pass the nanopore and are measured at the same time. Hence also here 
high sequencing error rates are obtained.115 Nevertheless, both SMRT and Nanopore 
sequencing have developed strategies to reduce error rates by repeated sequencing 
of the same molecule, though this reduces the throughput (and therefore increases 
the cost). 
3.4. RNA sequencing 
The complete set of RNA transcripts is called the transcriptome. The study of which 
chunks of DNA are (differentially) expressed in specific cells or samples, termed 
transcriptomics, was greatly facilitated by the development of RNA sequencing (RNA-
seq).120 The same techniques as for NGS can be applied, however an extra 
conversion step is necessary where RNA is converted into complementary DNA 
(cDNA) by a reverse transcriptase. The first step in RNA-seq is RNA extraction. 
Afterwards, only mRNA is retained by polyadenylation enrichment or ribosomal RNA 
is depleted for ncRNA analyses. Reverse transcriptase then makes cDNA from total 
or polyadenylated RNA and adaptors are added. The NGS methods outlined higher 
can subsequently be used for sequencing of these cDNA libraries.120,121 Like all NGS 
techniques, RNA-seq has a single-base resolution and it can therefore be used to 
study gene boundaries, and thus alternative splicing, to detect novel genes and to 
map transcription start sites. However, as RNA-seq is a quantitative methodology and 
gene expression levels are obtained, its main application is differential expression 
analyses.121 By altering the extraction and enrichment steps, RNA-seq can be used 
to study diverse types of RNA. Through RNA-seq, many insights into (epi)genomic 
regulation were obtained, but several disadvantages still limit a complete overview. 
Contaminating DNA, for example, is frequently present and also erroneous cDNAs 
are made due to template switching. Different transcripts of the same gene are often 
hard to discriminate given the short NGS read length. Furthermore, reverse 
transcriptase is often rather inefficient.122 The development of direct RNA sequencing 
(dRNA-seq) using third-generation sequencing methods, such as Oxford Nanopore 
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(see section 3.3), circumvents prior cDNA synthesis and its downsides. Here, 
however, throughput is lower and sequencing error rates are higher.123 
3.5. Identifying epigenetic modifications 
NGS techniques and RNA-seq increased our understanding of the genome and gene 
expression, respectively, but precise knowledge on epigenetic regulation was still 
missing. Although RNA-seq gives insights on expression and regulation of ncRNAs, 
no information on DNA methylation and chromatin modifications can be acquired. 
Several techniques, based on NGS, were hence developed for epigenetic analyses. 
The main methods for detection of DNA methylation already described are based on 
bisulphite conversion (Figure 8) and on precipitation of 5mC (Figure 9). Also detection 
of DNA methylation with methylation-specific restriction enzymes is possible, but this 
will not be elaborated here.124 Detection of PTMs, on the other hand, is done by 
chromatin immunoprecipitation with specific PTM targeting antibodies, followed by 
sequencing of captured DNA.125 
In bisulphite-based methods, such as whole genome bisulphite sequencing (WGBS), 
DNA is treated with sodium bisulphite in a first step. This way, unmethylated cytosines 
are converted into uracil by deamination, while methylated ones are protected from 
conversion and remain unaltered. Upon sequencing, an uracil, thus corresponding to 
an unmethylated cytosine, will be recognised as thymine and a methylated cytosine 
remains detected as a cytosine (Figure 8).126 WGBS has a single-base resolution and 
gives an accurate overview of genome-wide methylation.127 However, it is an 
Figure 8 In bisulphite sequencing, DNA is treated with 
sodium bisulphite. Methylated cytosines are protected 
from bisulphite, but unmethylated ones are deaminated 
to uracil. When afterwards the DNA is sequenced, 5mC 
is recognised as a cytosine, while an unmethylated one 
will be recognised as a thymine.126 
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expensive technique and the bisulphite treatment itself is difficult to optimise and 
compromises the subsequent analysis of the sequencing data due to DNA 
fragmentation and reduced sequence complexity (as cytosines turn de facto into 
thymines).124 To decrease the cost of bisulphite sequencing, reduced representation 
bisulphite sequencing (RRBS) was developed. The sequenced DNA is here enriched 
for CpGs by using a methylation-independent restriction enzyme that recognises 
CpGs. Restriction enzymes cut CpGs and specific fragment sizes are selected before 
the DNA is treated with bisulphite and sequenced. A reproducible (but less 
comprehensive) genome-scale single-base overview is obtained, yet the costs are 
strongly reduced.128 
Other techniques developed to reduce cost and downsides of bisulphite sequencing 
are based on enrichment of methylated DNA. Either a protein containing methyl-
binding domains (MBD) or antibodies targeting 5mC are used for enrichment (Figure 
9).129 In a first step, DNA is fragmented and methylated fragments are captured. The 
unbound fragments are subsequently washed away and the captured ones are 
sequenced. Enrichment with MBD proteins is called MBD-seq, while 
immunoprecipitation with antibodies is called methylated DNA immunoprecipitation 
sequencing (MeDIP-seq) or DIP-seq.130 The major advantage of these methods is 
that they are considerably cheaper than other methods, but are still genome-wide. 
Figure 9 Enrichment-based sequencing of epigenetic modifications. (a,b,c) DNA is 
fragmented and specific proteins or antibodies are added to enrich for specific modifications, 
such as DNA methylation. (d) Unbound DNA is washed away and the DNA bound by the 
antibody or protein is retained. (e,f) A next-generation sequencing method is used to 
sequence the DNA.129 
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Due to the enrichment step, however, these methods are less quantitative as no 
absolute methylation levels are obtained, and results are no longer at a nucleotide 
resolution. Also for (Me)DIP-seq, affinity of the antibodies is a major drawback.131 
The Infinium HumanMethylation450k BeadChip, developed by Illumina, is an 
alternative method for the detection of DNA methylation based on bisulphite 
conversion, yet without sequencing (Figure 10). The bisulphite converted DNA is 
hybridised against beads on a microarray containing over 450,000 CpG sites.132 Two 
different assays are used on the 450k BeadChip, namely Infinium I and Infinium II. In 
the former, hybridisation is done against two types of beads: one with a cytosine 
matching a methylated CpG and another with a thymine corresponding to an 
unmethylated one, which can be measured in the same colour channel. Only if the 
analysed DNA perfectly matches the bead, DNA extension occurs and a fluorescent 
signal will be observed (Figure 10(a)). In the Infinium II assay, on the other hand, a 
single bead is used with degenerate probes and determining the methylation status 
depends on the specific fluorescent signal, requiring two colour measurements 
(Figure 10(b)). The older 27k BeadChip only uses Infinium I assays, while on the 450k 
BeadChip both are combined.132,133 Both assays are also used on the newer 
HumanMethylationEPIC BeadChip, which contains 850,000 CpGs. Aside from beads 
targeting the same 450k BeadChip sites (only low quality probes were removed), also 
many CpG sites located in enhancer regions and CpGs outside of CpG islands are 
being queried.134 
As for detection of DNA methylation, PTMs can be identified with antibodies, called 
chromatin immunoprecipitation sequencing (ChIP-seq, Figure 9). Chromatin 
fragments with a specific modification are isolated with an antibody and afterwards 
sequenced using a NGS technique. Depending on the specific antibody used, single 
PTMs can be detected. Again, specificity of the antibody is a tricky aspect of ChIP-
seq and also the chromatin precipitation step is challenging.124,135 
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Figure 10 Two assays used on the Infinium HumanMethylation 
BeadChip, Infinium I and II. (a) In the Infinium I assays bisulphite 
converted DNA is hybridised against two types of probes, an 
unmethylated (U) and a methylated (M) one. Only if the DNA 
perfectly matches the probe, single-base extension and emission 
of a fluorescent signal occurs. (b) The Infinium II contains only one 
type of probe for methylated as well as unmethylated DNA. The 
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4  Analysis of sequencing data 
The output of sequencing technologies depends on the technique used and 
subsequent analyses largely rely on the biological question at hand. Improvement of 
existing sequencing techniques is ongoing to date and new methods are under 
development. Furthermore, as the cost of sequencing drastically decreased over the 
last years, the amount of data to be analysed massively increased. The bottleneck 
hence does not lie in the sequencing itself anymore, but rather in the analysis of 
thereby generated sequencing data. Many computational methods for various 
analyses are being developed and here only those of importance for the further 
research in this thesis will be discussed. 
4.1. Base calling and genome alignment 
In most NGS methods, the DNA is fragmented into small pieces which are 
sequenced. Before genomic analyses are possible, the required information has to 
be reconstructed from these pieces. The first step in piecing together the original 
(c)DNA fragments is transforming the raw sequencing data into base calls. NGS 
results in specific images of emitted signals depending on the used technique, such 
as fluorescent images for Illumina sequencing.136 These signals are converted into 
base calls, i.e. the actual nucleotide, for which mainly algorithms associated with the 
commercial sequencing platform itself are applied, though improved base calling 
algorithms have been described as well.136–138 A quality score is also assigned to the 
base calls, with the Phred quality score as the golden standard. Phred is calculated 
as −10 log10(𝑒𝑟𝑟𝑜𝑟) and defines the probability of an erroneous base call. Base 
calling mostly has FASTQ files as output listing the identified nucleotides and their 
corresponding Phred scores.139 The quality of the base call often depends on their 
position in the reads, with lower quality calls at the end of a read, especially for long 
reads. Therefore, trimming of the reads is recommended to only retain good-quality 
nucleotides.140 In the same step, also artefacts associated with the experimental 
procedures (such as remaining adapter sequences) can be deleted from the 
sequence reads. 
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After base calling, many short sequence reads are obtained, their length depending 
on the used NGS technique. The reads have to be either aligned to a reference 
genome, called mapping, or assembled de novo if no reference genome is available 
(Figure 11).141 Many different alignment algorithms exist and the decision of which 
one to apply depends on the trade-off between sensitivity and speed.140 Generally, a 
heuristic approach is used first to limit the possible places where reads most likely 
map, after which a more accurate but slower algorithm is used.142 The earliest 
mapping algorithms, such as MAQ, were developed for alignment of short reads with 
hash tables. As many repetitive sequences occur in the genome, mapping is a difficult 
task and some reads can map to multiple sites. MAQ was developed to take the Phred 
quality score into account and to report a quality score of the mapped read.143 
Algorithms developed later, such as BWA and BOWTIE, apply a Burrow-Wheeler 
transformation on the genome to efficiently map the reads in a faster but less sensitive 
way.140,144,145 Insertions and deletions in the genome and sequencing errors make 
correct mapping of the reads even harder. Therefore, alignment algorithms have to 
allow mismatches between the reads and the reference genome. Each algorithm has 
its own way of handling those mismatches and the right algorithm depends on read 
length as well as the used sequencing platform. RNA-seq data, for example, should 
ideally be aligned to a reference transcriptome, though this is not often available for 
non-model species. Reference genomes are thus used, hindering simple alignment 
due to alternative splicing. RNA-seq mapping algorithms, such as STAR and Tophat, 
allow large gaps, which represent the introns.146–148 The standard output of a mapping 
method is a Sequence Alignment Map (SAM) file or its binary equivalent, a Binary 
Alignment Map (BAM) file.149 Other methods, such as Kallisto and Salmon, are used 
to quantify abundance of specific transcripts. They perform pseudo-alignment or 
lightweight mapping, respectively, to reduce computational load. Instead of 
determining the exact sequence of the transcript, they search for and quantify the 
transcript from which the reads originate.150,151 
Figure 11 Overview of sequence read alignment. Short reads are either aligned to a reference 
genome or assembled de novo. Adapted from 141 
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4.2. SNP and genotype calling 
Upon pre-processing, several (epi)genomic analyses can be performed. Genome 
browsers exist, such as the UCSC genome browser, to visualise obtained information 
across the entire genome.152 Also variation in the genome, such as SNPs or CNVs, 
can then be studied. SNP and genotype calling is the process of detecting those 
polymorphisms in the genome and defining their genotype in an individual. A SNP is 
present when a nucleotide differs from the reference genome and the corresponding 
genotype can be determined, either with cut-offs or with a more elaborate probabilistic 
approach.138 The former first filters nucleotides on quality of the base call, typically on 
the Phred quality score. For good quality bases, alleles are then counted and 
genotypes are established based on predefined cut-offs. However, when sequencing 
depth is low, correct genotype calling is challenging. The probabilistic models, on the 
other hand, can also accurately call genotypes for lower sequencing depth. Here, 
sequencing depth as well as the quality scores can be taken into account. For each 
position, the probability of observing a specific genotype with those particular allelic 
counts is calculated. The most likely genotype is defined as the one with the highest 
posterior probability (and the position is called a SNP if this genotype differs from the 
reference).153 Bayes’ formula can be used to calculate genotype probabilities: 
𝑃(𝐺|𝑋) =  (𝑃(𝑋|𝐺)𝑃(𝐺)) 𝑃(𝑋)⁄  with 𝑃(𝑋) and 𝑃(𝐺) the prior probabilities of the data 
and the specific genotype, respectively, and 𝑃(𝑋|𝐺) the genotype likelihood given that 
genotype G. Prior genotype probabilities can be obtained from SNP databases, such 
as dbSNP, or the Hardy-Weinberg theorem can be used to infer priors by means of 
empirical Bayes when analysing many samples simultaneously.154,155 Interestingly, 
quality base call scores can be recalibrated and taken into account when calculating 
the genotype likelihoods.138 In more recent methods, error and genotypes estimates 
are obtained from the population itself, quality scores are ignored and prior estimates 
are no longer required. Important examples are Genome Analysis Toolkit (GATK), 
SeqEM and Samtools.149,156,157 SeqEM uses expectation-maximisation (EM) to infer 
genotypes from the whole population, optionally using HWE.156 GATK first performs 
base recalibration, upon which Bayes’ approach is used to perform the calculation of 
priors. The most recent versions of Samtools similarly rely on Bayes’ theorem.149,157 
4.3. Quantitative omics analysis 
Frequently, RNA-seq data are used for differential expression analysis, in which the 
expression level of genes is compared between different conditions or samples. The 
mapped reads listed in BAM files have to be converted into quantitative estimates per 
gene, or even per transcript, in order to perform DE. Whereas probabilistic RNA-seq 
aligners such as Kallisto directly estimate transcript abundance, and some aligners 
(such as STAR) have a built-in functionality, in most other cases tools such as HTSeq-
count are required to obtain count tables per gene (Figure 12).158,159 It uses BAM or 
SAM files as input together with a Gene Transfer Format (GTF) file, which contains 
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gene and exon annotation, and can be obtained from, for example Ensembl, but can 
also be in-house created.160 HTSeq-count will hence determine the number of reads 
overlapping the position of a specific gene (region) or transcript. As different samples 
are featured by different sequencing depths, the counts have to be rescaled prior to 
statistical analysis, called normalisation, to allow comparison between samples 
(Figure 12). Note that normalisation is the generic name for an omics strategy to 
remove putative non-biological, technical variation between samples, such as library 
size in sequencing experiments. Often library sizes are calculated as the total number 
of mapped reads. To obtain normalised gene counts, the raw gene counts per sample 
are essentially divided by their corresponding library size, divided by the average one 
over all samples. However, more elaborate methods, such as trimmed mean of M 
values (TMM), are often better suited for data normalisation.161 Different statistical 
methods for DE analysis therefore typically have their own way of normalisation and 
the DE models include obtained normalisation factors rather than using pre-
normalised count data as input. 
For statistical inference, sequencing count data were originally modelled with a 
Poisson distribution, but the latter only captures variance due to technical “sampling” 
effects, largely ignoring the excess variance caused by biological variability. Hence, 
new methods using a negative binomial distribution were developed, such as DESeq 
and edgeR (Figure 12).162,163 These methods have the additional advantage that they 
use moderation to estimate the parameters for this distribution. That is to estimate the 
variance for a locus they take into account that the variance typically depends on the 
mean expression, a trend which can be estimated empirically by borrowing 
information over all genes. Another method, called Limma, was originally created for 
DE analysis of micro-array data, which roughly follow a normal distribution. Limma-
voom was then developed to allow application of normal-based statistics on 
sequencing count data by logarithmic transformation of the counts, in addition to also 
modelling a mean-variance trend for moderated variance estimation.164 Afterwards, 
parametric or non-parametric statistics can be used to test for DE between genes. 
Next to DE, also differential methylation is an interesting topic to study. As described 
in section 3.5, sequencing of DNA methylation is either based on bisulphite 
conversion or enrichment. In the former, methylation percentages can be calculated 
and compared. For bisulphite sequencing, the number of methylated CpGs can be 
determined by calculating the ratio of Cs over the sum of Cs and Ts, the latter 
corresponding to an unmethylated C.165 For the Inifinium HumanMethylation 
BeadChips, β-values are similarly defined as the ratio of the methylated probe 
intensity on the intensity of methylated and unmethylated probes. M-values, on the 
other hand, are the binary logarithmic ratio of methylated probe intensity on 
unmethylated probe intensity.166 After optional normalisation of M-values or similar 
values for bisulphite sequencing, methods such as Limma can be applied for 
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detection of differential methylation.129 As different probes are often correlated, also 
methods that combine methylation levels of neighbouring CpGs were developed, 
such as BISEQ.167 For enrichment-based sequencing, be it to study enrichment of 
methylated CpGs, histone modifications or similar features, initial peak calling is 
common as data cannot be simply summarised per gene or transcript as done for 
RNA-seq data analysis. MACS is a peak calling algorithm that searches for positions 
in the genome enriched for mapped reads, taking into account several biases such 
as mapping bias and CNV.168 By creating GTF files based on these identified peaks, 
strategies from RNA-seq DE analysis, such as HTSeq-count-based data summary 
followed by edgeR and DEseq, can also be used to study differential enrichment.129 
 
Figure 12 Overview of the steps in a differential expression study. 
After alignment and quality control, counts per gene or transcript 
are determined. Data is then normalised and differential expression 
is calculated. Adapted from 153 
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5  Methods to detect allele-
specific expression 
The development of sequencing technologies, especially RNA sequencing, made it 
possible to study specific alleles at single base resolution. By analysing polymorphic 
sites in the genome, the distinct effect of each allele can be evaluated in the 
transcriptome. In contrast to mice experiments, where high levels of heterozygosity 
are achieved in single individuals by crossing different strains, the basic rationale of 
most human ASE studies is to identify allelic imbalance in RNA-seq data at 
heterozygous sites, which are identified by prior DNA genotyping. As ASE results in 
higher expression of one allele, the allelic ratio of RNA-seq data at a heterozygous 
SNP will be skewed towards higher counts of that allele.50 Many methods based on 
this concept have already been developed and are primarily used for detection of cis-
eQTLs.169–171 However, most methods require DNA data for the identification of 
heterozygous loci, which increases cost of the experiments. As two types of data are 
necessary, mostly small-scale studies were performed so far, and statistical ASE 
detection methodologies focus on individual samples. Only a few methods allow ASE 
detection in larger populations or allow meta-analysis across individuals.172,173 
In early methods, allelic counts of the reference and variant allele in heterozygous 
individuals were compared with a binomial test.174–176 However, at polymorphic sites, 
reads containing the reference allele will (in general) more easily map to the genome 
than the variant allele and RNA-seq data may thus entail a mapping bias. 
Furthermore, also other technical artefacts, such as nucleotide composition, increase 
technical variance in RNA-seq data. To address overdispersion present in RNA-seq 
data, more elaborate statistical methods were developed. Allelic read counts are often 
modelled with a beta-binomial distribution upon which a binomial test or likelihood 
ratio test can test for allele-specific expression.173,176–180 The beta-binomial 
distribution and modified binomial statistic improve technical biases, yet do not 
entirely eliminate mapping bias. The latter particularly prevents correct cis-eQTL 
detection as both mapping bias and cis-eQTL result in higher expression of a specific 
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allele. Many different techniques try to overcome the bias, such as remapping of the 
data or mapping to a polymorph-aware reference genome.173,181 
Imprinting is an extreme case of ASE, where one allele is (almost) completely 
silenced and only a single allele is expressed. However, partial imprinting is 
sometimes present, leaving the imprinted allele slightly expressed. In mice, imprinted 
genes are usually identified using genome and transcriptome data from reciprocally 
crossed subjects (Figure 13).182–185 In humans, trio data to infer parental genotypes 
are generally used. By validating the parental origin of the single expressed allele at 
heterozygous sites, many human imprinted genes were identified.186–188 As trio data 
are not always available (especially when studying tissue-specific imprinting), other 
methods that combine genotyping and expression data were developed. Without 
parental data, imprinting is, however, difficult to distinguish from other ASE effects. 
Baran et al. classified the degree of allelic imbalance at heterozygous sites and only 
those with the highest degree were deemed imprinted.189 Here, again, genotyping 
data are necessary to only retain heterozygous sites. Another study employed a 
Bayesian model with allele frequencies derived from dbSNP to detect imprinting in 
mRNA-seq data from multiple samples.190 
As imprinting is epigenetically regulated, studying epigenetic marks is an alternative 
approach for the detection of imprinted genes.191 Monoallelic expression is regulated 
by allele-specific methylation and detection of parent-of-origin-specific differential 
methylation between alleles in, for example, bisulphite sequencing data is thus 
Figure 13 Detection of imprinting in mice using reciprocal crosses. Two inbred 
parental strains, strain 1 and 2, produce genetically identical, but phenotypically 
different offspring. As the parental genotypes are known, the distinct offspring’s 
phenotypes show that coat colour is maternally expressed.179 
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representative for imprinting. This approach revealed known as well as novel 
candidate imprinted genes.192–194 Also chromatin modifications have a key role in 
healthy imprinting regulation and analysis of various chromatin marks was already 
performed to identify genome-wide imprinting.191,195  
In 2014, a method to study genome-wide monoallelic methylation in MBD-seq data 
was developed at the BIOBIX lab.196 By screening for deviation from biallelic 
methylation (indicated by heterozygous samples) in large datasets instead of single 
samples, monoallelically methylated sites (apparently homozygous) were detected. 
The method is based on a population genetics theorem, the Hardy-Weinberg 
Equilibrium (HWE). The theory states that in a random mating population genotype 
and allele frequencies remain constant and can be estimated. For monoallelically 
methylated sites less heterozygous samples will occur than expected by HWE, as 
only one allele is methylated and hence only homozygous samples will be observed 
in MBD-seq data. Firstly, the genotypes were estimated from the MBD-seq data in an 
iterative way to improve allele and genotype frequencies in every iteration. 
Afterwards, the allele frequencies were used to estimate the expected number of 
heterozygotes by HWE. The number of heterozygotes could then be compared to the 
expected number, and when significantly less heterozygous samples were observed 
the locus was called monoallelically methylated. Contrary to previous methylation 
studies, no expensive bisulphite sequencing was necessary. Yet studying methylation 
differences only offers a limited view of imprinting as it is not the sole epigenetic 
regulator. Furthermore, a difficult dataset with mixed tissues was studied and only 
monoallelic methylation, representing imprinting, was here taken into account. To 
date, no genome-wide methods solely using RNA-seq data exist that can distinguish 
between multiple types of ASE. Moreover, most methods focus on deviation from 
biallelic expression in individual or smaller sets of samples, which may result from 
technical artefacts, and ignore how population-level information can improve 
detection. Furthermore, no large-scale experiments have studied ASE aberrations in 
diseased tissue, as most studies focus on single loci instead on genome-wide 
deregulation of ASE.197 A comprehensive overview of imprinted genes as well as 
other ASE genes in distinct tissues and their deregulation in disease is therefore still 
lacking. 
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6  A comprehensive overview of 
imprinting in breast tissue and its 
deregulation in breast cancer 
6.1. Abstract 
Genomic imprinting plays an important role in growth and development. Loss of 
imprinting (LOI) has been found in cancer, yet systematic studies are impeded by 
data-analytical challenges. We developed a methodology to detect monoallelically 
expressed loci without requiring genotyping data, and applied it on The Cancer 
Genome Atlas (TCGA, discovery) and Genotype-Tissue expression project (GTEx, 
validation) breast tissue RNA-seq data. Here, we report the identification of 30 
putatively imprinted genes in breast. In breast cancer (TCGA), HM13 is featured by 
LOI and expression upregulation, which is linked to DNA demethylation. Other 
imprinted genes typically demonstrate lower expression in cancer, often associated 
with copy number variation and aberrant DNA methylation. Downregulation in cancer 
frequently leads to higher relative expression of the (imperfectly) silenced allele, yet 
this is not considered canonical LOI given the lack of (absolute) re-expression. In 
summary, our novel methodology highlights the massive deregulation of imprinting in 
breast cancer. 
6.2. Introduction 
Breast cancer is the most common type of cancer in women.198 It is a very 
heterogeneous disease with major differences in incidence, clinical outcome, 
prognosis and response to therapy.199,200 Gene expression profiling led to the division 
of breast cancer in five different molecular subtypes: Luminal A, Luminal B, HER2-
enriched, Basal-like and Normal-like.199,201 These subtypes differ amongst others in 
expression of the oestrogen receptor, progesterone receptor, human epidermal 
growth factor receptor 2 (HER2) and in histological grade.200 
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An early occurring aberration in cancer is LOI.91 Imprinting refers to the monoallelic 
expression of genes in a parent-of-origin-specific manner. In diploid eukaryotic 
organisms, the maternal and paternal copies of most genes are expressed at similar 
levels. For imprinted genes, however, only a single allele is transcriptionally 
active.65,202,203 Imprinting patterns may vary between tissues.189 Imprinted genes are 
mostly clustered and regulated by imprinting control regions, which are typically under 
DNA methylation control, though also H3K27me3 was demonstrated to be 
involved.204,205 Imprinted genes play an important role in development and placental 
biology.206 Furthermore, as dosage of imprinted genes is crucial, disruption of 
imprinting can result in a number of human imprinting syndromes and may predispose 
to cancer by promoting tumourigenic or suppressing antitumour mechanisms.207–210 
Some well-known diseases are Angelman Syndrome (functional loss of the maternal, 
active allele of UBE3A), Prader-Willi Syndrome (loss of the paternal, active allele of 
SNRPN) and Beckwith-Wiedemann Syndrome (LOI on chromosome 11).208,211 
LOI results in biallelic expression due to activation of the silent allele. Indeed, 
experiments in mice demonstrated that demethylation at imprinted genes leading to 
LOI made cells susceptible to cellular transformation and tumourigenesis.212 For 
instance, aberrant biallelic expression of the imprinted IGF2 locus is thought to 
promote tumourigenesis by inhibiting apoptosis in colorectal cancer213 and to lead to 
over-proliferation defects in lung, colon and ovarian cancer.90 LOI of other imprinted 
genes, such as H19, PEG3, MEST and PLAGL1, was also discovered in varying 
cancers.96 
However, several studies suggest a far more complicated story, where LOI is 
associated with silencing of the normally active allele.91 Indeed, recent studies 
identified major expression downregulation of reportedly imprinted genes in 
cancer.97,60 Moreover, in oesophageal cancer, LOI of IGF2 was specifically 
associated with expression downregulation, and improved survival.93 Also in prostate 
cancer, no increased expression was found for IGF2 despite LOI.214 Notwithstanding 
the major relevance of LOI in cancer, this fragmentary evidence demonstrates that 
the current paradigm of the role of LOI in cancer (i.e. growth & tumour promoting 
expression) requires additional evaluation. A recent study by Ribarska et al. found 
downregulation of several imprinted genes in prostate cancer, but stable DNA 
methylation.60 These results suggest the existence of an imprinted gene network in 
which these genes are co-regulated, as was also observed in mice.58 Recently, also 
copy number variation (CNV) was identified as important cause of imprinting 
deregulation in cancer.215 
Systematic analyses of LOI are still lacking. Indeed, although monoallelic expression 
is a well-investigated topic, only few regions are well-characterised in humans, and 
only a single study thoroughly evaluated tissue-specific imprinting patterns.189 To 
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date, the impact of aberrant monoallelic expression on cancer has typically been 
studied at single imprinted loci.212 Moreover, the practical applicability of existing high-
throughput methods is greatly hampered by the necessity for genotyping next to 
(typically) RNA-seq data. Thus, there is a need to systematically profile (i) 
monoallelically expressed/imprinted loci and (ii) their deregulation (LOI) in cancer, 
preferably solely based on RNA-seq data. 
Here, such a methodology is presented and - given indications for massive differential 
expression of imprinted genes in this tumour97 - applied on breast control (TCGA216, 
GTEx217) and cancer data (TCGA), leading to the identification of 30 putatively 
imprinted genes in breast of which 8 are featured by increased biallelic expression in 
at least one breast cancer subtype. Comparison with whole exome sequencing 
(WES) data demonstrates that (i) the RNA-seq-based results are generally reliable, 
and (ii) that avoiding the use of WES data leads to a far higher genome-wide 
character. Intriguingly, the results indicate that the increased frequency of biallelic 
expression is far more often associated with lower expression than higher expression 
of the corresponding locus, though exceptions exist (e.g. HM13). Therefore, this study 
demonstrate that deregulation of imprinting is an important feature in (breast) cancer 
but is not automatically associated with canonical LOI. Furthermore, these results 
underline the efficacy of the proposed strategy for the identification of imprinted 
regions and their deregulation. 
6.3. Results 
6.3.1. Detection of imprinting in healthy breast tissue 
First, a methodology was developed and applied to screen for imprinted loci in RNA-
seq data, using single nucleotide polymorphisms (SNPs) to discriminate between 
alleles. Contrasting previous genome-wide methods, no DNA genotyping data are 
required, as we solely rely on genotyping of RNA-seq data. The basic rationale is that 
in case of 100% imprinting, no heterozygous samples can be found in RNA-seq data, 
as they perfectly resemble homozygous samples (only a single allele is expressed) 
(see Methods section and Steyaert et al.196). The novel imprinting model describes 
the data for each SNP as a mixture of homozygous and heterozygous samples, more 
specifically as a mixture of genotype-dependent binomial distributions, with weights 
derived from Hardy-Weinberg equilibrium. The model allows for sequencing errors 
and partial imprinting. Indeed, one parameter describes the degree of imprinting, and 
it can be evaluated whether its estimate is significantly higher than 0 using a likelihood 
ratio test. 
Upon application on 113 TCGA breast control samples, 127 SNPs were considered 
to be possibly imprinted (false discovery rate (FDR) ≤ 0.05), and dbSNP annotation 
was found for 125 SNPs. The 125 possibly imprinted SNPs corresponded with 
approximately 35 genes, the majority already known to be imprinted (S.1.1-S.1.3). 
6 Imprinting in breast and its deregulation in breast cancer 42 
 
Note that annotation of the SNPs to specific genes was often difficult as many 
overlapping genes were found (S.1.1). For example, MCTS2P is a retrogene copy 
and located in HM13, making it uncertain in which gene the detected SNP was 
located.218 Similarly, for MTRNR2L1, imprinted SNPs with Ensembl annotation for this 
locus were found upstream of the gene, making correct annotation uncertain. Upon 
validation in GTEx healthy breast data, 121 SNPs corresponding to 30 genes 
remained (96.8% SNP validation rate). Table 1 lists the identified SNP loci and 
corresponding genes. As examples, the resulting mixture distributions of IGF2 and 
SNRPN are shown in Figure 14(a) and Figure 14(b), respectively. The distributions 
show that these loci are clearly depleted of samples featured by biallelic expression. 
In Figure 14(c) a non-imprinted SNP with a distinct heterozygous peak is shown. 
Moreover, Figure 14(a) indicates that IGF2 imprinting is only partial (97% imprinted), 
underscoring the suitability of the flexible distribution model used here. Similar figures 
for the other genes can be found in Supplementary Figures 1-11. In general, 
imprinting could be verified using TCGA WES data, yet for many SNPs this was 
technically infeasible due to too low coverages - supporting the value of the 
genotyping-free approach introduced here (S.1.3c). 
Next to imprinting, the model detects random monoallelic expression, as this can only 
be discriminated from imprinting by means of family data, unavailable in TCGA. As a 
consequence, several HLA, HLA-DR and HLA-DQ genes - important players in 
immune reactions known to be regulated by random monoallelic expression189 - were 
also picked up, but were excluded from further analyses. The remaining genes (Table 
1) represent the final list of putatively imprinted loci in normal human breast tissue 
further analysed throughout this manuscript. 
As typically only few putatively imprinted SNPs per gene were found, we evaluated 
the other SNPs in identified genes. Often SNPs were located in intronic regions or 
5’UTRs with too low coverage for accurate detection of imprinting. Other undetected 
SNPs in exons or 3’UTRs were typically featured by a high sequencing error rate, low 
minor allele frequency or inferior goodness-of-fit to the model (Supplementary Data 
Figure 14 Mixture distributions of (non-)imprinted SNPs. Observed (red) and modelled (blue) 
fraction of alternative alleles for two significantly imprinted SNP positions, i.e. (a) IGF2 
(rs2585, adj. p-value < detection limit (LRT), î = 0.97) (b) SNRPN (rs705, adj. p-value = 1.81E-
71 (LRT), î = 0.99), and a non-imprinted SNP, i.e. (c) CHMP6 (rs1128687, î = 0). 
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1-2). As a result, most of these missed SNPs were filtered out prior to application of 
the imprinting likelihood ratio test, or exhibited non-significant results due to 
aforementioned problems. In Supplementary Data 1 all SNPs in HM13 are shown, 
which clearly demonstrates that indeed mostly intronic SNPs with low coverages are 
missed. However, some genes showed evidence (ZNF300P1, LOC100294145, 
ZNF331 and GNAS-AS1/GNAS) or indications (HOTAIRM1) of transcript-specific 
imprinting with more complex mixture distributions and consistent differences 
between exons (Supplementary Figures 16-17 and Supplementary Data 2). On the 
other hand, for PTX3, RP11-109L13.1, PLIN1 and USP32P, inconsistent imprinting 
patterns could not be readily explained by gene isoforms, and these loci are denoted 
as candidate imprinted (Supplementary Figure 15 and Supplementary Data 2). 
Known possibly imprinted genes were clearly not imprinted in breast tissue 
independent of overlapping transcripts (Supplementary Figures 18-19). For possible 
pseudogenes, we evaluated misalignment as possible explanation. For MTRNR2L1 
and MTCO1P12, this additional curation step did not lead to unequivocal results, 
leading us to also designate these loci as candidate imprinted (Table 1, S.1.3e). 
As additional validation step, we examined whether DNA methylation levels were 
skewed towards putative monoallelic methylation for the imprinted loci. For the 18 
genes represented in the TCGA Infinium HumanMethylation data, at least one 
putative monoallelically methylated probe was found (median methylation in between 
33.3 and 66.7%) (Supplementary Data 3). Moreover, 46% of all probes for these loci 
were found to be featured by putative monoallelic methylation, a major enrichment 
compared to expected (all probes, 14%, p=1.84E-175, χ² test). However, monoallelic 
methylation is only a crude proxy for the presence of imprinting associated 
differentially methylated regions (DMR). We therefore analysed methylation in known 
DMR locations, provided in Table 1 of Court et al.193 As summarised in Supplementary 
Data 3, DMRs were found for all identified imprinted loci, except for PTX3, PLIN1 and 
BCR, which may be regulated in a different manner. Typically, each of these DMRs 
featured multiple putatively monoallelically methylated probes in the control samples, 
and often even largely coincided with putatively monoallelically methylated regions 
(e.g. PEG10, PLAGL1 and HM13). For ZDBF2 and DLK1, the DMR methylation 
status could not be evaluated since no probes were present. 
Table 1 Genes featured by monoallelic expression/imprinting in breast tissue. The columns show the gene 
symbol (Gene symbol) and the ID of significantly imprinted SNP locus falling in these genes (SNPs) with 
its LRT FDR-adjusted p-value between brackets.*  
Gene symbol SNPs Gene symbol SNPs 
MTCO1P12*** rs112232512 (1.42E-75) MEG3 rs4906022 (8.42E-204) 
LINC01139 rs61746209 (6.14E-29) SNRPN rs705 (1.81E-71) 
ZDBF2 rs7582864 (1.02E-21) SNHG14 rs2732028 (3.33E-15) 
ZDBF2 rs3732084 (6.54E-26) SNHG14 rs74335291 (5.12E-24) 
ZDBF2 rs1975597 (7.97E-30) SNHG14 rs2732029 (6.71E-28) 
ZDBF2 rs1448902 (2.02E-17) SNHG14 rs765438 (1.96E-28) 
ZDBF2 rs4673350 (2.56E-23) SNHG14 rs2732030 (9.43E-12) 
PAX8-AS1 rs7585510 (0.0068) SNHG14 rs10451029 (6.14E-22) 
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Table 1 Continued 
Gene symbol SNPs Gene symbol SNPs 
PTX3** rs73158510 (5.44E-07) SNHG14 rs2052723 (1.14E-25) 
NAP1L5 rs8605 (3.77E-22) SNHG14 rs2554419 (7.96E-31) 
NAP1L5 rs710834 (9.10E-21) SNHG14 rs719704 (3.32E-22) 
ZNF300P1 rs17800987 (4.87E-11) SNHG14 rs34316840 (1.13E-25) 
PLAGL1 rs2328535 (3.09E-10) SNHG14 rs2732031 (1.23E-26) 
PLAGL1 rs9373409 (1.40E-27) PWAR6 rs2732041 (1.60E-12) 
PLAGL1 rs73006222 (2.41E-15) PWAR6 rs2732043 (1.78E-13) 
PLAGL1 rs17615967 (1.76E-14) PWAR6 rs2732044 (1.42E-26) 
PLAGL1 rs77203559 (3.76E-15) PWAR6 rs1030389 (1.68E-28) 
PLAGL1 rs9321953 (1.48E-21) PWAR6 rs62001981 (1.41E-26) 
LOC100294145 rs241407 (2.71E-07) PWAR6 rs62001982 (1.09E-19) 
PEG10 rs35237090 (1.69E-17) PWAR6 rs1045935 (6.76E-29) 
PEG10 rs13073 (3.35E-13) SNHG14 rs11637436 (1.44E-11) 
PEG10 rs7810469 (6.18E-29) SNHG14 rs4344720 (7.48E-20) 
MEST rs10863 (<det. limit) SNHG14 rs3863396 (2.68E-19) 
HOTAIRM1 rs706018 (5.67E-36) SNHG14 rs62002013 (3.83E-12) 
RP11-109L13.1** rs201284359 (4.97E-10) SNHG14 rs2356294 (4.96E-24) 
H19 rs2075744 (3.21E-27) SNHG14 rs1043164 (6.41E-12) 
H19 rs2839698 (3.18E-57) SNHG14 rs691 (6.11E-33) 
H19 rs2067051 (1.94E-57) SNHG14 rs13526 (3.74E-29) 
H19 rs2839701 (3.29E-61) PLIN1** rs4578621 (3.29E-06) 
H19 rs2839704 (1.40E-44) ZNF597 rs37822 (1.47E-18) 
H19 rs2839702 (2.94E-50) ZNF597 rs37823 (3.08E-18) 
H19 rs10840159 (2.28E-50) ZNF597 rs11639510 (3.42E-25) 
H19 rs3741219 (1.01E-107) ZNF597 rs12737 (1.01E-21) 
H19 rs2075745 (6.63E-34) USP32P2** rs141915702 (0.0093) 
IGF2 rs7873 (1.08E-268) MTRNR2L1*** rs3931649 (3.16E-28) 
IGF2 rs2585 (<det. limit) MTRNR2L1*** rs113014658 (6.82E-09) 
DLK1 rs1802710 (2.68E-28) MTRNR2L1*** rs113626706 (5.74E-12) 
MEG3 rs78793760 (4.16E-21) MTRNR2L1*** rs3931650 (7.67E-29) 
MEG3 rs35458454 (5.16E-21) ZNF331 rs113983639 (1.99E-13) 
MEG3 rs35431412 (1.62E-29) ZNF331 rs8110350 (4.12E-106) 
MEG3 rs10147988 (1.07E-26) ZNF331 rs8110538 (1.74E-109) 
MEG3 rs3087918 (5.47E-27) ZNF331 rs8109631 (8.52E-175) 
MEG3 rs3087917 (1.64E-30) PEG3 rs4801386 (0.00011) 
MEG3 rs3742391 (2.13E-19) PEG3 rs1558355 (0.00027) 
MEG3 rs12897172 (2.31E-17) PEG3 rs723082 (1.62E-31) 
MEG3 rs1884540 (1.78E-26) PEG3 rs3143 (7.86E-06) 
MEG3 rs2400941 (1.64E-29) PEG3 rs1055359 (9.07E-20) 
MEG3 rs77658190 (2.45E-17) PEG3 rs11666110 (8.06E-28) 
MEG3 rs10132552 (4.26E-17) PEG3 rs1860565 (1.02E-21) 
MEG3 rs3194464 (1.43E-23) PEG3 rs33931963 (6.73E-28) 
MEG3 rs11160606 (1.53E-23) HM13 rs6058058 (1.33E-10) 
MEG3 rs1950628 (1.01E-26) HM13 rs6059869 (4.04E-14) 
MEG3 rs1053900 (4.91E-34) HM13 rs6059873 (1.29E-19) 
MEG3 rs1054000 (7.58E-27) HM13 rs6059874 (4.88E-14) 
MEG3 rs8013873 (6.63E-27) HM13 (MCTS2P) rs1115713 (7.94E-09) 
MEG3 rs11859 (2.17E-25) GNAS/GNAS-AS1 rs1800900 (5.02E-16) 
MEG3 rs74080162 (1.15E-24) BCR rs550197 (7.93E-50) 
MEG3 rs4378559 (8.76E-25) CPHL1P rs12497062 (0.00027) 
MEG3 rs12890215 (8.74E-25) ATP8A1 rs11940243 (3.21E-08) 
MEG3 rs55996894 (5.63E-21) GLIPR1/KRR1 rs1056905 (1.20E-06) 
MEG3 rs3742390 (6.24E-31) TPSB2 rs77309587 (1.52E-08) 
*Genes which are known to be imprinted or for which there is prior evidence of imprinting are marked 
in bold. Genes eliminated from our set of imprinted genes upon unsuccessful validation in GTEx are 
underlined. 
**candidate imprinted genes due to limited coverage/allele frequency in GTEx or inconsistent results 
per exon. 
***candidate imprinted pseudogenes, involvement original mitochondrial genes could not be fully 
excluded (S.1.3e) 
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6.3.2. Differential imprinting in breast cancer 
To examine possible deregulation of imprinting in breast cancer, alterations in allelic 
expression patterns of imprinted genes were investigated. Differential imprinting (DI) 
is defined here as different relative expression of both alleles in cancer vs controls. 
We reserve the term LOI solely for DI caused by re-expression of the silenced allele 
(i.e. absolute higher expression). We determine biallelic expression per sample by 
the allelic ratio (allele count with lowest expression/allele count with highest 
expression), which varies from 0 (perfect monoallelic expression) to 1 (perfect biallelic 
expression) and is independent of expression level differences in cancer. For these 
analyses, it should be noted that power is compromised by the fact that DI cannot be 
observed in homozygous individuals, which constitutes the majority for each locus. 
We try to compensate this by allowing more false positives in the results (FDR of 
10%), but also by enriching for likely heterozygous samples. As samples with a high 
allelic ratio represent heterozygotes, looking at the 2PAPT highest fraction of samples 
(cf. Hardy-Weinberg theorem) allows us to only take the most likely heterozygotes 
into account. DI in cancer for a specific SNP was thus defined as a significant 
difference of the allelic ratios between putative heterozygous cancer and control 
samples (see Methods, section). Though only technically feasible for a limited set of 
the data, this allelic ratio was verified to be a good measure for DI using WES data 
(S.1.14). 
When considering the full set of 506 breast cancer samples, four SNP loci with 
significant DI, i.e. higher relative expression of the silenced allele, could be identified 
(FDR ≤ 0.1; Table 2). These SNPs correspond to three genes, namely MEST, H19 
and HM13. Figure 15 shows the mixture distributions of these genes for both control 
and tumour samples. The plots demonstrate that for MEST (and to a minor extent for 
HM13) also some control samples are featured by residual biallelic expression. This 
may suggest that this locus is less stringently imprinted and further lost its imprinting 
signature in breast cancer. Alternatively, this may be due to the fact that a mixture of 
imprinted and non-imprinted transcripts is present, with a shift towards expression of 
the latter in cancer.  
Subsequently, the different breast cancer subtypes, namely basal-like (BL), HER2-
enriched (HER2), luminal A (LumA) and luminal B (LumB), were analysed individually 
for DI compared to normal samples (Table 2, significant results are shown in bold). 
The normal-like (NL) subtype was not considered due to a too low number of samples. 
Compared to the results for all tumour samples, significant DI of MEST was detected 
at the same SNP position in all subtypes except for BL, whereas HM13 and H19 were 
significantly deregulated in all but LumA. In summary, most deregulation was found 
in HER2 and BL. The deregulated loci corresponded to eight genes, i.e. ZDBF2, 
PEG10, MEST, H19, IGF2, MEG3, ZNF331 and HM13. For each of these genes, the 
frequency of samples featuring biallelic expression in cancer was estimated, going up 
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to 100% for MEST in LumB and HER2 (Supplementary Table 5). For LumB, DI was 
found in MEST, H19, HM13, IGF2, ZNF331 and PEG10, whereas for LumA only one 
DI locus was identified (Figure 16). Distributions of the other loci featured by DI in 
cancer subtypes are displayed in Supplementary Figures 20-23. Particularly the 
H19/IGF2 locus showed striking evidence for DI in HER2 and BL samples: all 12 
SNPs were found to be deregulated in BL, whereas for HER2 10 SNPs were DI. DI 
was not associated with survival, except for two SNPs in ZDBF2, nor with age (Figure 
17, S.1.4c). 
Though most often the case, SNPs in the same imprinted gene did not always show 
consistent (in)significant results (Supplementary Data 4). This can typically be 
attributed to technical/power associated causes, such as lower coverage, though also 
transcript-specific effects may be present. For example, for ZNF331, two DI SNPs 
were found in the 3’UTR, and one non-DI SNP in the first exon. Again, verification of 
DI by comparison of RNA- and DNA-based genotypes was successful (i.e. re-
expressed allele agreed with DNA-based genotype), though complicated due to the 
low coverage WES data (Supplementary Figures 14). 
Figure 15 SNP positions differentially imprinted between normal and cancer samples. (a) 
MEST (rs10863, adj. p-value = 0.022). (b) H19 (rs2839704, adj. p-value = 0.069). (c) H19 
(rs2839703, adj. p-value = 0.082). (d) HM13 (rs6059873, adj. p-value = 0.062). When 
differential imprinting occurs, more heterozygous samples (indicating biallelic expression) are 
observed. Indeed, the right figures (“Tumour”) are featured by more samples around an allelic 
fraction of 0.5, i.e. heterozygotes, compared to the left plots (“Control”). 
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6.3.3. Differential expression of imprinted genes 
In 2015, Kim et al. found 21 of their 23 (91%) analysed putatively imprinted genes to 
be differentially expressed in breast cancer.97 As they had compiled imprinted genes 
from literature irrespective of tissue type, we performed differential expression (DE) 
analysis in control vs tumour and control vs breast cancer subtypes for the here 
detected imprinted SNPs and genes. Significant DE was found in almost all (92%) of 
the imprinted SNPs for all tumour samples. Imprinting is thus indeed heavily 
HER2-enriched 
(adj. p-value = 0.02) 
Basal-like 
(adj. p-value = 0.02) 
Luminal B 
(adj. p-value = 0.02) 
(c, HM13) 
Luminal B 
(adj. p-value = 0.03) 
Basal-like 
(adj. p-value = 0.02) 
HER2-enriched 
(adj. p-value = 0.02) 
(b, H19) 
HER2-enriched 
(adj. p-value < 0.002) 
Luminal A 
(adj. p-value = 0.03) 
Luminal B 
(adj. p-value < 2.2E-16) 
(a, MEST) 
Figure 16 SNP positions differentially imprinted between normal and cancer subtypes. (a) 
MEST (rs10863). (b) H19 (rs2839704). (c) HM13 (rs6059873). 
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deregulated in breast cancer (Supplementary Tables 7 and 9). Far more loci were 
downregulated than upregulated: 87% were detected with a negative log-fold change. 
The FDR-adjusted p-values and log fold changes of all SNPs showing DI can be found 
in Table 2 (Supplementary Data 5 and Supplementary Table 8 show results for all 
SNPs and genes, respectively). 
One would expect that DI, i.e. relative higher expression of the silenced allele, implies 
upregulation of the imprinted gene as in canonical LOI. However, at least in breast 
cancer, DI was not associated with overexpression of the corresponding gene. The 
only clear exception was HM13, for which DI implied higher expression in most 
subtypes (and IGF2 in BL and PEG10 in LumB to a lesser extent, Table 2) in line with 
canonical LOI. For most other SNPs, DI was associated with expression 
downregulation.  
We verified these results in heterozygous samples, as DI cannot be observed in 
homozygotes (S.1.5). Only for 5 SNPs (located in ZNF331, HM13, USP32P2, ZDBF2 
and H19) sufficient WES data were available to accurately evaluate DI and DE 
results. In ZNF331, significant downregulation was found in biallelically expressing 
tumour samples compared to monoallelically expressing control samples, but also 
when compared to monoallelically expressing tumour samples. HM13, on the other 
hand, was significantly upregulated in biallelically expressing samples (compared to 
monoallelically expressing tumours as well as monoallelically expressing controls), 
further confirming the results presented above. For the other SNPs no differences 
were detected, particularly due to low power (insufficient WES coverage). 
 
(a) (b) 
Figure 17 Kaplan-Meier plot of the Cox proportional hazards model for survival as a function 
of differential imprinting. Differential imprinting is implemented continuously as the allelic ratio 
(AR) of the least expressed allele over the most expressed allele (with AR as categorical 
variable for the Kaplan-Meier plot: AR ≤ 0.2 (blue curve) and AR > 0.2 (red curve)), and age. 
(a) rs3732084 (ZDBF2, FDR-adjusted p-value = 0.027) (b) rs1975597 (ZDBF2, FDR-adjusted 









TUMOUR HER2-ENRICHED BASAL-LIKE LUMINAL A LUMINAL B 
DI_p logFC DE_p DI_p logFC DE_p DI_p logFC DE_p DI_p logFC DE_p DI_p logFC DE_p 
rs1053900 (MEG3) 0.49 -2.4 6.6E-45 0.07 -2.2 5.6E-18 1.00 -3.0 1.8E-37 0.90 -2.2 1.6E-29 0.46 -2.7 1.1E-35 
rs4378559 (MEG3) 0.49 -1.7 2.8E-27 0.04 -1.0 2.0E-08 1.00 -2.4 6.8E-26 0.92 -1.4 1.6E-16 0.46 -2.2 2.2E-26 
rs12890215 (MEG3) 0.47 -1.7 5.1E-29 0.10 -1.0 5.7E-09 0.76 -2.3 8.0E-27 0.87 -1.4 9.1E-18 0.44 -2.2 6.7E-28 
rs10863 (MEST) 0.02 -1.6 1.3E-31 0.00 -1.7 3.0E-13 0.70 -0.9 6.5E-15 0.03 -1.9 5.4E-31 0.00 -1.7 2.7E-19 
rs3741219 (H19) 0.17 -0.9 1.4E-02 0.00 -1.1 1.4E-03 0.03 -0.8 4.5E-04 0.77 -0.7 3.5E-01 0.38 -1.3 7.8E-04 
rs2839704 (H19) 0.07 -0.9 2.1E-02 0.01 -1.2 8.1E-04 0.02 -0.8 9.7E-04 0.40 -0.7 4.5E-01 0.03 -1.2 8.3E-04 
rs2839703 (H19) 0.08 -0.9 2.7E-02 0.01 -1.3 9.8E-04 0.02 -0.8 1.4E-03 0.56 -0.8 4.7E-01 0.03 -1.3 9.8E-04 
rs10840159 ( H19) 0.17 -1.0 3.4E-02 0.01 -1.4 2.3E-03 0.02 -0.9 1.3E-03 0.85 -0.8 4.8E-01 0.27 -1.3 1.3E-03 
rs2839702 (H19) 0.17 -0.7 3.3E-02 0.01 -1.0 7.0E-03 0.02 -0.5 4.9E-04 0.65 -0.5 4.1E-01 0.16 -1.0 4.2E-03 
rs2839701 (H19) 0.17 -0.6 6.4E-02 0.01 -0.9 9.5E-03 0.03 -0.5 1.1E-03 0.76 -0.5 4.9E-01 0.22 -0.9 8.7E-03 
rs2067051 (H19) 0.19 -0.3 4.8E-01 0.05 -0.6 4.8E-01 0.02 -0.2 1.1E-01 0.91 0.0 4.7E-03 0.20 -0.6 1.9E-01 
rs2075745 (H19) 0.17 -0.4 8.6E-01 0.04 -0.8 3.3E-01 0.02 -0.4 6.1E-02 0.78 -0.2 2.6E-02 0.16 -0.7 1.4E-01 
rs2075744 (H19) 0.27 -0.2 4.1E-01 0.17 -0.6 2.8E-01 0.02 -0.3 1.9E-01 0.92 0.0 1.7E-02 0.57 -0.4 3.6E-01 
rs2839698 (H19) 0.23 -0.3 4.5E-01 0.08 -0.7 3.8E-01 0.02 -0.4 1.4E-01 0.90 -0.1 1.4E-02 0.38 -0.5 3.7E-01 
rs7582864 (ZDBF2) 0.49 -1.7 2.7E-25 0.75 -2.8 1.1E-21 0.10 -1.5 8.5E-14 0.87 -1.6 2.1E-18 0.75 -1.4 7.1E-16 
rs3732084 (ZDBF2) 0.17 -1.6 1.2E-28 0.14 -2.3 1.9E-19 0.02 -1.5 5.7E-17 0.53 -1.6 2.0E-21 0.46 -1.5 3.8E-19 
rs1975597 (ZDBF2) 0.27 -1.5 3.6E-29 0.08 -2.2 4.0E-19 0.15 -1.5 9.9E-17 0.52 -1.4 5.4E-22 0.57 -1.3 1.2E-19 
rs2585 (IGF2) 0.17 -1.1 5.9E-33 0.02 -2.3 3.0E-22 0.08 0.2 1.3E-35 0.44 -1.3 7.3E-15 0.10 -2.3 6.1E-29 
rs7873 (IGF2) 0.43 -1.2 2.9E-33 0.14 -2.4 3.9E-22 0.03 0.1 5.3E-36 0.78 -1.4 2.1E-15 0.92 -2.3 1.8E-28 
rs6059869 (HM13) 0.17 0.3 8.3E-02 0.10 0.0 3.8E-01 0.13 0.2 4.0E-01 0.68 0.3 3.1E-02 0.03 0.6 7.2E-03 
rs6059873 (HM13) 0.06 0.4 3.2E-03 0.02 0.2 2.8E-01 0.02 0.4 9.1E-02 0.33 0.4 1.5E-03 0.02 0.6 5.6E-04 
rs8110538 (ZNF331) 0.27 -0.9 3.2E-25 0.63 -1.1 9.1E-18 0.08 -1.0 4.5E-16 0.75 -0.9 4.3E-19 0.08 -0.8 3.3E-15 
rs8110350 (ZNF331) 0.30 -0.9 3.5E-25 0.44 -1.0 5.8E-18 0.08 -1.0 1.0E-15 0.81 -0.9 1.4E-19 0.10 -0.7 2.1E-14 
rs7810469 (PEG10) 0.19 1.0 8.3E-03 0.04 0.9 1.2E-01 0.58 1.2 1.2E-01 0.53 1.0 2.8E-04 0.10 0.9 8.3E-04 
*FDR adjusted p-values are shown in column DI_p with significant results (FDR≤0.1) shown in bold. Also log fold changes (logFC) and FDR adjusted p-values of 
differential expression analysis (DE_p) are shown with significant results (FDR≤0.05) shown in bold. 
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6.3.4. Residual biallelic expression as potential cause of DI 
Previous studies suggested that the basic concept of LOI in which re-expression of 
the imprinted allele leads to higher expression of imprinted genes is incomplete. Also 
here we found that DI is particularly associated with expression downregulation. 
We hypothesise that DI/apparent LOI may also be caused by the presence of residual 
biallelic expression, i.e. incomplete silencing of the imprinted allele, cf. IGF2 Figure 
14(a). If expression of the normally active allele is downregulated, expression levels 
for both alleles become more similar, which can be incorrectly perceived as LOI. To 
evaluate this hypothesis, the expression of the normally silenced allele (i.e. allele with 
least expression) was used as a measure for LOI. Results indicated no significant DE 
between cancer and controls of the silenced allele, supporting the hypothesis that the 
perceived LOI in breast cancer is particularly a by-product of the silencing of the active 
allele. Nevertheless, also the low number of biallelically expressing samples and thus 
decreased power may have an impact. It should be noted that for HM13 - clearest 
example of an upregulated imprinted gene - a significant (unadjusted) p-value was 
observed for SNP rs6059873 (higher expression of silenced allele) whereas this was 
not the case for the other imprinted loci (Supplementary Table 14). 
Subsequently, we evaluated whether CNV aberrations may explain imprinted gene 
silencing (and thus DI) in breast cancer. Contrasting controls, significant associations 
were found between imprinted gene expression and CNV in cancer samples for 17 of 
the 23 genes present in TCGA CNV data (Supplementary Figure 24, Supplementary 
Table 12 and Supplementary Data 6). For example, in cancer, GNAS, BCR and 
SNRPN showed both expression downregulation and CNV losses, while for HM13, 
gains were linked with overexpression. As we did not observe this for all loci and 
samples, we also evaluated DNA methylation. For most imprinted genes 
downregulated in cancer (15 of the 16 covered in TCGA), probes differentially 
methylated between cancer and controls were found. However, though these 
included many probes located in known DMRs and/or featured by putative monoallelic 
methylation in controls (particularly in MEG3 and MEST loci, over 25% methylation 
difference in DMRs), there was no clear enrichment for putative imprinting regulating 
loci among differentially methylated probes (Supplementary Data 3). These results 
suggest that imprinted gene silencing in breast cancer is common and often 
associated with CNV and deregulated methylation, and is the most likely cause of DI 
in cancer (rather than its consequence). 
6.3.5. LOI, DE, CNV and differential methylation of HM13/MCTS2P 
HM13 is the only gene in which both DI and higher expression in cancer was identified 
(Table 2), indicating LOI. However, not all SNPs in this gene showed consistent DI 
and DE results. 80 SNPs were initially analysed in the full HM13 gene, yet only 5 
SNPs were maintained upon initial data filtering (see Methods section and 
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Supplementary Data 1). Of all SNPs detected to be imprinted, 4 located in exon 3 of 
HM13 transcript 4, and a 5th one intronic in HM13 but exonic in MCTS2P retrogene 
(Supplementary Figure 27). Of the 4 detected imprinted SNPs in exon 3 of transcript 
4, 3 demonstrated DE and 2 also DI (particularly in LumB), whereas the 5th SNP 
(exonic in MCTS2P) did exhibit DE but no DI. For SNPs featured by significant DI, we 
estimated that over 50% of all samples may be affected (Supplementary Table 5). 
Moreover, HM13 DI was independent of lymphocyte infiltration (S.1.8). Subsequently, 
it was evaluated whether there was evidence for transcript-specific DE, as the other 
exons lack the informative SNPs required to evaluate DI directly. All exons were 
significantly upregulated in breast cancer (subtypes), suggesting no transcript-
specific effects (Supplementary Table 15). 
Given that HM13 is located on the 20q locus, often gained in cancer, we also 
evaluated whether CNV gains may explain DI, but DI appeared independent from 
CNV for all imprinted HM13 SNPs (Supplementary Table 13). Subsequently, ten 
Infinium HumanMethylation450k probes demonstrating approximately 50% 
methylation (see Joshi et al. Table S2 and MEXPRESS219,220, Supplementary Figure 
28) and located in the HM13 DMR (193, except for cg18471488) were analysed in 
TCGA. Methylation was significantly lower for two probes (cg18471488 - located near 
HM13 promoter region - and cg24607140 - located near MCTS2P and already 
associated with imprinting control of the latter gene219) in tumour compared to control 
samples (Supplementary Table 16). Also in the subtypes, methylation of cg18471488 
was significantly lower. HER2 and LumB did not show any other differential 
methylation, while in BL methylation levels were lower for almost all probes 
(Supplementary Table 16). Only in LumA significantly higher methylation was found, 
which concurs with results mentioned higher (i.e. DE but no DI was found in LumA). 
Methylation of probe cg18471488 was significantly correlated with expression of the 
last exon of transcript 4 (possibly the UTR of this transcript) but also the full HM13 
gene in the whole dataset (control and tumour data, Supplementary Table 17). In 
summary, these results show that LOI of the HM13/MCTS2P locus is linked to DNA 
methylation aberrations, but that a more precise description is hampered by the 
resolution of the data at hand. 
6.4. Discussion 
Genomic imprinting is important for normal development and growth. The genome-
wide evaluation of imprinting deregulation in cancer and diseases is currently 
hampered by a lack of appropriate data-analytical strategies. We hence developed a 
new methodology for the genome-wide detection of imprinting and its deregulation. 
After application on breast tissue, we were able to detect many imprinted genes and 
confirm major deregulation of imprinted genes in breast cancer and the varying 
subtypes. Imprinted genes exhibited clear differential expression, particularly 
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downregulation, in tumour samples. Strikingly, in HER2 and BL tumours, 
downregulation was associated with massive induction of biallelic expression. A 
similar pattern has been described earlier for individual genes, e.g. for IGF2 in 
oesophageal cancer.93 However, most likely, this is merely the result of a higher 
relative expression of the (not completely silenced) imprinted allele due to 
downregulation of the expressed allele. Given that the imprinted allele itself is not 
affected, we refrain from using the term LOI, and proposed the more generic term 
differential imprinting to indicate a relative shift in allelic expression independent of 
the underlying cause. The sole example where DI could be attributed to LOI was 
HM13, which exhibited overexpression in cancer, particularly in LumB tumours, due 
to re-expression of the normally silenced allele. 
We analysed RNA-seq data of 113 breast tissue samples and 127 putatively 
imprinted SNPs in approximately 35 genes were identified and used for further 
analysis. For 2 SNPs no dbSNP annotation could be retrieved, though later manual 
curation suggested rs2269621 to be located in the known imprinted gene L3MBTL1 
(Supplementary Figure 11b). Validation in GTEx data was possible for 121 SNPs 
corresponding to 30 genes. Although our methodology cannot assess whether the 
expression status of each allele is indeed determined by the parent of origin (which 
would require unavailable trio data), visual evaluation of the different mixture 
distribution plots as well as the clearly significant adjusted p-values strongly support 
at least monoallelic expression. Also, note that all genes demonstrating relevance in 
breast cancer had been associated with imprinting before. Moreover, the observation 
that newly identified putatively imprinted genes demonstrate similar differential 
expression patterns as known ones provides more evidence for their imprinting 
status. Finally, the identified loci largely featured known imprinting associated 
DMRs.193 
Compared to the study by Baran et al., which only used 27 breast samples, 13 genes 
were detected by both Baran’s and our method.189 One gene (PPIEL) was not 
evaluated by our methodology due to low coverage, whereas imprinted SNPs for the 
second gene (SNURF) were detected yet annotated as the overlapping gene 
(SNRPN). Of the 19 genes detected by our method only, at least 7 are known 
imprinted genes, also detected by Joshi et al.219, or genes located in the 
neighbourhood of imprinted genes. It should be noted that accuracy of these results 
largely depends on the accuracy of the underlying annotation. Nevertheless, 
inconsistent results between SNPs in the same gene were evaluated, and appeared 
to be mainly caused by technical reasons, i.e. low coverage of intronic SNPs, low 
goodness-of-fit to the model or low allele frequency, as demonstrated for HM13 in 
Supplementary Data 1. On the other hand, interestingly, for ZNF300P1, 
LOC100294145, ZNF331 and GNAS-AS1/GNAS, we observed transcript-specific 
imprinting to be a more likely explanation. 
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Subsequently, we analysed 506 breast cancer samples for DI. One gene, MEST, 
showed significant DI and two genes, H19 and HM13, were borderline significant. 
MEST is already known to show DI in varying cancers, including breast cancer.96,221–
223 Aberrant H19 imprinting is often seen in cancer as well and is thought to have an 
important role in cancer development.224,225,96 When taking into account the different 
tumour subtypes, we detected 24 SNPs (in eight genes: ZDBF2, PEG10, MEST, H19, 
IGF2, MEG3, ZNF331 and HM13) exhibiting DI in at least one subtype compared to 
the normal tissue samples. DI was particularly present in BL and HER2 tumours. 
Many of these genes had been linked with DI and cancer development 
before.96,221,226–229 DI was typically not associated with survival, except for 2 SNPs in 
ZDBF2, a zinc-finger containing protein, yet this finding requires additional validation. 
We found most of the imprinted genes to be downregulated in tumour samples, often 
leading to DI (but not canonical LOI). As recently demonstrated, particularly CNV was 
associated with expression deregulation of imprinted genes.215 Methylation was also 
found to be significantly different between tumours and controls, though without clear 
enrichment for imprinting associated DMRs. For these loci, DI is thus most likely the 
consequence of transcriptional silencing. Previously, studies in murine and human 
prostate tissue and cancer detected a transcriptional network of co-regulated 
imprinted genes58,60, with PLAGL1 as putative key player.58,59,230,231 Results from 
preliminary analyses (S.1.7) are compatible with the presence of an imprinted gene 
network in cancer as well, but an elaborated co-expression analysis is required to 
formally test this. 
Contrasting other loci, HM13 clearly exhibited canonical LOI, i.e. re-expression of the 
normally silenced allele leading to overexpression in cancer, particularly in the LumB 
subtype. Both significant SNPs appear to be present in the third (and last) exon of 
transcript variant 4, possibly the UTR of this transcript. Though other evidence for 
imprinting of HM13 exists, only little information is available on its function - a signal 
peptide peptidase involved in the immune system.232,233 Importantly, deregulation of 
HM13 - located on 20q - has been revealed in colorectal carcinoma: the often 
observed 20q gain in this tumour is associated with higher HM13 expression, which 
was demonstrated to lead to accelerated growth of the tumour.234 Also in the study at 
hand, CNV gain led to increased HM13 expression, yet this was independent of LOI. 
Interestingly, in an imprinting study in normal blood samples by our group, HM13 also 
appeared to be featured by LOI and higher expression in a subset of samples, 
particularly in older individuals (unpublished results, https://bit.ly/2oCR6eD). With 
respect to the mechanism of HM13 deregulation in breast cancer, we demonstrated 
that aberrant methylation in the neighbourhood of the HM13 promoter was linked to 
deregulation of its expression. Differential methylation may lead to different 
polyadenylation (as described in mice235) and hence varying transcripts, yet we found 
differential expression of all exons in HM13. Our methodology also did not allow to 
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exclude promoter switching from an imprinted promoter to a non-imprinted one, as 
already described for IGF2 and MEST215,222, as cause of HM13 LOI in cancer. Further 
research is, therefore, necessary to unravel the exact mechanism(s) and 
consequences of (de)regulation of HM13 in breast cancer. 
Throughout the manuscript, results were verified by comparison with available WES-
based genotyping data. However, low or absent coverage of WES for the 
corresponding loci led to a massive loss of imprinted SNPs that could be evaluated. 
This further underscores the benefits and more general applicability of the introduced 
methodology, which solely focusses on RNA-seq data. Also, this may explain why 
novel imprinted loci were found in our analysis, compared to methods where 
genotyping data are used to identify heterozygous samples prior to detecting 
imbalanced allelic expression in the latter, e.g. Baran et al.189 Some methodological 
improvements could however further increase sensitivity and specificity. For example, 
the current method relies on Hardy-Weinberg equilibrium, but could be modified to 
take into account population substructure. Additionally, the current mixture of binomial 
distributions could be updated to a mixture of beta-binomial distributions, as the latter 
captures more natural variation in expression between alleles. Nevertheless, the 
current study (cf. Figure 14 and Supplementary Figures 1-11) clearly demonstrates 
that the proposed methodology is sufficiently robust. Another putative limitation of this 
study is the fact that tumour impurity, e.g. by infiltrating lymphocytes, may lead to the 
erroneous conclusion of LOI. This may be particularly relevant for HM13, given that 
HM13 is expressed in blood and that admixture of biallelically expressed HM13 could 
theoretically lead to both higher HM13 expression and LOI in cancer. Nevertheless, 
we have previously found imprinting of HM13 in blood (unpublished results, 
https://bit.ly/2oCR6eD), and could not find a significant correlation between infiltrating 
lymphocytes and HM13 LOI, thereby rejecting confounding due to lymphocyte 
infiltration. As a final limitation, it is important to note that no distinction between 
primary and secondary imprints is possible with our methodology. 
In conclusion, this study demonstrates that imprinting is indeed heavily deregulated 
in breast cancer, though the mechanism of its deregulation is complex. Many 
imprinted genes are downregulated in cancer, likely leading to DI without actual 
higher expression of the silenced allele. One clear exception was found, HM13, with 
LOI and upregulation in cancer samples. We were able to detect these putatively 
imprinted genes and their deregulation with a newly developed method solely based 
on RNA-seq data. The effectiveness of our novel methodology and the advantage of 
solely using RNA-seq data was hence also confirmed. 
 




RNA-seq data of 113 human healthy control and 506 diseased samples (only those 
for which a PAM50 subtype was available) of the TCGA breast invasive carcinoma 
dataset were used in this study.236 RNA-seq BAM-files were downloaded from the 
prior TCGA data portal (https://portal.gdc.cancer.gov/legacy-archive/search/f). 
Invasive ductal carcinoma, which starts in the milk ducts of the breast, and invasive 
lobular carcinoma, which originates in the lobules, were both studied.216 For all cancer 
samples, additional expression subtypes based on the PAM50 classifier were 
obtained from the UCSC cancer genome browser (8 NL, 92 BL, 228 LumA, 121 LumB 
and 57 HER2).236 In all of these samples, variants were called using Samtools 
mpileup/bcftools (v0.1.19).149 Female breast samples (92 samples) from GTEx data 
(in dbGaP under accessions phs000424.v6.p1) were used for validation.217 
Significance threshold 
Throughout the manuscript, the Benjamini-Hochberg procedure was used for false 
discovery rate estimation.237 For detection of imprinting and differential expression 
analysis, an FDR of 5% was used as significance threshold. For analyses where loss 
of power is anticipated due to non-informative homozygous samples (e.g. differential 
imprinting detection), an FDR of 10% was used. 
Genotype calling 
Genotype probabilities and corresponding nucleotide-read/sequencing error rates 
were calculated from RNA-seq data using SeqEM (v1.0)156, a fast Bayesian 
genotype-calling algorithm based on the expectation-maximisation (EM) algorithm to 
estimate the prior allele frequencies and the nucleotide-read error rate in an iterative 
way. Note that imprinting biases RNA-seq-based genotyping (i.e. less heterozygous 
samples will be detected), yet that allele frequency estimates are unbiased as both 
alleles have an equal chance to be imprinted. Genotyping with SeqEM was done 
without the HWE option, only for estimation of the number of biallelically expressing 
samples in RNA-seq data HWE was assumed (S.1.4b). 
Detection of imprinting 
Rationale: The rationale behind the proposed methodology is that biallelic expression 
yields RNA-seq data (or other similar sequencing data) that is in HWE for each locus, 
i.e. if SNPs are present for a locus, both homozygous and heterozygous subjects will 
be detected at a predictable rate (under HWE assumptions).238 However, in case of 
monoallelic expression, heterozygous samples will no longer be detected in RNA-seq 
data resulting in deviation from the HWE, which can be measured (Figure 18(a)). So 
for imprinted loci, no distinction can be made between homozygous and heterozygous 
samples. Throughout the Methods section, we assume a locus with two alleles, A and 
6 Imprinting in breast and its deregulation in breast cancer 56 
 
T (with allele frequencies PA and PT, respectively), yet this of course applies to all 
possible nucleotides. 
Note that the same is true for enrichment-based sequencing data. Indeed, monoallelic 
histone modifications, as well as monoallelic DNA methylation, lead to ChIPseq and 
MethylCap-seq data, respectively, that is no longer in HWE, e.g. 196. 
To enable screening for loci featuring imprinting, a probability mass function (PMF) 
describing the probability of observing specific coverages for each allele for a specific 
SNP locus was developed. As the probabilities depend on the underlying genotypes, 
the PMF was created as a mixture model of genotype-dependent binomial 
distributions with weights corresponding to the probabilities under Hardy-Weinberg 
Figure 18 Graphical representation of rationale of the PMF. (a) The PMF is defined as a 
mixture model of genotype-dependent binomial distributions and describes the probability of 
observing specific RNA-seq coverages for each allele for a specific SNP locus. In these 
binomial probabilities, sequencing error rates, degree of imprinting (i) as well as the specific 
genotype are taken into account. For non-imprinted loci, the PMF results in two homozygous 
peaks and one heterozygous peak. For imprinting, on the other hand, no heterozygous can 
be detected on RNA-level and this peak is hence eliminated. Heterogeneous data leads to the 
detection of partial imprinting. (b) PMF for different degrees of imprinting. In this mixture 
model, the genotype-dependent binomial distributions have weights corresponding to their 
Hardy-Weinberg theorem derived expected chances. 
(a) 
(b) 
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(Figure 18(b)).238 Sequencing error rates (median per chromosome) are here taken 
into account. Subsequently, maximum likelihood estimation was used to estimate the 
degree of imprinting (i) and a likelihood ratio test was constructed to detect significant 
imprinting. A detailed discussion of the different elements of this PMF and the 
analytical framework can be found in the following subsections. All analyses were 
performed in R (v3.3.2), scripts are available upon reasonable request.239 
Data filtering using an empirical Bayes approach: After SNP calling, for each SNP 
position samples were filtered and corrected to obtain nucleotide sequences 
containing a maximum of two alleles. Using a maximum of two alleles per locus 
ensures high-quality sequences, but was also a prerequisite for the genotype calling 
step later on (by SeqEM). As dbSNP was used for SNP calling, the dbSNP alleles 
were chosen as the two standard alleles. In case dbSNP contained three or more 
alleles for a particular SNP position, the standard alleles were chosen as the two 
dbSNP alleles with the highest mean allele frequencies for that locus over all samples. 
A quality filtering procedure was included to retain only those samples featuring one 
(homozygous) or both (heterozygous) standard alleles (= reference alleles defined by 
dbSNP for that particular SNP position). By default, samples already containing the 
two standard alleles as most frequent alleles were retained, whereas samples for 
which the allele with the highest frequency was not a standard allele were filtered out. 
However, for samples characterised by a non-standard allele as the second most 
abundant allele, an empirical Bayes approach was implemented to filter out putative 
heterozygous samples (one standard allele and one non-standard allele) yet keeping 
homozygous samples (one standard allele and sequencing errors). This procedure 
goes as follows: 
(i) • The posterior probability of obtaining a specific observation given a heterozygous 
sample was determined using a multinomial distribution: 
 𝑃(𝑑𝑎𝑡𝑎|ℎ𝑒𝑡𝑒𝑟𝑜𝑧𝑦𝑔𝑜𝑢𝑠) = 𝑀(𝑑𝑎𝑡𝑎; 𝑥1, 𝑥2, 𝑥3, 𝑥4) (1) 
With 
- 𝑥1 = 𝑥2 =  
(𝑃1+𝑃2)
2




- 𝑃1 and 𝑃2 the highest estimated allele frequencies of the sample, 𝑃3 and 𝑃4 the 
lowest estimated allele frequencies. Note that the two alleles corresponding to 
these latter two frequencies could only be obtained due to sequencing errors. 
• The probability that the sample is heterozygous is calculated as: 
 𝑃(ℎ𝑒𝑡𝑒𝑟𝑜𝑧𝑦𝑔𝑜𝑢𝑠) = 2𝑝𝑞 (2) 
with p and q the mean allele frequencies over all samples of the standard and non-
standard allele, respectively. 
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(ii) • Similar to the approach for heterozygous samples, the posterior probability of the 
obtained nucleotide sequence in case of a homozygous sample is again defined with 
a multinomial distribution: 
 𝑃(𝑑𝑎𝑡𝑎|ℎ𝑜𝑚𝑜𝑧𝑦𝑔𝑜𝑢𝑠) = 𝑀(𝑑𝑎𝑡𝑎; 𝑥1, 𝑥2, 𝑥3, 𝑥4) (3) 
With 




- 𝑃1 the highest estimated allele frequency of the sample (represents the allele 
frequency of the ‘true’, standard allele), 𝑃2, 𝑃3 and 𝑃4 the lowest estimated allele 
frequencies. Here only one allele is genuine while the other three are the result 
of sequencing errors. 
• The probability of the sample originally being homozygous is next defined as: 
 𝑃(ℎ𝑜𝑚𝑜𝑧𝑦𝑔𝑜𝑢𝑠) = 𝑝2 (4) 
as in equation (2) p again represents the mean allele frequency of the standard allele 
over all samples. 
(iii) Finally, following criterion was used to identify putative heterozygous samples: 
 𝑃(ℎ𝑒𝑡𝑒𝑟𝑜𝑧𝑦𝑔𝑜𝑡𝑒|𝑑𝑎𝑡𝑎) ≥ 𝑃(ℎ𝑜𝑚𝑜𝑧𝑦𝑔𝑜𝑡𝑒|𝑑𝑎𝑡𝑎) (5) 
Using Bayes’ theorem and knowing that 𝑃(𝑑𝑎𝑡𝑎) is equal for both 
𝑃(ℎ𝑒𝑡𝑒𝑟𝑜𝑧𝑦𝑔𝑜𝑡𝑒|𝑑𝑎𝑡𝑎) and 𝑃(ℎ𝑜𝑚𝑜𝑧𝑦𝑔𝑜𝑡𝑒|𝑑𝑎𝑡𝑎), this can also be written as: 
𝑃(𝑑𝑎𝑡𝑎|ℎ𝑒𝑡𝑒𝑟𝑜𝑧𝑦𝑔𝑜𝑢𝑠) ∗ 𝑃(ℎ𝑒𝑡𝑒𝑟𝑜𝑧𝑦𝑔𝑜𝑢𝑠)
≥ 𝑃(𝑑𝑎𝑡𝑎|ℎ𝑜𝑚𝑜𝑧𝑦𝑔𝑜𝑢𝑠) ∗ 𝑃(ℎ𝑜𝑚𝑜𝑧𝑦𝑔𝑜𝑢𝑠)  
(6) 
Next, identified putative heterozygous samples are removed from the dataset for the 
locus under study. 
Genotype calling and filtering: Calculation of genotype probabilities and 
corresponding nucleotide-read/sequencing error rate was done using SeqEM (v1.0), 
a fast Bayesian genotype-calling algorithm based on the expectation-maximisation 
(EM) algorithm to estimate the prior genotype frequencies and the nucleotide-read 
error rate in an iterative way. 
As model-based approaches (such as SeqEM) are prone to false positives due to 
pre-processing induced artefacts (e.g. alignment errors), only reliable loci were used 
for further analysis. The standard approach of filtering is based on HWE and not 
applicable here, leading to the necessity to use a combination of alternative criteria. 
Therefore, after obtaining estimates of both the allele frequencies and sequencing 
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error rate, the SNP loci were subjected to extra filtering steps: (i) minor allele 
frequency > 0.1, (ii) median coverage > 4, (iii) estimated sequencing error rate ≤ 0.035 
and finally, (iv) the number of samples covering the specific locus had to be at least 
75. Loci which successfully passed these previous filters were subsequently tested 
with two final quality checks based on ‘goodness-of -fit’ criteria. 
Additional data filtering using a goodness-of-fit test: SNPs that already passed 
the basic filtering steps were subjected to two final checks based on two methods 
assessing their goodness-of-fit in the model, independent of the presence of (partial) 
imprinting. This approach is particularly aimed to remove loci exhibiting good 
sequencing characteristics, yet with properties that indicate deviation from the 
standard genetic models. This may be due to technical (e.g. mismapping) but also 
biological (e.g. presence of SNP dependent expression differences) reasons. 
As a first control, the χ² test is used for goodness-of-fit. Though the exact distribution 
depends on the level of imprinting, this is not the case for the fractions of samples 
with respectively a higher reference allele (expected 𝑃𝐴² + 𝑃𝐴𝑃𝑇) resp. variant allele 
count (expected 𝑃𝑇² + 𝑃𝐴𝑃𝑇). Upon comparison of the observed and expected sample 
counts using the χ² test, only loci with a resulting p-value > 0.05 were retained. 
Next to a χ² test, likelihoods are also a benchmark for goodness-of-fit. As likelihoods 
strongly depend on coverage (e.g. impact binomial coefficient), the likelihood of each 
individual measurement was multiplied by its coverage+1. The mean of these 
corrected log-likelihoods was next used as measure for the goodness-of-fit: loci with 
a mean ≤ 1.2 were filtered out. Though empirical in nature, this filter setting largely 
removed remaining loci featured by aberrant allelic distributions. 
After prior filtering of the data, the remaining SNPs were screened for imprinted 
regions by a likelihood ratio test (LRT). 
PMF calculation: First, the probability mass function describing the probability of 
observing specific coverages for each allele for a specific SNP locus was established. 
As the probabilities depend on the underlying genotypes, we established the PMF as 
a mixture model of genotype-dependent binomial distributions with weights given by 
the expected probabilities under Hardy-Weinberg equilibrium (Figure 18(a)). 
Importantly, in these binomial probabilities, sequencing error rates, degree of 
imprinting as well as the specific genotypes are taken into account. Ultimately this 
leads to the following PMF for e.g. a locus with two alleles A and T (equivalent for any 
other combination of two alleles) (Figure 18(b)): 
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𝑃𝑀𝐹(𝑥, 𝑖)  =  𝑃𝐴
2𝐵(𝑥; 𝑝𝐴 = 1 − 𝑆𝐸, 𝑝𝑇 = 𝑆𝐸) +  𝑃𝑇
2𝐵(𝑥; 𝑝𝐴 = 𝑆𝐸, 𝑝𝑇 = 1 − 𝑆𝐸) 
+𝑃𝐴𝑃𝑇𝐵 (𝑥; 𝑝𝐴 =  
0.5 − 𝑖 2⁄
1 − 𝑖 2⁄
(1 − 𝑆𝐸) +
0.5
1 − 𝑖 2⁄
𝑆𝐸, 𝑝𝑇 =
0.5
1 − 𝑖 2⁄
(1 − 𝑆𝐸) +  
0.5 − 𝑖 2⁄
1 − 𝑖 2⁄
𝑆𝐸) 
+𝑃𝐴𝑃𝑇𝐵 (𝑥; 𝑝𝐴 =  
0.5
1 − 𝑖 2⁄
(1 − 𝑆𝐸) + 
0.5 − 𝑖 2⁄
1 − 𝑖 2⁄
𝑆𝐸, 𝑝𝑇 =
0.5 − 𝑖 2⁄
1 − 𝑖 2⁄
(1 − 𝑆𝐸) +
0.5




- x the coverages for alleles A and T, i.e. x = (nA, nT) 
- PA and PT the estimated population allele frequencies for a specific locus over 
all samples (obtained by SeqEM) 
- SE the estimated sequencing error rate (median per chromosome, obtained by 
SeqEM) 
- i the degree of imprinting (varying from not (i = 0) to fully (i = 1) imprinted) 
- B(x; pA, pT) the binomial probability for x given the probabilities for each allele, 
i.e. pA and pT, which depend on the specific genotype, SE and imprinting factor i 
One already familiar with binomial distributions will notice that this is a somewhat 
alternative representation than typically used. However, it is simple to see that here, 
the chance of ‘success’ is represented by pA (indeed, pA + pT = 1) whereas the ‘total 
number of trials’ equals nA + nT. 
Note that this PMF can be easily extended towards four alleles by considering a 
mixture of multinomial instead of binomial distributions. However, for simplicity - and 
as SeqEM can only handle two alleles per locus - we considered only two alleles. 
From a practical point of view, the binomial coefficient is identical for each binomial 
distribution (within a sample, not between samples) and expressed as: 




As ideally only a single allele is observed for homozygous samples, potential 
imprinting cannot be deduced from the allelic coverages. Here, the binomial 
probability will depend only on the SE - which is obtained by SeqEM. Because this 
error rate is assumed to be equal for all loci but can be ill-estimated when imprinting 
is present, the median SE over all loci is used. For homozygote AA, for example, the 
chance of observing allele A (= pA) is 1-SE, while the chance of observing allele T (= 
pT) is equal to SE, as T can only be present in the data due to a sequencing error. 
P(nA, nT) then becomes: 
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𝑃(𝑛𝐴, 𝑛𝑇) = 𝐵(𝑥; 𝑝𝐴 = 1 − 𝑆𝐸, 𝑝𝑇 = 𝑆𝐸)  
= 𝑏 𝑝𝐴
𝑛𝐴𝑝𝑇
𝑛𝑇   
= 𝑏 (1 − 𝑆𝐸)𝑛𝐴  𝑆𝐸𝑛𝑇 
(9) 
In the PMF this value of P(nA, nT) is multiplied by the probability of the sample being 
homozygous AA. Assuming Hardy-Weinberg equilibrium (HWE), this equals the 
respective population allele frequency squared, i.e. PA². 
For heterozygotes, for example AT, potential imprinting has to be taken into account. 
This is done by including an imprinting factor i that can vary between 0 (no imprinting) 
and 1 (fully imprinted) and is estimated using maximum likelihood estimation (MLE, 
see below). Without imprinting, in theory both alleles A and T will be expressed to a 
similar extent so that pA and pT can be set to 0.5. However, when imprinting is present, 
the probability of observing the imprinted allele diminishes with a factor 𝑖 2⁄ . As the 
probabilities for both alleles need to sum to one, both probabilities are normalised by 
dividing them by a factor 1 − 𝑖 2⁄  (= 0.5 + 0.5 − 𝑖 2⁄ ). Also sequencing error rates 
have to be taken into account, as a fraction SE of the normalised probability of one 
allele will be observed as the other allele and vice versa. Thus, when allele A is 
imprinted, the probability of observing allele A (= pA) equals: 
 
0.5 − 𝑖 2⁄
1 − 𝑖 2⁄
(1 − 𝑆𝐸) +
0.5
1 − 𝑖 2⁄
𝑆𝐸 (10) 
While for the probability of pT this becomes: 
 
0.5
1 − 𝑖 2⁄
(1 − 𝑆𝐸) +
0.5 − 𝑖 2⁄
1 − 𝑖 2⁄
𝑆𝐸 (11) 
Leading to the following formula: 
𝑃(𝑛𝐴, 𝑛𝑇|𝐴 𝑖𝑚𝑝𝑟𝑖𝑛𝑡𝑒𝑑) = 
𝑏 (
0.5 − 𝑖 2⁄
1 − 𝑖 2⁄
(1 − 𝑆𝐸) +
0.5





1 − 𝑖 2⁄
(1 − 𝑆𝐸) +
0.5 − 𝑖 2⁄






However, the possibility of imprinting of allele T also has to be taken into account: 
𝑃(𝑛𝐴, 𝑛𝑇|𝑇 𝑖𝑚𝑝𝑟𝑖𝑛𝑡𝑒𝑑) = 
𝑏 (
0.5
1 − 𝑖 2⁄
(1 − 𝑆𝐸) +
0.5 − 𝑖 2⁄




0.5 − 𝑖 2⁄
1 − 𝑖 2⁄
(1 − 𝑆𝐸) +
0.5






Likewise as for homozygotes, the binomial probability for the heterozygous fraction 
has to be multiplied by the genotype frequency 2PAPB. As from the underlying biology 
both alleles can be assumed to have an equal chance of imprinting (= 50%), this 
ultimately leads to the mixture PMF denoted in equation (7). 
6 Imprinting in breast and its deregulation in breast cancer 62 
 
Imprinting factor: In a next step, the degree of imprinting (or imprinting factor) i for 
a specific SNP locus is estimated using MLE. The likelihoods are calculated as the 
sum of the logarithmic values of the PMF-derived probabilities (Equation (7)) over all 
samples. In summary, for each locus, i is varied from 0 to 1 (step size = 0.01), 
retaining the value of i corresponding to the highest likelihood (î =
 𝐴𝑟𝑔𝑀𝑎𝑥𝑖 ∏ 𝑃𝑀𝐹(𝑥𝑎 , 𝑖)
𝑛
𝑎=1 =  𝐴𝑟𝑔𝑀𝑎𝑥𝑖 ∑ log (𝑃𝑀𝐹(𝑥𝑎 , 𝑖))
𝑛
𝑎=1 ). Hence, for every SNP 
locus a degree of imprinting is obtained. 
Likelihood ratio test: Finally, in order to screen for imprinted loci a likelihood ratio 
test is performed. The respective null and alternative hypotheses for a locus are: 
𝐻0: the locus is not imprinted 
𝐻1: the locus is imprinted 
With the previous definitions this translates into: 
𝐻0: 𝑖 = 0 
𝐻1: 𝑖 > 0 
Thus, the null hypothesis of no imprinting (i = 0) is compared to the alternative 
hypothesis that the locus is imprinted (i > 0). Practically, in a first step, the PMF 
(Equation (7)) for the locus under study is calculated with i equal to 0. Next, the PMF 
is determined with the estimated value of i as explained in the previous section. The 
obtained PMFs are then used in a LRT: 







 =  
𝑃𝑀𝐹(𝑥1, 𝑖 = 0)𝑃𝑀𝐹(𝑥2, 𝑖 = 0) … 𝑃𝑀𝐹(𝑥𝑛 , 𝑖 = 0)
𝑃𝑀𝐹(𝑥1, 𝑖 = î)𝑃𝑀𝐹(𝑥2, 𝑖 = î) … 𝑃𝑀𝐹(𝑥𝑛, 𝑖 = î)
 
 =  
∏ 𝑃𝑀𝐹(𝑥𝑎 , 𝑖 = 0)
𝑛
𝑎=1





As the null hypothesis is a special case of the alternative hypothesis, the test statistic 
for nested models −2ln(Λ) can be used. This test statistic is χ² distributed and 𝐻0 will 
be rejected if its value is greater than 𝜒𝛼
2. However, because we are testing at the 
border of a constrained parameter space (i equal to 0), a mixture of χ² distributions is 
used: under the null hypothesis, the test statistic is distributed as an equal mixture of 
two χ² distributions, namely 𝜒0
2 and 𝜒1
2 with 0 and 1 degrees of freedom, 
respectively.240 Finally, a locus is called imprinted if the corresponding FDR-corrected 
p-value was smaller than the nominal FDR level of 0.05 (Benjamini-Hochberg 
correction for multiple testing). 
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Median imprinting 
A robust measure for degree of imprinting, called median imprinting, was developed 
to enable the identification of a robust set of imprinted loci from the significant set 
identified higher. For each SNP locus, sample-specific ratios (= Ri,s for SNP i and 
sample s) are calculated as the lowest allele count over the highest allele count, 
yielding values between 0 (only one allele expressed) and 1 (both alleles expressed 
to an equal extent). Next, the values of these ratios are sorted over all samples and 
the value of the ‘median putatively heterozygous sample (sm)’ is calculated. This 
sample corresponds with rank round(samplesize*(1−PA−PT−PAPT)) = 
round(samplesize*(PAPT)). The median imprinting value is then calculated as 
2*(0.5−Ri,sm). In a last step, SNP positions with a median imprinting level ≥ 0.8 were 
considered as robust (TCGA). For GTEx (validation), we used a median imprinting 
level of 0.4 as cut-off, given that typical artefacts had already been eliminated. 
Detection of differential imprinting 
Next to the detection of imprinted loci, we also examined possible deregulation of 
imprinting in cancer. This was done by testing for different relative expression of both 
alleles, here termed DI. When associated with absolute re-expression of the originally 
silenced allele, this is coined LOI. Briefly, ratios of the lowest allele count over the 
highest allele count (i.e. Ri,s) are calculated for each single SNP, over all samples. 
These ratios are sorted per SNP in an ascending order separately for control and 
tumour samples. As the lowest ratios are expected for homozygous samples (ratios 
theoretically equal to 0, yet slightly higher due to the presence of sequencing errors), 
one can consider samples with the highest 2PAPT ratios as putative heterozygous 
samples for that specific locus. In practice: samples with rank higher than 
samplesize*(PA2+PT2) are considered as the heterozygous samples for a specific 
locus. After determining the mean ratio of these heterozygotes (Ri,stumour and Ri,control), 
parameter Ri,diff is calculated as the difference between these values, i.e. Ri,diff = 
Ri,stumour - Ri,scontrol. Upon random assignment of the tumour and control labels to the 
present samples by permutation, 10,000 random values of Ri,diff are simulated to 
generate a null distribution. Loci with an FDR-adjusted p-value smaller than the 
nominal 10% FDR level were concluded to be differentially imprinted between control 
and tumour samples. We were solely interested in DI in cancer and hence we 
exclusively tested for higher ratios in tumour compared to control data. The different 
breast cancer subtypes were also tested for DI (though the Normal-like subtype was 
not studied here, as only 8 samples were available) in which the p-value was 
corrected over all samples. Here, it should be noted that considering the ratios allows 
for detecting differences independent of alterations in expression levels of imprinted 
genes, which are also prominent in breast cancer.241 
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Subsequently, for loci featured by DI, the latter was linked to survival. A continuous 
DI variable, which was defined as the allelic ratio (allele count least expressed 
allele/allele count most expressed allele), was associated with survival and adjusted 
for age with a Cox proportional hazard model. To anticipate assumption violations, a 
null distribution was constructed by 10,000 permutations by randomly shuffling the 
ratios over the samples. Loci with an FDR-adjusted p-value ≤ 0.1 were called 
significant. The analysis was also performed on solely the putative heterozygous 
samples, meaning that the 2PAPT fraction of samples with the highest allelic ratios 
were used (see higher). 
Differential expression of the silenced (lowest expressed) allele was analysed as well 
to assess whether expression of the normally silenced allele was higher in tumour 
data. Here, counts per million (CPM) reads of the least expressed allele count were 
calculated as described in the next paragraph. The same permutation test as 
mentioned higher yet based on the logCPM-values rather than ratios, was performed 
on the SNPs showing significant DI. 
Detection of differential expression 
DE analysis was performed to further evaluate deregulation of imprinted genes in 
cancer. EdgeR normalisation factors were calculated from the breast cancer RNA-
seq expression count file downloaded from firebrowse.org.242 Afterwards, CPM-
values for the imprinted SNPs were computed with these normalisation factors and 
library sizes (available for 100 control samples and 469 tumour samples: 87 BL, 54 
HER2, 210 LumA, 111 LumB and 7 NL). EdgeR-based DE analysis was developed 
to increase power, at the cost of several assumptions. As the sample size and thus 
power is sufficiently high in the case at hand, we opted to use more robust standard 
non-parametric methods. Differential expression in control versus tumour samples 
was analysed with a Wilcoxon Rank Sum test for detected SNPs as well as the 
corresponding genes (sum of the CPM-values of the matching SNPs were used). To 
test for DE in the different breast cancer subtypes, a Kruskal-Wallis test and Dunn’s 
post-hoc test were performed on the CPM-values of the varying subtypes. 
To study transcript-specific effects in HM13, logCPM-values of exonic expression 
data (of 14 exons, downloaded from firebrowse.org242) were normalised and analysed 
for DE between control and tumour samples as described in the previous paragraph. 
Exon data were available for 468 tumour samples (85 BL, 54 HER2, 211 LumA, 111 
LumA and 7 NL) and 100 control samples. Exonic RPKM values, available from 
firebrowse.org as well, were used for additional verification and consistently yielded 
the same conclusions. 
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CNV and methylation analyses 
Infinium HumanMethylation450k data were downloaded from firebrowse.org242 and 
CNV data from the GDC portal of TCGA. Infinium methylation data (450k) could be 
retrieved for 84 control and 207 tumour samples (35 BL, 14 HER2, 107 LumA, 46 
LumB and 5 NL), whereas CNV data were available for 92 control and 506 tumour 
samples. A Wilcoxon Rank Sum test was performed to screen for significant 
differential methylation in probes located in imprinted genes. In the CNV data, gains 
and losses were called as segment mean >0.2 and <-0.2, cf. 243. A linear model was 
constructed to model expression (gene-based logCPM counts) as a function of CNV 
(factor), adjusting for breast cancer subtype. 
For HM13, also the link between CNV and LOI was of interest. A χ² test comparing 
LOI/not LOI (based on genotype calling with SeqEM on RNA-seq data, see S.1.4c 
and Supplementary Table 5) with CNV was performed for all imprinted HM13 SNPs. 
Subsequently, methylation of 10 probes (listed in Joshi et al., with additionally 
cg18471488 as identified using MEXPRESS in the breast cancer population219,220) 
and exonic expression data (See Methods, section) were correlated to identify which 
methylated locus might control expression. Both expression and methylation data 
were available for only 72 control and 192 tumour samples. A Spearman correlation 
test was performed for detecting correlation between the β-values of the 10 probes 
and i) logCPM-values of the whole HM13 gene (gene counts obtained from 
firebrowse.org242 and normalised with EdgeR) and ii) logCPM-values of the 3rd exon 
of transcript 4 (as most of the imprinted SNPs were located in the neighbourhood of 
this exon). Again, RPKM values were successfully used for verification. 
Quality control 
To additionally verify the imprinting and deregulation results, corresponding WES 
data (BAM files) were downloaded from TCGA to obtain the underlying genotypes. 
However, only for 93 control samples and 464 tumour samples WES data were 
available. Concordance between WES and RNA genotypes was examined to validate 
the quality of genotyping with RNA-seq data (S.1.3.c). 
Data Availability 
The authors declare that all data supporting the findings of this study are available 
within the article and its Supplementary Information or from the corresponding author 
on reasonable request. Access to controlled GTEx (phs000424) and TCGA 
(phs000178) data was obtained through the database of Genotypes and Phenotypes 
(dbGaP). The TCGA data were accessed through the Genomic Data Commons portal 
(https://portal.gdc.cancer.gov/ and https://portal.gdc.cancer.gov/legacy-
archive/search/f) and Broad Institute’s Firebrowse data portal (http://firebrowse.org/). 
GTEx data were obtained from the dbGaP database directly 
(https://dbgap.ncbi.nlm.nih.gov/). 
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7  Modeller of Allelic Gene 
Expression (MAGE) unlocks the 
RNA-seq-based study of allele-
specific expression mechanisms 
in health and disease 
7.1. Abstract 
Here, MAGE (Modeller of Allelic Gene Expression) is presented, which unlocks the 
study of different allele-specific expression effects through population-level modelling 
of solely RNA-seq data. In a kidney study, MAGE improved RNA-based genotyping 
for eQTL analysis, and led to the detection of 42 putatively imprinted loci in healthy 
kidney, of which seven featured imprinting deregulation in clear cell renal cell 
carcinoma. Moreover, MAGE demonstrated massive induced allelic imbalance in 
carcinoma, including consistent 3p loss and supporting tumour suppressor roles for 
e.g. SFRP1, SERPINA5 and WT1. Moreover, our results suggest that metabolic 
reprogramming in carcinoma is achieved through rewiring of transmembrane 
transport. 
Keywords: Imprinting, Warburg effect, KIRC, eQTL, monoallelic expression, Hardy-
Weinberg theorem, inbreeding, HM13 
7.2. Introduction 
The decreasing cost of next-generation sequencing has made RNA-seq a standard 
methodology in molecular biology. Though typically used to compare gene expression 
between conditions, obtained RNA sequences also allow for the identification of 
genetic variants, such as single nucleotide polymorphisms (SNPs).120 As a 
consequence, RNA-seq can be used to assess expression of both alleles separately 
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in heterozygous individuals.175 Though both alleles of a gene are typically expressed 
to the same extent, many genes feature allele-specific expression (ASE).244,245 For 
some genes, only the allele inherited from one specific parent is expressed, a 
phenomenon called genomic imprinting. Imprinted genes typically control growth and 
their deregulation (for example, by loss of imprinting) has been demonstrated in 
several human congenital and acquired diseases, including cancer.246 For other 
genes, ASE is associated with the underlying genotype (in cis), not the parental origin, 
i.e. cis expression quantitative trait loci (cis-eQTLs).175 Finally, abnormal ASE 
patterns are also observed in disease, due to e.g. epigenetic artefacts, (promoter) 
mutations and copy number alterations (CNA) acting on individual alleles. Importantly, 
when recurring among affected individuals and associated with gene expression 
differences, this type of induced ASE points to causal quantitative impact of the gene 
in the disease.247–250 This contrasts the concerted transcriptional response to or 
consequence of disease, where both alleles are equally affected, and complements 
other analyses (e.g. CNA and mutation analyses) aiming at the identification of fully 
(functionally) lost loci. To avoid confusion with other types of ASE, we further refer to 
this phenomenon as induced allelic imbalance (iAI). 
Although the advent of high-throughput sequencing has led to several new 
approaches for ASE detection, studying the phenomenon in a comprehensive manner 
remains far from trivial, especially for species where breeding designs to increase 
heterozygosity are practically or ethically unfeasible. Early methods used in human 
studies often applied the simple strategy to identify ASE as a deviation from the 1:1 
allelic expression ratio per heterozygous locus for each individual (e.g. by means of 
a χ² test171,247,251 or a binomial test170,179). However, these approaches are artefact-
prone as they ignore the complexity of transcriptomics data, e.g. with respect to 
alignment-related problems. In recent years, more advanced statistical methods, 
such as Bayesian approaches or generalised linear models, have been developed, 
but significant shortcomings remain. Next to RNA-seq data, DNA data (often 
phased173,177,189,252–254) obtained by sequencing99,169,180,247,248,255,256 or by SNP 
arrays172 are typically required as input, e.g. to perform identification of heterozygous 
individuals, bias correction, model construction and calibration and power 
augmentation. Large sample sizes (order of magnitude of 100) are required to obtain 
a truly genome-wide overview, as for all but the very common SNPs the number of 
heterozygous individuals will be limited. The need for genotyping data, often even for 
parent-offspring trios174,181,186–188,256–258, not only leads to very expensive studies, but 
also limits the subsequent analyses to included (e.g. SNP array) or sufficiently 
covered (sequencing-based) SNP loci, implying a major bottleneck for practical 
application. Moreover, to date, most strategies measure ASE to identify cis-regulatory 
variation effects (to improve eQTL mapping) or allelic imbalance in the general sense. 
Some exceptions specifically detect cis-eQTLs173 or imprinting186–189,258 or distinguish 
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between degree of ASE.178 Very recently two statistical models were proposed that 
discriminate between different types of ASE effects, yet relying on data from crossing 
designs in simple organisms.259,260 Currently, no methodology is capable to study the 
different effects resulting in ASE in large-scale human data. Furthermore, the 
framework of existing methods focussing on normal ASE effects does not allow to 
test for iAI. Even more, existing methods that do (solely) test for differential ASE are 
often limited to paired data.247,248 Finally, most available software tools focus on 
individual RNA-seq samples rather than populations. A few tools do evaluate results 
across individuals173,254, but often post hoc.169,172,245 In summary, to date no 
population-level methods enable simultaneous testing for different(ial) ASE effects, 
let alone that they solely rely on RNA-seq data to allow for a cost-efficient yet 
comprehensive study. 
In a breast (cancer) imprinting study, we have recently demonstrated that it is feasible 
to study allelic effects using solely large-scale RNA-seq data. This can be achieved 
through the incorporation of population genetics concepts in statistical models 
explicitly describing the allele-specific effect rather than solely relying on significant 
deviation from the 1:1 allelic expression ratio in heterozygous individuals.261 
Removing DNA sequencing from the equation not only dramatically reduces cost, but 
also increased net sensitivity as genotyping data were often incomplete. Here, we 
used the same strategy to enable an improved evaluation of other allelic effects, i.e. 
cis-eQTLs and iAI, and integrated these methods in the Modeller of Allelic Gene 
Expression (MAGE) software suite, next to an updated methodology for imprinting 
(deregulation) detection. We applied MAGE on healthy kidney tissue and clear cell 
renal cell carcinoma (KIRC) RNA-seq datasets from The Cancer Genome Atlas 
(TCGA). In the GTEx study, eQTLs and imprinted loci were detected by combining 
genotype and transcriptomics data, yet power was clearly limited for healthy kidney 
due to the small sample size (N = 45). Moreover, worldwide renal cell carcinoma is 
the sixth and tenth most common cancer in men and women, respectively, indicating 
major relevance. Nevertheless, the incidence is too low for general cost effective 
screening programs, and there is an unmet need for accurate (diagnostic) 
biomarkers.262 Using MAGE, we improved RNA-based genotyping by taking into 
account allelic expression bias, be it caused by cis-eQTLs themselves or alignment 
bias, enabling more accurate RNA-based cis-eQTL studies. Using strict filtering 
criteria, we identified 105 imprinted SNPs in 42 genes, of which seven featured 
differential imprinting (DI, e.g. ZDBF2 and MEST) in KIRC. The latter included one 
gene, HM13, showing canonical loss of imprinting, i.e. expression upregulation 
associated with re-expression of the silenced allele. Next to demonstrating the 
anticipated impact of consistent 3p loss and supporting tumour suppressor functions 
for e.g. SFRP1, SERPINA5 and WT1 in KIRC, iAI results were particularly enriched 
for membrane transporter proteins. These results suggest that rewiring of metabolite 
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transport by monoallelic silencing may be an important mediator of the metabolic 
reprogramming (Warburg effect) observed in KIRC. 
7.3. Results 
First we introduce the basic rationale behind MAGE and the kidney (cancer) case 
study population, upon which we further elaborate on the application of MAGE to 
study allele-specific effects in healthy kidney, as well as in KIRC. 
7.3.1. MAGE rationale and kidney (cancer) case study population 
MAGE allows for the population-level statistical modelling of different ASE effects per 
SNP. More specifically, we implemented distinct mixture models to improve RNA-
based genotyping, enabling more accurate eQTL detection, and to identify loci 
featuring (putative) imprinting. Additionally, a logistic regression-based strategy has 
been implemented to compare allele-specific expression between cases and controls, 
which is useful to identify aberrations of imprinting as well as induced allelic imbalance 
(iAI) in disease. In the subsequent paragraphs we further elaborate on the rationale 
behind each type of (aberrant) ASE detection. As we illustrate the latter by real-life 
examples (Figure 19), we first introduce the case study. For details of the 
implementation, including filtering strategies, we refer to the Methods section. 
7.3.1.1. Case study 
As case study, we applied MAGE on healthy kidney and KIRC RNA-seq data from 
TCGA. As healthy kidney samples (N = 128), we combined KIRC controls (N = 72) 
with those from kidney renal papillary cell carcinoma (N = 32) and chromophobe renal 
cell carcinoma (N = 24). All kidney controls were combined for detection of imprinting 
and variant bias. For the study of differential imprinting and induced allelic imbalance, 
solely KIRC controls were used. Given the aim to identify causal relations rather than 
consequences, we initially focussed on stage 1 KIRC samples (N = 265) for both iAI 
and DI analyses, though also all KIRC samples (N = 538) were considered. 
7.3.1.2. A population-based allele-specific mixture model for a non-ASE 
locus 
MAGE evaluates individual SNPs in RNA-seq data of a large number of samples. For 
a specific SNP with two alleles, the fraction of reads covering the reference allele 
(over all reads covering the SNP) can be calculated per sample. For the SNP under 
study, these fractions can be plotted for all samples combined by means of a 
histogram, which we will further refer to as an allele frequency plot. Figure 19(a) 
depicts such an allele frequency plot for a SNP not featured by ASE effects. On the 
far right of the plot (near 100% reference allele), individuals homozygous for the 
reference allele of the SNP are depicted, whereas homozygous individuals for the 
alternative allele can be found on the far left side. Note that the allele frequencies for 
these homozygous samples often slightly differ from 0 or 100% due to sequencing 
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errors. Heterozygous samples are located near the middle of the plot (50%), where 
reference and alternative allele are expressed to the same extent, yet variation is 
expected due to sampling effects. At the population level, these data can be modelled 
as a mixture of three binomial distributions, with the binomial success probability 
equal to 50% (heterozygous peak) or relating to the sequencing error rate 
(homozygous peaks). 
Figure 19 Overview of the different types of allele-specific expression (ASE). Three types of 
ASE are studied in healthy tissue and are identified with different models. (a) Allele frequency 
plot of a non-ASE locus (rs10071, APPL2). In RNA-seq data, non-ASE SNPs are featured by 
homozygous and heterozygous samples, which are observed as two homozygous peaks near 
0 and 100% reference allele and one heterozygous peak in the middle. For the homozygous 
peaks, typically less than 100% of one allele is observed due to sequencing errors. For non-
ASE heterozygous samples, each allele is expressed to the same extent, though sampling 
effects are present, cf. the middle peak. (b) For cis-eQTLs, but also due to alignment bias, 
one allele is expressed to a higher extent (called variant bias; rs1781, SNX19). The same 
three peaks are present on the allele frequency plot, yet the heterozygous peak is shifted 
towards one of the alleles (the reference allele in case of alignment bias). (c) Imprinting results 
in monoallelic expression and hence no heterozygotes are observed in expression data 
(rs3194464, MEG3). The heterozygous peak is therefore eliminated on the (RNA-seq-based) 
allele frequency plot and solely two homozygous peaks are observed. (d) For healthy non-
ASE loci, ASE in diseased tissue can be observed as a significant elimination of heterozygous 
samples compared to healthy controls (rs11870209, CA10). (e) Differential imprinting results 
in biallelic expression in diseased tissue compared to healthy tissue, observed as an 
increased number of heterozygous samples on the allele frequency plot (rs8109631, 
ZNF331). Loci detected as significantly imprinted according to (c) in control data can be 
analysed for differential imprinting in tumour data. The observed data is shown in red, while 
the fitted model is shown in blue. Note that detection of (non-)ASE loci in healthy tissue is 
done by fitting a model, while deregulation in diseased tissue is tested for by comparing allelic 
fractions in diseased data to healthy, control data (and no model is fitted here). 
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In a population, the frequencies of each genotype for a SNP are not identical, which 
should be reflected in the weights of the corresponding binomial distributions in the 
mixture distribution. The weight per genotype exactly corresponds to the genotype 
frequency, which can be successfully estimated from the allele frequencies by means 
of the Hardy-Weinberg equilibrium (HWE), as we have demonstrated before.196,261 
More specifically, assuming random mating, reference and alternative allele 
frequencies of respectively p and q (with p + q = 1) give rise to genotype frequencies 
(and therefore mixture weights) of respectively p² (homozygous reference), 2pq 
(heterozygous) and q² (homozygous alternative), with p² + 2pq + q² = 1. Violation of 
the random mating assumption, particularly due to inbreeding, leads to deviation from 
Hardy-Weinberg-based estimates, but can be adjusted for by estimating the degree 
of inbreeding. The inbreeding coefficient can be considered a hyperparameter (as it 
is the same for all SNPs under study) and be inferred by considering the median 
deviation from HWE over all SNPs (see Methods section). For normal SNPs, the allele 
frequencies themselves can easily be obtained by applying empirical Bayes-based 
genotyping tools on the RNA-seq data, e.g. SeqEM.156 As a consequence, for SNPs 
not exhibiting ASE effects, there is no need to estimate additional SNP-specific 
parameters. 
7.3.1.3. Variant bias-aware genotyping 
In theory, eQTL analysis can be performed using solely RNA-seq data, by RNA-based 
genotyping. However, linkage of the SNP under study with a cis-eQTL may lead to 
higher expression of a single allele, resulting in a shift of the heterozygous peak away 
from the middle, i.e. towards a homozygous one (Figure 19(b)). Moreover, alignment 
bias will cause a comparable shift, making heterozygous samples more similar to 
homozygous reference allele samples, potentially leading to incorrect genotypes and 
bias in eQTL studies. Here we call this shift the variant bias, to explicitly denote the 
fact that the bias relates to the SNP variant present, thereby contrasting imprinting 
and random monoallelic expression, which by definition do not depend on a specific 
SNP variant. 
We have therefore implemented a robust expectation-maximisation (EM) algorithm 
that iteratively estimates the heterozygous peak shift as a function of the difference 
in expression between both SNP variants over all samples, while simultaneously 
updating the allele and genotype frequency estimates by means of an empirical 
Bayes approach (see Methods section for details). Note that this approach also allows 
to genotype low coverage sample-locus combinations, which is particularly relevant 
for eQTL studies. Next to calling the most likely genotype, also the expected number 
of reference alleles per genotype is calculated (i.e. typically non-integer value), which 
provides a better estimate for correlation analyses by eQTL software. A likelihood 
ratio test (LRT) was implemented to evaluate whether the estimated shift significantly 
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deviates from 0. Finally, we also evaluate the goodness-of-fit of the data to the model, 
which reflects the robustness of the obtained genotypes. 
7.3.1.4. Detection of imprinting 
As elaborated before, the rationale of imprinting detection is that in RNA-seq data, 
imprinted loci largely deviate from HWE.196,261 Indeed, for monoallelically expressed 
loci, only a single allele is expressed in a parent-of-origin-specific fashion. Hence, at 
the RNA level, virtually no heterozygous samples can be observed. In practice, similar 
to the models higher and cf. earlier 261, the RNA-seq data per SNP is modelled as a 
weighted mixture of binomial distributions, yet with two binomial components for the 
heterozygous fraction. Contrary to the mixture model for possible variant bias, a 
different model with two binomial distributions representing the heterozygous fraction 
is used for imprinting detection. These two distributions reflect the fact that for 
heterozygous samples at imprinted loci, the expressed allele solely depends on the 
parental origin. As each allele is assumed to have equal chance to be paternally 
respectively maternally inherited, the weights of both peaks are equal (pq, in the 
current version also adjusted for inbreeding). When imprinting is absent, both 
heterozygous peaks converge, leading to a model that is mathematically equivalent 
to the one for a non-ASE SNP. When imprinting is present, both heterozygous peaks 
symmetrically shift away from the 50% reference allele fraction, until they fully 
resemble homozygous samples in case of 100% imprinting (Figure 19(c)). Also here, 
a LRT is used to assess whether the estimated shift (i.e. degree of imprinting) 
significantly differs from 0. Note that the presence of imprinting will lead to incorrect 
RNA-based genotyping, but not to biased allele frequencies. Indeed, the chance to 
incorrectly label a heterozygous sample as homozygous for the reference allele due 
to imprinting, equals the chance to incorrectly label it as homozygous for the 
alternative allele. 
7.3.1.5. Induced allelic imbalance and aberrant imprinting 
We hypothesise that loci featuring recurrent induced allelic imbalance (iAI) are more 
likely to be causally involved in disease. This contrasts a mere focus on differential 
expression (DE), where differences are often the consequence of the disease, for 
example through activated or silenced transcription factors. 
To identify iAI for a given SNP, we assume equal sequencing error rates and 
heterozygous fractions in cases and controls, but also that the corresponding 
genotype is itself not associated with disease susceptibility (i.e. the chance of an allele 
being affected is independent of the allele itself). For each sample, the coverage of 
both variants is determined, and the lowest coverage is considered as the number of 
successes, the highest coverage the number of failures (thus independent of the 
actual variant). Subsequently, logistic regression can be used to compare the 
numbers of failures and successes between cases and controls. Given the 
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assumptions, an overall lower success rate in cases can be attributed to an increased 
discrepancy in expression between both alleles, i.e. iAI (Figure 19(d)). 
Note that clonal expansion of a tumour cell expressing a single allele due to random 
monoallelic expression may also lead to (more pronounced) allelic disequilibrium in 
bulk RNA-seq data of cancer tissue. However, clonal expansion as such will not lead 
to DE between cases and controls. As iAI of interest should be accompanied by either 
silencing (due to differential knock down of both alleles) or activation (differential 
activation of both alleles), we use DE as extra post hoc criterion to infer iAI of interest. 
Similarly, we also evaluate the presence of normal HWE profiles in controls, as 
discussed in the Methods section. 
Finally, a similar strategy can be used to identify differential imprinting: whereas 
imprinting leads to coverages approximating zero for the silenced allele, aberrant 
imprinting is associated with the latter’s re-expression, detectable as higher success 
rates in the logistic regression approach introduced higher (Figure 19(e)). Given that 
we reserve the term loss of imprinting for the phenomenon where the silenced allele 
is re-expressed in absolute terms, and not solely featured by relative increase (which 
may be due to silencing of the active allele), also here filtering on differential 
expression (i.e. overexpression in cases) is warranted.261 Note that the current 
implementation improves our earlier strategy that merely evaluated the ratios of least 
over most expressed allele per SNP, which did not take into account variable 
sequencing depth.261 
7.3.2. Imprinting and cis-eQTLs in healthy kidney tissue 
7.3.2.1. Variant bias-aware genotyping  
MAGE genotyping results for 128 renal controls samples were compared with those 
from SeqEM, which uses a similar expectation-maximisation approach, yet without 
taking into account variant bias. Using the locus-specific coverage cut-offs outlined in 
the Methods section, both methods estimated genotypes for 53,779 SNPs. MAGE 
detected 1,170 SNPs (2%) featuring significant variant bias (p-value ≤ 0.05 and 
showing a good model fit; Figure 20 and Supplementary Data 7), of which 78% 
showed a shift towards the reference allele. This fraction is far larger than anticipated 
for SNPs linked to cis-eQTLs (anticipated prior chance of 50%, binomial test p-value 
< 2.2E-16), indicating major impact of alignment bias. 
Matching TCGA Affymetrix Human SNP array 6.0 data (906,600 SNPs assayed) were 
used as gold standard data, leading to a total of 1,024,137 MAGE and SeqEM 
sample-SNP combinations for evaluation (for 126 samples with Affymetrix data and 
8,350 overlapping SNPs). MAGE featured a genotyping error of 4.38%, which was 
slightly lower than the SeqEM genotyping error rate (4.65%, 5.8% relative difference). 
However, when only considering loci with a good MAGE model fit (GOF > 1, 3,750 
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overlapping SNPs), sequencing error rates of 1.47% and 1.57% for MAGE and 
SeqEM, respectively, were obtained. Additionally, when considering only those 
genotype calls with a MAGE or SeqEM estimated posterior likelihood higher than 99% 
(97.7% and 97.9% of the sample-locus combinations remaining, respectively), MAGE 
and SeqEM demonstrated genotyping error rates of 1.17% respectively 1.30% (i.e. 
10% relative difference). Finally, we specifically considered those SNPs with evidence 
for a significant variant bias (cf. higher, non-adjusted p-value < 0.05), i.e. which are 
more prone to biased eQTL study conclusions. For the 123 loci also covered by 
Affymetrix, MAGE obtained a genotyping error rate of 1.86%, whereas this was 2.70% 
for SeqEM (31% relative difference) (Figure 20), which further dropped to 1.11% 
respectively 1.85% when only considering genotypes with a posterior likelihood 
higher than 99% (40% relative difference). 
7.3.2.2. Detection of imprinting 
Using MAGE, 129 SNPs corresponding with 48 genes were detected as putatively 
imprinted in healthy kidney tissue (Table 3, Figure 21 and Supplementary Data 8). 
Allele frequency plots of all significantly imprinted SNPs are shown in Supplementary 
Figures 29-37. In this set of putatively imprinted SNPs, 24 SNPs with likely random 
monoallelic expression (located in the HLA gene cluster), were detected and were 
denoted as “likely random monoallelically expressed”.189 105 SNPs remained (of 
which four located in intergenic regions), corresponding to 42 putatively imprinted 
genes. These include 18 known imprinted genes such as H19 (Figure 21(c)) and 
MEG3 (Figure 19(c)), while also a few new genes were identified as putatively 
imprinted, such as PCBD2 and MTDHP3. 
Non-detected SNPs in the identified putatively imprinted genes were further analysed 
to evaluate their imprinting status. If the other SNPs of a gene appeared non-
imprinted rather than featured by low quality or transcript-specific imprinting, we 
denoted those genes as “candidate imprinted”. BCR and MTRNR2L1 were identified 
Figure 20 Allele frequency plots of SNPs with alignment bias or possible cis-eQTLs in healthy 
kidney tissue, observed as a shift of the heterozygous peak away from a fraction of 0.5. Two 
examples where MAGE outperforms SeqEM genotyping are provided in (a) and (b): (a) 
rs7005936 (PTK2B, estimated shift = -0.54 and p-value = 8.93E-106); (b) rs6598 
(GIMAP1/GIMAP5, estimated shift = -0.58 and p-value = 2.15E-77). Panels (c) depicts an 
example of a SNP with an opposite shift direction, rs14221 (GOT2, estimated shift = 0.25 and 
p-value < detection limit). 
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in our previous breast study as well.261 However, BCR is here denoted as candidate 
because it was also detected to be featured by possible variant bias. FRG1BP and 
CRYBB2P1 were termed candidates on similar grounds. Furthermore, as only 
downstream gene annotation of MTRNR2L1 was available for rs1363029012, this 
gene was denoted as candidate imprinted as well. 
Table 3 Putatively imprinted SNPs in healthy kidney tissue (128 samples from TCGA). The imprinted 
genes are shown in column “Gene”, while the dbSNP id are given in “SNP” with their FDR-adjusted p-
value for imprinting between brackets. Known imprinted genes are shown in bold. 
Gene SNP Gene SNP 
CROCCP2* rs113317316 (4.22E-10) MEG3 rs8013873 (1.01E-17) 
CYP4A11 rs12735774 (< det. limit) MEG3 rs11859 (5.17E-12) 
LOC107985522 rs141018108 (1.18E-28) NDN rs2192206 (6.79E-25) 
ADORA2BP1* rs7532324 (2.59E-04) SNRPN rs705 (< det. lim) 
ZDBF2 rs10932150 (1.23E-20) SNHG14 rs74335291 (3.81E-27) 
ZDBF2 rs7582864 (7.83E-26) SNHG14 rs6576398 (3.09E-29) 
ZDBF2 rs3732084 (4.56E-27) SNHG14 rs2732029 (2.24E-30) 
ZDBF2 rs1975597 (1.42E-22) SNHG14 rs765438 (1.10E-32) 
ZDBF2 rs1448902 (1.66E-29) SNHG14 rs10451029 (2.04E-33) 
ZDBF2 rs4673350 (6.97E-38) SNHG14 rs2052723 (8.87E-28) 
NDUFC1* rs6851954 (9.23E-19) SNHG14 rs2554419 (1.57E-35) 
CYP4V2* rs10033577 (7.17E-46) SNHG14 rs719704 (2.30E-39) 
CYP4V2* rs10033581 (5.29E-61) SNHG14 rs34316840 (5.52E-42) 
PCBD2 rs878896752 (5.86E-16) SNHG14 rs2732031 (1.12E-38) 
PCBD2 rs113201302 (1.20E-23) SNHG14 rs2732040 (3.05E-21) 
SLC25A48* rs4312874 (1.21E-25) SNHG14 rs1541759 (8.42E-25) 
HCG4,HLA-V** rs764034588 (2.85E-173) SNHG14 rs2554441 (1.38E-26) 
HLA-A** rs77467746 (9.27E-09) PWAR6 rs2732044 (1.99E-34) 
HLA-A** rs41551619 (2.87E-75) PWAR6 rs1030389 (1.65E-33) 
HLA-A** rs1632885 (5.94E-32) PWAR6 rs62001981 (5.39E-43) 
HLA-A** rs1655895 (4.08E-45) PWAR6 rs1045935 (1.09E-44) 
HLA-DRB5** rs62405576 (1.02E-18) SNHG14 rs4344720 (1.67E-31) 
HLA-DRB5** rs1137470 (< det. limit) SNHG14 rs3863396 (4.06E-27) 
HLA-DRB5** rs372470599 (< det. limit) IPW rs691 (1.52E-49) 
HLA-DRB5** rs112839628 (3.61E-14) IPW rs13526 (6.93E-42) 
HLA-DRB5** rs201239487 (4.26E-14) SLC28A2 rs61300393 (5.96E-05) 
HLA-DRB5** rs143960829 (4.43E-12) SCAMP5* rs8034149 (9.75E-49) 
HLA-DRB5** rs112641502 (1.34E-27) ACSM1 rs2301672 (7.14E-07) 
HLA-DRB5** rs115627609 (1.75E-24) ZNF597 rs37823 (3.74E-20) 
HLA-DRB5** rs67598791 (2.79E-179) ZNF597 rs11639510 (2.31E-26) 
HLA-DQA1** rs28383439 (4.20E-07) ZNF597 rs37824 (6.32E-17) 
HLA-DQA1** rs34965214 (2.71E-09) ZNF597 rs12737 (2.86E-32) 
HLA-DQA1** rs4476870 (1.12E-19) ZNF597 rs2270494 (1.98E-17) 
HLA-DQA1** rs72852237 (1.04E-10) FANCA* rs1800358 (4.30E-22) 
HLA-DQA2** rs200493696 (1.18E-53) RPH3AL rs62057050 (1.66E-20) 
Figure 21 Allele frequency plots of significantly imprinted SNPs in healthy kidney tissue. (a) 
rs13073 (PEG10, adj. p-value = 2.36E-49 and î = 0.98) (b) rs3732084 (ZDBF2, adj. p-value = 
4.56E-27 and î = 0.97) (c) rs2839701 (H19, adj. p-value = 1.58E-129 and î = 0.93). 
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Table 3 Continued 
Gene SNP Gene SNP 
HLA-DQA2** rs1363919586 (5.36E-73) MTRNR2L1* rs1363029012 (1.82E-06) 
ZNF107 rs10263594 (3.87E-19) ZNF506* rs72620574 (1.05E-70) 
TYW1B rs117110249 (1.68E-16) MTDHP3 rs12461329 (2.16E-12) 
PEG10 rs13073 (2.36E-49) MTDHP3 rs12973337 (2.16E-21) 
MEST rs1050582 (9.39E-96) MTDHP3 rs12973147 (8.52E-09) 
MEST rs10863 (4.12E-175) MTDHP3 rs12975447 (1.31E-05) 
COPG2 rs974384588 (3.81E-12) MTDHP3 rs16998334 (1.31E-02) 
COPG2 rs36165261 (8.52E-10) ZNF331 rs8109631 (1.08E-79) 
COPG2IT1 rs1044074180 (9.73E-13) ZNF331 rs8110538 (7.90E-74) 
COPG2IT1 rs11538696 (8.64E-16) ZNF331 rs8110350 (3.03E-69) 
COPG2IT1 rs975058179 (7.41E-17) PEG3 rs4801386 (5.25E-19) 
COPG2IT1 rs36183797 (2.29E-16) PEG3 rs1558355 (4.23E-06) 
COPG2IT1 rs1127302 (6.01E-12) PEG3 rs723082 (2.04E-33) 
TUBBP5 rs4088486 (2.22E-03) PEG3 rs3143 (1.37E-19) 
H19 rs2839702 (3.73E-153) PEG3 rs34051133 (8.03E-09) 
H19 rs2839701 (1.58E-129) PEG3 rs33931963 (1.48E-21) 
LOC105369972 rs368092436 (5.19E-04) PEG3 rs1860565 (1.87E-32) 
MDM2* rs2870821 (1.66E-102) PEG3 rs2302376 (4.57E-17) 
MEG3 rs3742390 (3.95E-10) FRG1BP* rs564196523 (8.62E-19) 
MEG3 rs12878222 (1.46E-05) FRG1BP* rs532953935 (1.56E-21) 
MEG3 rs1884540 (2.99E-07) HM13 rs6059873 (2.85E-44) 
MEG3 rs10132552 (3.39E-07) HM13 rs6059874 (4.32E-34) 
MEG3 rs3194464 (1.59E-21) HM13 rs1115713 (6.69E-16) 
MEG3 rs11160606 (8.08E-08) L3MBTL1 rs2269621 (1.60E-09) 
MEG3 rs1950628 (3.37E-08) GNAS rs1800900 (5.58E-20) 
MEG3 rs1053900 (2.40E-08) BCR* rs712967 (2.77E-34) 
MEG3 rs1054000 (6.66E-10) CRYBB2P1* rs7288843 (4.81E-92) 
MEG3 rs4906022 (1.67E-08)   
*Candidate imprinted gene 
**Likely random monoallelically expressed gene 
7.3.3. ASE in clear cell renal cell carcinoma 
7.3.3.1. Identification of differential imprinting 
Loss of imprinting in cancer tissue results in biallelic expression of normally imprinted 
genes and its detection thus translates into the identification of imprinted genes with 
a significantly higher fraction of heterozygous samples in cancer tissue (Figure 22(a) 
and (b)). Here, the 72 KIRC control samples were compared with 265 stage 1 KIRC 
samples from TCGA (SNP-level results are presented in Figure 22 and 
Supplementary Figures 38-46). DI parameters for all putatively imprinted SNPs can 
be found in Supplementary Data 8 and 9 for stage 1 KIRC samples and all stages, 
respectively. Upon integrating SNP p-values per gene (harmonic mean, see Methods 
section) and evaluation of differential expression, seven putatively imprinted genes 
were identified with deregulated imprinting (not including candidates or likely random 
monoallelic genes). HM13 was detected to be featured by canonical loss of imprinting, 
i.e. more biallelic expression combined with expression upregulation (Figure 22(b)). 
Other known imprinted genes, such as ZDBF2, SNRPN and MEST, were also 
discovered with DI in KIRC (Table 4). Additionally, results for three candidate 
imprinted loci were compatible with DI: BCR and ZNF506, FANCA, of which the latter 
even with canonical loss of imprinting. However, their (loss of) imprinting status 
should be validated. Finally, also several HLA-cluster genes exhibited relative re-
7 Modeller of Allelic Gene Expression (MAGE) 80 
 
expression of the silenced allele, yet it remains unclear whether these loci are actually 
imprinted or feature random monoallelic expression. Note that only loci also featured 
by DE are called differentially imprinted. Similar results were observed when taking 
all KIRC tumour samples, not only stage 1, into account (Supplementary Table 18). 
Table 4 Differential imprinting (DI) in stage 1 clear cell renal cell cancer. p_DI indicates FDR-adjusted 
harmonic p-values for (candidate) imprinted genes (including HLA genes) of DI analysis, p_DE the FDR-
adjusted harmonic p-values (over imprinted SNPs) of the differential expression Welch t-test and logFC 
the mean bas 2 logarithmic fold change. In bold, significant p-values (≤ 0.05) and thus significant DI/DE 
is shown.* 
Gene p_DI p_DE logFC Gene p_DI p_DE logFC 
CYP4A11 1.01E-28 2.11E-02 -1.83 SNRPN 2.63E-15 3.89E-33 -1.48 
LOC107985522 3.75E-02 3.76E-01 -0.27 SNHG14 0.29 5.51E-24 -1.13 
ADORA2BP1* 0.45 1.63E-08 -1.79 PWAR6 0.86 2.08E-21 -1.01 
ZDBF2 2.50E-02 5.66E-20 -0.68 IPW 0.29 4.77E-12 -0.53 
NDUFC1* 1 1.34E-04 -0.73 SCAMP5* 0.86 2.90E-02 -0.36 
CYP4V2* 0.24 4.75E-01 0.05 ZNF597 0.23 7.63E-01 0.04 
PCBD2 2.86E-03 2.37E-01 -1.06 ACSM1 0.29 2.11E-01 0.5 
SLC25A48* 1 2.24E-03 -1.91 FANCA* 1.90E-04 1.29E-10 1.15 
ZNF107 1.28E-01 8.90E-02 0.33 RPH3AL 3.50E-03 3.35E-01 -0.17 
TYW1B 1 1.73E-01 -0.51 MTRNR2L1* 1 6.40E-01 0.25 
PEG10 0.86 1.49E-10 -0.43 ZNF506* 7.30E-07 3.89E-02 -0.83 
MEST 2.29E-09 3.90E-25 -1.04 MTDHP3 1.23E-05 1.43E-04 -0.61 
COPG2 0.4 5.04E-13 -1.66 ZNF331 5.72E-17 1.20E-17 -1.34 
COPG2IT1 0.29 6.06E-15 -1.57 PEG3 1.28E-01 4.75E-36 -2.01 
TUBBP5 0.13 1.69E-05 -1.14 FRG1BP* 9.30E-02 1.06E-01 -0.31 
H19 2.23E-08 7.63E-01 1.55 HM13 2.71E-02 2.37E-03 0.27 
LOC105369972 1.74E-01 4.37E-01 -0.28 L3MBTL1 0.86 8.27E-14 1.26 
MDM2* 0.24 4.64E-05 1.14 GNAS 7.35E-02 5.41E-01 2.58 
MEG3 7.33E-07 5.83E-02 0.39 BCR* 1.27E-02 1.12E-05 -1.08 
NDN 0.2 7.17E-03 0.11 CRYBB2P1* 0.66 8.51E-04 0.6 
HLA-A** 2.50E-02 1.66E-20 1.76 HLA-DQA1** 3.07E-06 5.44E-05 1.11 
HLA-DRB5** 5.72E-17 9.19E-04 0.94 HLA-DQA2** 3.50E-13 1.34E-04 1.98 
*Candidate imprinted gene 
**Likely random monoallelically expressed gene 
7.3.3.2. Induced allelic imbalance in KIRC 
The same rationale as for DI can be applied to study iAI. Here, however, a mixture of 
homozygous and heterozygous samples under HWE is expected for control RNA-seq 
data, while tumour data will apparently deviate from the normal HWE profile due to 
less expression of one allele (Figure 23). We only evaluated SNPs with non-ASE 
profiles in control data (see Methods section), resulting in 15,765 SNPs in 72 healthy 
kidney TCGA samples. In this set of SNPs, 11,580 showed significant iAI in 256 stage 
1 clear cell renal cell cancer samples. Similar results were obtained when taking into 
account all tumour stages. Thus, the large majority of SNPs show significant iAI in 
KIRC, which could be visually verified, in line with general cancer instability. 
Subsequently, we evaluated to which extent iAI was associated with DE (Figure 24, 
also includes non-iAI SNPs), using the median allelic ratio difference (ΔAI, see 
Methods section) as measure for the degree of iAI. Figure 24(a) depicts that iAI is 
indeed tightly but not completely linked with DE. Many SNPs with strong to moderate 
iAI did not feature DE, which may be attributed to a combination of random 
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monoallelic expression and compensation mechanisms, though of course technical 
artefacts can never be completely excluded. Vice versa, a large number of SNPs were 
clearly differentially expressed without featuring moderate or strong iAI. Strikingly, this 
was particularly the case for overexpressed loci, which may relate to increased 
transcription factor activity, in line with the original rationale and supporting the notion 
to study iAI next to DE. Virtually equal results were observed for all tumour samples 
(Supplementary Figure 47). 
Figure 22 Allele frequency plots of imprinted SNPs in healthy 
kidney tissue (left) and stage 1 clear cell renal cell carcinoma 
(right). In (a) and (b) two SNPs are shown with significant 
differential imprinting, rs8109631 (ZNF331, adj. p-value = 4.03E-
17) and rs6059874 (HM13, adj. p-value = 1.62E-02) respectively, 
and in (c) a SNP without differential imprinting, rs2732040 
(SNHG14, adj. p-value = 1). In (a) and (b) more heterozygous 
samples are observed, while in (c) still only homozygous samples 
are seen. (a) shows an example of differential imprinting with 
expression downregulation, while in (b) the expression is 
upregulated, i.e. loss of imprinting. 
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The large majority of KIRC samples is characterised by loss of the short (p) arm of 
chromosome 3.263 This was also clearly reflected in Figure 24(a), which illustrates that 
most 3p SNPs (blue) were featured by moderate to strong iAI and moderate DE. This 
includes SNPs located in the VHL locus, which is additionally frequently mutated in 
cancer (Figure 24(a)). SNPs located on 3q, on the other hand, did not particularly 
show iAI, though clear exceptions were present. Nevertheless, it should be noted that 
several 3p SNPs, including the two VHL SNPs under study (ΔAI of 0.32 and 0.27), 
exhibited relatively low iAI scores. These SNPs were spread across the 3p arm (data 
not shown). This can be explained by tumour impurity, notably high in KIRC264, which 
is supported by the observation that those 3p SNPs without clear iAI also exhibited 
far less downregulation compared to those with major iAI. Additionally, it should be 
noted that, by design, iAI only poorly detects loci regularly featuring loss of both alleles 
in many samples, cf. VHL (see Discussion section). 
Subsequently, SNPs were summarised per gene (see Methods section), revealing 
that gene identifier explained 87.9% of total variance per SNPs (considering non-
Figure 23 Allele frequency plots of SNPs with significant induced allelic 
imbalance (iAI) between healthy (left) and stage 1 cancer (right) kidney tissue. 
iAI results in less heterozygous samples in diseased samples compared to 
control data. This is either observed as a depletion of heterozygous samples, 
such as (a) rs2231828 (ELF5, ΔAI = 0.92), or as a wider range of allelic fractions, 
such as (b) rs1136249 (VHL, ΔAI = 0.32). 
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ambiguously annotated genes for which at least two SNPs were available), supporting 
the fact that ΔAI is a robust measure. Parameters of iAI analysis summarised per 
gene can be found in Supplementary Data 10 and 11 for stage 1 KIRC samples and 
all stages, respectively. We further evaluated to which extent iAI results complement 
statistical mutation analysis on the gene level (see Methods section). Significantly 
mutated genes in stage 1 tumour samples were PBRM1, VHL, SETD2, KDM5C, 
BAP1 and ARID1A, of which VHL, SETD2 and PBRM1 showed significant iAI (ΔAI 
around 0.30, Figure 24(a) and Supplementary Table 19). KDM5C, BAP1 and ARID1A 
were not represented in the final iAI results due to insufficient coverage, low allele 
frequency or ASE in control data. Mutation analysis of all available KIRC samples 
detected 11 significantly mutated genes, namely BAP1, CYB5B, MAX, PBRM1, 
PTEN, SETD2, VHL, XCL1, KDM5C, ZNF800 and TP53, largely corresponding with 
previous analyses.264 Of these genes VHL, SETD2, PBRM1, MAX and CYB5B also 
exhibited statistically significant but at most moderate ΔAI on the summarised gene 
level, PTEN did not show significant iAI (Supplementary Table 19 and Supplementary 
Figure 47). Other genes were filtered out prior to analysis due to reasons given higher. 
One assumption of the developed iAI methodology is that the observed effect is 
independent of the higher (or lower) expressed allele, which may not hold true for 
genetic risk loci. Therefore, 13 renal cancer risk loci previously identified in genome-
wide association studies (GWAS) (Supplementary Table 20) were compared to the 
iAI results for stage 1 tumour samples and all tumour samples (Supplementary Table 
21), for which results were highly similar. For two known GWAS SNPs, rs2241261 
(RHOBTB2) and rs1049380 (ITPR2) information about the exact same SNP could be 
consulted in the iAI results, however, only rs1049380 exhibited significant but weak 
iAI (Supplementary Table 22). Comparison was also performed on a gene level, i.e. 
comparison of genes associated to the GWAS identified risk loci to the iAI results. 10 
GWAS associated genes were included in the final iAI analysis, most notable iAI 
effects were seen in RPL14 (located on chromosome 3p), STN1 (previously known 
as OBFC1), ITPR2 and SCARB1 (Supplementary Table 23). When evaluating the 
allele frequency plots, both alleles for these loci appeared to be equally affected by 
iAI, implying that iAI results are generally not confounded by genetic risk loci (data 
not shown). 
Subsequently, WebGestalt Over-Representation Analysis (a gene set analysis tool) 
was used to identify enriched gene sets among loci showing clear iAI (ΔAI ≥ 0.25; 
512 out of 5,404 genes with non-ambiguous annotation), demonstrating a crucial role 
for iAI among transmembrane ion transport loci in stage 1 KIRC (Supplementary Data 
12).265 This was supported by multiple clearly enriched Gene Ontology gene sets 
relating to ion transport (GO biological process), plasma membrane (GO cellular 
component) and transmembrane transporter activity (GO molecular function). An 
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important example was the GO term sodium ion transmembrane transporter activity, 
which was 6.0x enriched (FDR-adjusted p-value < 1E10-07, Figure 24(b)). The same 
conclusions were obtained from Reactome pathway analysis (e.g. SLC-mediated 
transmembrane transport, 3.3x enriched, FDR-adjusted p-value < 1E10-05). Other 
pathway analyses (KEGG, WikiPathways, Panther) did not lead to significant results. 
Figure 24 Induced allelic imbalance (iAI) versus differential expression (DE) between healthy 
kidney tissue and stage 1 renal cancer. The median allelic ratio differences (ΔAI) and base 2 
logarithmic fold changes (logFC) are used as measures for iAI and DE, respectively. In (a) the 
ΔAI and logFC of all SNPs with a normal non-ASE distribution are plotted in grey. The SNPs 
on chromosome 3 are highlighted with SNPs on the short arm in blue and SNPs on the long 
arm in orange. In purple, SNPs in significantly mutated genes, such as VHL, are plotted with 
their gene names. In (b) the gene level ΔAI and logFC (mean ΔAI and logFC over all SNPs) 
are plotted in grey. Examples of transmembrane transport genes are highlighted in orange 
and of tumour suppressor genes in purple (labelled with their gene names). 
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Finally, chromosomal location analysis clearly supported the 3p loss (8.1x enriched 
and more for ten 3p chromosomal bands, all FDR-adjusted p-value < 0.001). 
As anticipated by the gene set analysis, loci with very strong evidence for iAI included 
large numbers of proteins involved in transmembrane transport, which were typically 
also heavily downregulated (e.g. AQP2, KCNJ10, SLC4A11, SCNN1G and SLC9A4), 
though upregulated exceptions were present (e.g. SLC5A8, Figure 24(b) and Table 
5). Moreover, top hits also include several (putative) tumour suppressor genes, 
including SERPINA5 and RASSF10, whereas also others (next to VHL, see higher) 
exhibited high iAI and DE, e.g. SFRP1 and TCF21 (Figure 24(b) and Table 5). The 
mechanisms underlying iAI may vary, but most likely include CNA and epigenetic 
differences, such as DNA methylation alterations. Therefore, we evaluated whether 
ΔAI was associated with copy number gain and loss, as well as with promoter 
hypermethylation in cancer (see Methods section and Supplementary Data 10 and 
11). ΔAI was clearly negatively associated with copy number loss (R = 0.35) and 
promoter methylation (R = 0.21, both p-values < 2.2E-16), but not with copy number 
gain (borderline significant association: R = -0.029, p-value = 0.025). The latter may 
be explained by the fact that copy number gains do not automatically lead to 
expression of the amplified fragment, but also due to the fact that high ΔAI loci are 
devoid of gains (as, contrasting copy number loss, both alleles are still expressed). 
Interestingly, several loci combined high ΔAI with relatively high rates of both 
promoter hypermethylation and copy number loss, suggesting multiple causes for 
silencing and AI induction. CCBE1, for example, was identified as a tumour 
suppressor in ovarian cancer, and features a high ΔAI (0.73) with heavy promoter 
hypermethylation (33% in cases and <1% in controls) and frequent copy number loss 
(14% of cases) most likely leading to expression downregulation (logFC of -1.35).266 
Similar examples include TFAP2A and PPP4R2 (Figure 24(b)).267,268 
Table 5 Examples of loci with strong evidence for induced allelic 
imbalance (iAI) in stage 1 renal cancer. SNPs were summarised per gene 
and for each gene the mean of the median allelic ratio difference (ΔAI) 
and mean base 2 logarithmic fold change (logFC) over all SNPs are 
shown. 
gene ΔAI logFC gene ΔAI logFC 
AQP2 0.95 -6.6 WT1 0.81 -2.3 
KCNJ10 0.88 -5.2 SERPINA5 0.77 -4.5 
SLC4A11 0.88 -4.7 RASSF10 0.75 -2.6 
SCNN1G 0.86 -3.6 SFRP1 0.48 -5.1 
SLC9A4 0.81 -4.4 WT1 0.81 -2.3 
AQP2 0.95 -6.6    
7.4. Discussion & conclusion 
In this manuscript, we have introduced MAGE, Modeller of Allelic Gene Expression, 
the first comprehensive methodology that solely relies on RNA-seq data to enable 
screening for different ASE effects, more specifically (loss of) imprinting, eQTLs and 
iAI. Contrasting previous studies, basic concepts from population genetics and 
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molecular biology are used to explicitly model these ASE effects rather than simply 
inferring deviation from normal biallelic expression.259 Molecular biology-driven 
statistical modelling not only allows to discriminate between different types of allele-
specific expression, it also reduces the impact of sample-specific artefacts and avoids 
the need for crossing designs. Though the use of genotyping data provides a solution 
for human experiments, comprehensive analyses require a large number of 
individuals, as sufficient heterozygous subjects are required for SNPs featuring low 
alternative allele frequencies. Removing the requirement of genotyping thus improves 
cost-efficiency by a great margin. Moreover, genotyping data are often incomplete, 
due to (locally) low sequencing coverage or loci not measured by design (e.g. exome-
seq, SNP-arrays), and genotyping errors may lead to additional artefacts. Other 
genotyping-free methods exist, e.g. 269, yet they largely focus on individual samples 
and detect ASE effects only for those loci that remain discernible from homozygous 
ones. These limitations are largely overcome by MAGE, which uses basic concepts 
from population genetics and molecular biology to test for specific ASE effects by 
explicit statistical modelling. Other advantages are that low coverage RNA-seq loci 
remain suitable for modelling and that batch effects typically jointly affect both alleles, 
i.e. they are not expected to induce ASE-like effects. 
Nevertheless, also MAGE has several general limitations and assumptions that could 
be addressed in future versions, or that entail the necessity of additional experimental 
validation. For example, simultaneous analysis of all SNPs within transcripts or 
genes, similar to Xie et al., would further improve power and interpretability of 
results.252,270 The possibility for jointly testing multiple effects, e.g. the presence of 
imprinted cis-eQTLs, would improve interpretability and should decrease the filtering 
stringency required to study individual effects.259 MAGE may also benefit from using 
mixtures of beta-binomial models, rather than binomial ones, to take into account 
overdispersion of allele-specific read counts.173,178,258,271 However, the added value 
for MAGE remains to be evaluated, given that we test against an explicitly formulated 
alternative hypothesis (i.e. overdispersion will lead less to type 1 errors) and that 
additional flexibility may sometimes lead to aberrant results. Furthermore, additional 
validation is required to fully exclude the potential impact of random monoallelic 
expression on MAGE results, e.g. to shed light on the currently unclear imprinting 
status of HLA genes or to avoid mislabelling random monoallelically expressed loci 
as iAI due to cancer-related clonal expansion.189,261 Importantly, also the RNA-seq 
data pre-processing steps performed may have a major impact on the final results. 
MAGE has been designed to be generically applicable to any diploid organism, yet in 
the study at hand we solely focussed on known high-quality SNPs obtained from 
dbSNP.155 Additional quality control and improved pre-processing may be necessary 
to remove artefacts due to aberrant de novo SNP calling. Note that improved pre-
processing may also have led to better results here. For example, MAGE is the first 
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RNA-based genotyper that empirically estimates all parameters from the data while 
explicitly taking into account variant bias, but is also compatible with improved data 
pre-processing methods that e.g. reduce alignment bias, such as incorporated in the 
GATK RNA-seq variant calling pipeline or the WASP remapping method.157,173 
Nevertheless, as alignment bias cannot be completely resolved, robust modelling 
combined with adequate filtering as available in MAGE will always remain an 
advantage.170 Moreover, MAGE also provides an indication of genotyping inaccuracy 
by estimating the expected number of reference alleles per sample (often non-
integer), which can immediately be used as regressor in eQTL analyses, e.g. of Matrix 
eQTL.272 
The MAGE results on (loss of) imprinting in renal (clear cell cancer) identified HM13 
to clearly exhibit canonical loss of imprinting - i.e. re-expression of the silenced allele, 
which is similar to our previous breast cancer results.261 Compared to the previous 
imprinting methodology, MAGE now also adjusts for inbreeding and sequencing 
depth (when studying differential imprinting) through a logistic regression strategy. 
The latter is also used to study iAI. The significant iAI observed for the majority of loci 
is in line with the global genomic deregulation observed in cancer. We demonstrated 
the relevance of studying iAI next to DE, as not all iAI genes showed strong DE and 
vice versa (Figure 24). Strikingly, genes with iAI in KIRC were clearly enriched for 
transmembrane (ion) transporters. The metabolism of renal and many other cancer 
types is known to be altered from oxidative phosphorylation to (less efficient) 
glycolysis (even in aerobic conditions), i.e. the Warburg effect.273 Interestingly, a 
recent study discovered that, contrasting most other cancer types, KIRC mainly 
exhibited aerobic glycolysis and decreased mitochondrial metabolism.274 The hypoxia 
inducible factor (HIF) induces glycolysis, which plays an important role in this 
metabolic switch. As HIF is degraded by VHL, the key silenced protein in KIRC, a 
central role of the Warburg effect in renal cancer is anticipated.275 Many transporters 
proteins, including solute carriers, were already identified as tumour suppressor 
genes and/or have been associated with the Warburg effect.276,277 This supports the 
hypothesis that their iAI in KIRC (associated with expression deregulation) is required 
by the tumour to alter the metabolic equilibrium, thereby contributing to the Warburg 
effect. 
When focussing on loci featuring iAI over a substantial number of samples, we could 
confirm the central role for chromosomal 3p loss. Moreover, evidence supports a 
central role in KIRC for several known tumour suppressor genes, including SFRP1, 
SERPINA5, WT1 and CCBE1.266,278–280 Nevertheless, it should be noted that iAI 
reflects allelic imbalance, and that samples with complete loss of both alleles cannot 
be readily discerned from normal samples, cf. the relatively low iAI score for VHL. To 
that extent, iAI complements other strategies, e.g. CNA and mutation analyses. It is 
particularly useful to identify quantitative effects relying on silencing (or amplification) 
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of individual alleles rather than complete knock-out. Most likely, allele-specific 
silencing is a strategy by the tumour to quantitatively optimise gene expression 
without complete knock-out, as appears to be the case for many transporter proteins. 
Finally, it should be noted that also high tumour impurity will affect iAI results, as is 
the case for renal cancer.264 Particularly for loci with high expression in the 
contaminating non-tumour tissue, allelic differences in the actual tumour fraction will 
be diluted. As a consequence, the ΔAI score will be biased and provides only a partial 
appreciation of the actual iAI. It remains to be further evaluated whether adjusted ΔAI 
scores or alternative measures incorporating tumour impurity may further improve the 
ranking of most relevant results. 
In conclusion, this study introduces the MAGE toolbox to study different ASE effects 
through statistical modelling of RNA-seq data. Its features were illustrated through 
improved RNA-seq-based genotyping, important for eQTL studies, and detection of 
putatively imprinted loci in healthy renal tissue. HM13 was found to be featured by 
loss of imprinting in KIRC, yet MAGE identified far more loci featuring allele-specific 
aberrations. Indeed, in KIRC, most loci show evidence of iAI, indicating general 
genomic instability in cancer. Finally, there was a striking enrichment for 
transmembrane transport-related proteins featuring iAI, supporting a central role of 
metabolite transport deregulation to rewire renal cancer metabolism. 
7.5. Methods 
Kidney case study 
RNA-seq BAM-files (GRCh38) of 128 control kidney samples (matched normal tissue 
adjacent to the tumour) and 538 KIRC samples, including 126 stage 1 tumour 
samples, were downloaded from TCGA (https://portal.gdc.cancer.gov/). Control 
samples from the KIRC, kidney renal papillary cell and chromophobe renal cell 
carcinoma TCGA datasets were downloaded, yet only tumour data from the KIRC 
dataset were used for tumour-specific analyses (with KIRC controls). TCGA 
Affymetrix Human SNP array 6.0 data (906,600 SNPs assayed, GRCh37) were 
downloaded from the prior TCGA data portal (https://portal.gdc.cancer.gov/legacy-
archive/search/f). Affymetrix ids were linked to SNP ids from dbSNP using the 
GenomeWideSNP_6 annotation file, release 35, accessible from Affymetrix 
(downloaded from  
http://www.affymetrix.com/support/technical/byproduct.affx?product=genomewidesn
p_6) Genotyping data were available for 126 matching stage 1 KIRC samples. 
Methylation data and CNA data were obtained from the updated version of 
MEXPRESS.281 InfiniumHumanMethylation450k data for 155 stage 1 (319 for all 
stages) tumour samples and 160 KIRC control samples were considered. Annotation 
was obtained from Illumina on 
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https://emea.support.illumina.com/downloads/humanmethylation450_15017482_v1-
2_product_files.html?langsel=/be/. For CNA data analysis, 256 stage 1 (525 for all 
stages) KIRC samples were assessed (control CNA data are not present, as they are 
assumed to be normal diploid). Mutation annotation format (MAF) files from 
harmonised KIRC TCGA data (GRCh38) were downloaded on 28/3/2019 using the 
TCGAbiolinks package (v2.12.6) from Bioconductor.282 Mutation information was 
available for 336 KIRC samples, of which 192 samples originated from stage 1 
tumours. 
Data pre-processing 
Variants are called over all samples from sorted BAM files with Samtools 
mpileup/bcftools (v0.1.9) after indexing, if necessary.149 Only variants with a preferred 
minimal raw read depth (with a default of 10) in at least one sample and present in 
dbSNP are retained.155 By default, non-uniquely mapped reads are filtered out to 
reduce noise, but this option can be adjusted to retain all reads. Allelic counts of all 
variants are acquired from each SAM file for all samples. The results are written into 
count files per chromosome listing all variants with their standard alleles, variation 
type, gene annotations, allelic counts and in which sample the specific counts were 
observed. These count files can be used as input for the imprinting analyses in R. If 
no dbSNP file is available or if the standard alleles of a SNP are unknown, count 
information on all four possible alleles can be used in the R analysis. Nevertheless, 
the count data are pre-processed as described earlier to only retain data for samples 
with genotypes consisting of one or both major alleles.261 SeqEM is then used to 
estimate allele frequencies from counts of the two standard alleles, as described in 
our previous study.156,261 All analyses on the pre-processed count files were 
performed in R. The pipeline developed to pre-process individual BAM files into a 
format to be imported in the MAGE R package is available through Github A Conda 
environment file is provided to facilitate reproducibility. 
Inbreeding coefficient estimation 
HWE assumes a panmictic population and provides a biased estimate of genotype 
frequencies in the presence of effects such as inbreeding. To circumvent deviation 
from HWE, we correct for inbreeding in the population. For computational reasons, 
the degree of inbreeding in the population is estimated per chromosome. Upon 
genotyping with SeqEM, the number of observed heterozygous samples (𝑂𝑏𝑠𝐻𝑧) is 
known, while the number of expected ones (𝐸𝑥𝑝𝐻𝑧) can be calculated as 2𝑝𝑞𝑁 (with 
𝑝 and 𝑞 the estimated allele frequencies and 𝑁 the number of samples for that SNP). 
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For each SNP, an inbreeding coefficient is obtained and the median per chromosome 
is used as a measure of the degree of inbreeding in the population. This estimate is 
afterwards recalculated for only those loci with a good model fit (i.e. high quality loci). 
Detection of variant bias 
(SNP loci linked to) cis-eQTLs will show allele-specific expression. In RNA-seq data, 
one allele will be expressed to a higher extent and the allelic ratio will deviate from 
1:1. On the allele frequency plots this can be seen as a shift of the heterozygous peak 
away from an allelic fraction (AF) of 0.5 to the homozygous peaks. This may bias 
RNA-seq-based genotyping. Moreover, also alignment bias will cause a similar shift, 
yet typically in the direction of the reference homozygous peak. Given that both 
mechanisms will lead to higher counts for one allele compared to the other, we use 
the term variant bias. For homozygotes, the probability of observing a specific allele 
solely depends on the sequencing error rate (SE). For a heterozygous SNP without 
variant bias, the expected allele frequency (eAF) equals 0.5, whereas in case of 
variant bias the eAF will be significantly different. The following probability mass 
function (PMF) was therefore developed as a mixture of three binomial distributions, 
taking into account genotype frequencies, with eAF as variable for the heterozygous 
samples. Note that we refer to the different alleles here as A and T, but that the same 
is valid for any set of variants for a SNP. 
𝑃𝑀𝐹(𝑥, 𝑒𝐴𝐹)  =  𝑃𝐴𝐴𝐵(𝑥; 𝑝𝐴 = 1 − 𝑆𝐸, 𝑝𝑇 = 𝑆𝐸) 
+  𝑃𝑇𝑇𝐵(𝑥; 𝑝𝐴 = 𝑆𝐸, 𝑝𝑇 = 1 − 𝑆𝐸) 
+  𝑃𝐴𝑇𝐵(𝑥; 𝑝𝐴 = 𝑒𝐴𝐹, 𝑝𝑇 = 1 −  𝑒𝐴𝐹) 
(16) 
With 
- 𝑥 the coverages for alleles A and T, i.e. 𝑥 = (𝑛𝐴, 𝑛𝑇) 
- 𝑃𝐴𝐴 = (𝑝
2 + 𝑓𝑝𝑞), 𝑃𝑇𝑇 = (𝑞
2 + 𝑓𝑝𝑞) and 𝑃𝐴𝑇 = 2𝑝𝑞(1 − 𝑓)  
- 𝑝 and 𝑞 the estimated population allele frequencies for a specific locus over 
all 𝑁 samples (obtained by SeqEM) 
- eAF the expected allelic fraction of the reference allele (here A) 
- 𝑆𝐸 the estimated sequencing error rate (median per chromosome, obtained 
by SeqEM) 
- 𝑓 the median inbreeding coefficient per chromosome 
- 𝐵(𝑥; 𝑝𝐴, 𝑝𝑇) the binomial probability for 𝑥 given the probabilities for each allele, 
i.e. 𝑝𝐴 and 𝑝𝑇, which depend on the specific genotype, 𝑆𝐸 and 𝐴𝐹 
However, the initial estimates for allele frequencies p and q obtained by SeqEM may 
be biased, as (particularly lowly covered) heterozygous samples may be mistaken for 
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homozygous ones. Note that this bias only arises in case of variant bias, not when 
(differential) imprinting or iAI is studied, as the latter are independent of the exact 
allele under study (i.e. the genotyping errors will cancel each other out). Additionally, 
also the expression differences between the different genotypes provide information 
regarding variant bias, as the expression levels of heterozygous samples (i.e. sum of 
both alleles, library size normalised) are expected to be intermediate between those 
for both homozygous fractions. Therefore, an expectation-maximisation algorithm 
was implemented that, until convergence (or a maximum of 100 iterations), iteratively: 
(i) Estimates eAF based on robust linear regression (rlm function of MASS 
package for R) of normalised expression (per SNP) as a function of the 
estimated number of reference alleles in the genotype of the sample. This 
number is based on the current posterior likelihood for each genotype for a 
sample and is therefore typically not an integer. 
(ii) Estimates novel posterior likelihoods for each genotype given the eAF 
updated PMF. 
(iii) Estimates novel allele frequencies p and q based on the updated 
genotypes, which allows to estimate novel genotype frequencies based on 
HWE (taking into account inbreeding, see equation 16). 
Note that (optional) step (iii) enforces the SNP genotype frequencies to follow 
inbreeding-adjusted HWE, leading to more robustness. Afterwards, a LRT is used to 
test whether the estimated eAF significantly deviates from 0.5. Given the general 
purpose to evaluate whether the MAGE genotyper works better for loci featuring 
variant bias, an anti-conservative cut-off (non-adjusted p-value < 0.05) is used. 
The estimated allelic fraction can be converted to an estimation of the heterozygous 
shift: 




The shift represents the extent to which the heterozygous fraction is shifted away from 
the normal probability to observe heterozygotes of 0.5. A negative shift indicates that 
the reference allele is expressed to a higher extent, while higher expression of the 
variant allele is illustrated by a positive shift. 
In the previous imprinting methodology, a robust measure of imprinting, called median 
imprinting, was defined. Also here, the median shift can be calculated, which may 
provide additional support to evaluate the robustness of the model. Therefore, 
samples are sorted on the ratio of the lowest allele count on the highest count and 
the sample with rank closest to 2𝑝𝑞(1 − 𝑓)𝑁 is called the median heterozygote 
sample. The median heterozygote ratio (𝐻𝑅) is the ratio of the reference count on the 
total count of this median heterozygote sample, the median shift can subsequently be 
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calculated as (𝐻𝑅 − 0.5) 0.5⁄ . The same quality filters as in the original paper for 
imprinting detection can also be applied here to retain a robust set of loci featuring 
variant bias. An extra quality step was, however, added. Firstly, basic filtering on allele 
frequency (> 0.15), coverage (≥ 4), number of samples (≥ 40) and estimated SE (≤ 
0.035) is performed. The goodness-of-fit (GOF) of the mixture model is subsequently 
calculated as elaborated before and loci with a bad fit can be filtered out (GOF < 1) 
to only retain good quality loci (i.e. suitable for genotyping)261. After this filtering step, 
the SE and inbreeding coefficient are recalculated. Again, the median of the 
inbreeding coefficients per chromosome is used, however, now only the good quality 
SNPs are taken into account. The sequencing error rate, on the other hand, is 
calculated in a more robust way which takes into account more than two alleles: 
𝑆𝐸 =  
𝑥𝑛𝑜𝑛−𝑟𝑒𝑓 +  𝑥𝑛𝑜𝑛−𝑣𝑎𝑟
2(𝑥𝐴 + 𝑥𝑇 + 𝑥𝐶 + 𝑥𝐺)
 (18) 
With 
- 𝑥𝑛𝑜𝑛−𝑟𝑒𝑓 and 𝑥𝑛𝑜𝑛−𝑣𝑎𝑟 the coverage of the non-reference and the non-variant 
allele, respectively, over all good quality SNPs 
- 𝑥𝐴, 𝑥𝑇, 𝑥𝐶, 𝑥𝐺 the coverage of A, T, C and G, respectively, over all good quality 
SNPs 
The PMF is recalculated with the re-estimated parameters and the remaining loci are 
screened for significant loci clearly featuring variant bias (p-value ≤ 0.05), only 
retaining those of interest (|shift| and |median shift| ≥ 0.2). 
Matching TCGA Affymetrix Human SNP array 6.0 data were used as gold standard 
data to evaluate MAGE-based genotyping. Matching data were available for a total of 
1,026,699 MAGE/SeqEM sample-SNP combinations for evaluation (for 126 matching 
samples with Affymetrix data and 8,371 overlapping SNPs). All Affymetrix alleles 
corresponded to the (reverse complements of) dbSNP alleles, except for 21 SNPs 
where denoted strand was switched between reference genome builds. The latter 
were hence eliminated from further analyses. 
Detection of imprinting 
Following the rationale outlined higher, the implementation regarding imprinting 
detection has been described earlier.261 The PMF described in Goovaerts et al. is 
adapted to include the effect of inbreeding, resulting in the following mixture 
distribution for alleles A and T: 
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𝑃𝑀𝐹(𝑥, 𝑖)  =  𝑃𝐴𝐴𝐵(𝑥; 𝑝𝐴 = 1 − 𝑆𝐸, 𝑝𝑇 = 𝑆𝐸) + 𝑃𝑇
2𝐵(𝑥; 𝑝𝐴 = 𝑆𝐸, 𝑝𝑇 = 1 − 𝑆𝐸) 
+ 𝑃𝐴𝑇𝐵 (𝑥; 𝑝𝐴 =  
0.5 − 𝑖 2⁄
1 − 𝑖 2⁄
(1 − 𝑆𝐸) +
0.5
1 − 𝑖 2⁄
𝑆𝐸, 𝑝𝑇 =
0.5
1 − 𝑖 2⁄
(1 − 𝑆𝐸) + 
0.5 − 𝑖 2⁄
1 − 𝑖 2⁄
𝑆𝐸) 
+ 𝑃𝐴𝑇𝐵 (𝑥; 𝑝𝐴 =  
0.5
1 − 𝑖 2⁄
(1 − 𝑆𝐸) +  
0.5 − 𝑖 2⁄
1 − 𝑖 2⁄
𝑆𝐸, 𝑝𝑇 =
0.5 − 𝑖 2⁄
1 − 𝑖 2⁄
(1 − 𝑆𝐸) +
0.5




- 𝑥 the coverages for alleles A and T, i.e. 𝑥 = (𝑛𝐴, 𝑛𝑇) 
- 𝑃𝐴𝐴 = (𝑝
2 + 𝑓𝑝𝑞), 𝑃𝑇𝑇 = (𝑞
2 + 𝑓𝑝𝑞) and 𝑃𝐴𝑇 = 𝑝𝑞(1 − 𝑓)  
- 𝑝 and 𝑞 the estimated population allele frequencies for a specific locus over 
all 𝑁 samples (obtained by SeqEM) 
- 𝑆𝐸 the estimated sequencing error rate (median per chromosome, obtained 
by SeqEM) 
- 𝑓 the median inbreeding coefficient per chromosome 
- 𝑖 the degree of imprinting (varying from not (𝑖 = 0) to fully (𝑖 = 1) imprinted) 
- 𝐵(𝑥; 𝑝𝐴, 𝑝𝑇) the binomial probability for 𝑥 given the probabilities for each allele, 
i.e. 𝑝𝐴 and 𝑝𝑇, which depend on the specific genotype, 𝑆𝐸 and imprinting 
degree 𝑖 
As described in Goovaerts et al., 𝑖 is estimated with maximum likelihood estimation 
and a LRT is used to identify significant imprinting. The same quality filters as in the 
original paper are available and used to retain a robust set of imprinted genes. Again, 
basic filtering on allele frequency (> 0.15), coverage (≥ 4), number of samples (≥ 30), 
estimated SE (≤ 0.035) and symmetry (≤ 0.05) is performed, upon which the 
inbreeding coefficient and SE are recalculated by only taking into account good-
quality loci (GOF > 0.8, see previous section). Imprinting detection is performed on 
the remaining loci and only significant loci with î ≥ 0.6 and median î ≥ 0.8 are defined 
as imprinted. Annotation of thus identified imprinted SNPs was often complicated due 
to overlapping genes, in which case we selected those genes for which the SNP was 
located in exonic regions. 
Differential imprinting 
Detection of DI in cases is performed by screening for loci which are featured by 
significantly more heterozygous samples in cases compared to controls. For each 
SNP, the coverage of the least (“successes”) and most (“failures”) expressed alleles 
are linked to the disease status with a logistic regression model, independent of the 
SNP variants present. Logistic regression is used to compare the number of 
successes and failures between cases and controls to identify DI. In R this is 
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implemented using the glm function of the stats package. Note that we assume equal 
genotype frequencies between cases and controls, implying that the non-informative 
homozygous samples (with number of successes approximating zero, cf. sequencing 
errors) will have equal impact on cases and controls. Subsequently, the harmonic 
mean is used to combine p-values of different SNPs in one gene to obtain one DI p-
value per gene:283 
 





The logistic regression model takes into account expression as total number of 
events, but does not depend on DE between cases and controls. Therefore, we also 
considered DE by means of a Welch t-test on logarithmic counts (+ 0.5). Again, the 
harmonic mean of the p-values over SNPs, but also the average of the base 2 
logarithmic fold changes over all SNPs, for a gene is used as a measure for DE per 
gene. If the FDR-adjusted harmonic p-values for a gene, DI as well as DE p-value, is 
significant (≤ 0.05), this gene is featured by significant DI in cases compared to 
controls. Only for those loci with expression upregulation in cases this is coined “loss 
of imprinting”. 
Induced allelic imbalance 
The difference in number of heterozygous samples between cases and controls can 
also be used as a measure to study iAI. Here, however, the controls samples show 
non-ASE expression and the number of heterozygotes will approximate the number 
expected by HWE. As induced allelic imbalance leads to a different relative 
expression of both copies in cases, the observed number of heterozygous samples 
in RNA-seq data will deviate from HWE, i.e. with less apparently heterozygotes in 
cases. The same logistic regression model as for detection of DI can be used to study 
iAI, again combined with DE analysis. Only loci with a GOF ≤ 0.4 (see below) are 
retained. SNPs with an FDR-adjusted p-value from the logistic regression model ≤ 
0.05 are denoted as SNPs with significant iAI. 
Goodness-of-fit of the control data: Here, we are particularly interested in loci 
featuring ASE in cases, but non-ASE in controls. Therefore, we applied an extra filter 
to remove potential ASE loci in controls (besides basic filtering on coverage (≥ 4), 
number of samples (≥ 30), estimated SE (≤ 0.0075) and allele frequency (> 0.15)). To 
verify that loci indeed feature a normal heterozygous peak in the control samples, cf. 
HWE, rather than demonstrating a scattered distribution over different allelic ratio’s, 
we compared the fit to the HWE model (described in (19) with 𝑖 equal to 0) with one 
partially based on a uniform distribution, given by the following PMF: 
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𝑃𝑀𝐹𝑢𝑛𝑖𝑓(𝑥) =  𝑃𝐴𝐴𝐵(𝑥; 𝑝𝐴 = 1 − 𝑆𝐸, 𝑝𝑇 = 𝑆𝐸) 
  +  𝑃𝑇𝑇𝐵(𝑥; 𝑝𝐴 = 𝑆𝐸, 𝑝𝑇 = 1 − 𝑆𝐸) 
  + 
𝑃𝐴𝑇




- 𝑥 the coverages for alleles A and T, i.e. 𝑥 = (𝑛𝐴, 𝑛𝑇) 
- 𝑃𝐴𝐴 = (𝑝
2 + 𝑓𝑝𝑞), 𝑃𝑇𝑇 = (𝑞
2 + 𝑓𝑝𝑞) and 𝑃𝐴𝑇 = 2𝑝𝑞(1 − 𝑓)  
- 𝑝 and 𝑞 the estimated population allele frequencies for a specific locus over 
all 𝑁 samples (obtained by SeqEM) 
- 𝑆𝐸 the estimated sequencing error rate (median per chromosome, obtained 
by SeqEM) 
- 𝑓 the median inbreeding coefficient per chromosome 
- 𝐵(𝑥; 𝑝𝐴, 𝑝𝑇) the binomial probability for 𝑥 given the probabilities for each allele, 
i.e. 𝑝𝐴 and 𝑝𝑇 
Per SNP, the ratio 
𝑃𝑀𝐹(𝑥)𝑢𝑛𝑖𝑓
𝑃𝑀𝐹(𝑥)𝐻𝑊𝐸
 is calculated for each sample (coverages 𝑥) and only the 
putatively heterozygous samples are retained, i.e. the 2𝑝𝑞(1 − 𝑓)𝑁 samples with the 
lowest ratio (with 𝑝 and 𝑞 the estimated allele frequencies, 𝑓 the inbreeding coefficient 
and 𝑁 the number of samples for that SNP). Note that selecting putatively 
heterozygous samples is required to eliminate the impact of different genotype 
frequencies between SNPs, as for homozygous samples the likelihood for each PMF 
will be very similar (ratio’s approximating 1). The geometric mean of the remaining 
ratios is retained as a measure for the goodness-of-fit. 
Median allelic imbalance: As a robust measure for iAI, we implemented the median 
allelic ratio difference (ΔAI) to identify the clearest iAI loci. For controls as well as 
cases the ratio of the lowest expressed allele on highest is calculated. The ratios of 
the putative heterozygous samples are retained for both, i.e. the ratio of the 2𝑝𝑞(1 −
𝑓)𝑁 samples with the highest ratio (with 𝑝 and 𝑞 the estimated allele frequencies, 𝑓 
the inbreeding coefficient and 𝑁 the number of samples for that SNP). Samples 
without expression for that SNP are given a ratio of 0, and divided over homo- and 
heterozygous samples according to the inbreeding adjusted HWE-derived genotype 
frequencies. The median of those heterozygous ratios is calculated for both cases 
and controls and the absolute difference between both is calculated as the ΔAI. 
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R package 
The ASE and deregulation analyses were developed into an R package, called 
MAGE, available on GitHub (https://github.com/Biobix/MAGE). Four scripts are 
available in the package: (i) analysis of imprinting in control data, (ii) analysis of 
imprinting and its deregulation in control vs cases, (iii) analysis of variant bias in 
control data and (iv) analysis of allelic imbalance between cases and controls. All 
scripts first upload control count files upon which basic quality filtering is performed. 
Afterwards, parameters, such as allele frequency, inbreeding and SE, are estimated 
and the corresponding LRT is performed on the filtered SNPs. Significant SNPs are 
retained and mixture distribution plots are saved. If case data are analysed, the case 
count files are loaded into R and deregulation statistics are calculated. All filters 
described above can be easily adjusted in the scripts. 
Mutation analysis 
Mutation statistical analysis was performed with the MutSigCV software (v1.3.4), the 
software detects genes that are significantly mutated compared to the background 
mutation rate.284 MutSigCV was run on the public GenePattern server.285 To deal with 
synonymous gene names, MAF files were prepared for MutSig analysis with the 
prepareMutSig function from TCGAbiolinks. MutSigCV was performed on the 
mutation data from all samples as well as the mutation data from stage 1 samples. 
iAI results were evaluated for the significantly mutated genes detected by MutSigCV, 
synonymous gene names were also taken into account (information was retrieved 
from the HUGO Gene Nomenclature Committee on 12/08/2019). 
GWAS comparison 
GWAS studies previously identified 13 risk loci (Supplementary Table 20) in KIRC. 
Overlap of these risk loci with iAI results was evaluated on a SNP and gene level. 
Synonymous gene names were taken into account in the analysis, which was 
performed separately for stage 1 samples as well as for all cases combined. 
Methylation and CNA analysis 
To compare differences in methylation, only generally unmethylated loci in the control 
data were considered (average DNA methylation beta-value < 0.2, n = 52,109, similar 
to the TCGA Research Network) and assessed for hypermethylation in both control 
and tumour samples.264 A sample was considered hypermethylated when the 
methylation beta-value was higher than 0.2. On the gene level, the percentage of 
tumour samples showing hypermethylation (corrected for the percentage of control 
samples showing hypermethylation) was determined over all promoter CpGs and the 
maximal difference was listed. For CNA data, discretised losses and gains are 
expressed as a percentage in function of the amount of tumour samples for genewise 
comparison, as described by MEXPRESS.281 
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FDR 
Throughout the study, tests leading to a Benjamini-Hochberg-adjusted p-value (FDR) 
below 0.05 are deemed statistically significant, unless explicitly mentioned otherwise 
(cf. variant bias). 
Ruleset for simplified annotation 
For loci with an ambiguous, but unique annotation (i.e. multiple annotated genes were 
only present in this combination throughout the dataset), the ambiguous annotation 
was maintained. For other genes with an ambiguous annotation, ambiguities were 
resolved as follows: (i) if a gene was only present in two unique combinations but not 
on its own, it was removed; (ii) a simpler (i.e. less abundant) annotation was preferred 
over a more complex annotation. 
For ambiguous annotations where both parts were annotated uniquely as well as in 
combination, both unique annotations as well as the full annotation were retained 
(ambiguous annotation received a weight depending on the multiplicity of the 
ambiguous annotation in downstream calculations). More complex cases and cases 
with more than five annotations were not considered. 
Summarising per gene 
Allelic imbalance data were summarised at the gene level. Ambiguous gene 
annotation was simplified as explained higher. For each gene, the averaged ΔAI, 
average change in expression (base 2 logarithmic fold change) and the harmonic p-
value were calculated.283 If the simplified annotation did not fully resolve ambiguities, 
weights were used to incorporate uncertainty in the calculation of averages or 
harmonic p-values. 
Data availability 
The data that support the findings of this study are available from TCGA 
(https://portal.gdc.cancer.gov/) but restrictions apply to the availability of the aligned 
RNA-seq data due to ethical constraints. Data are, however, available from TCGA 
through the database of Genotypes and Phenotypes (dbGAP) upon motivated 
application and approval. 
Code availability 
Pre-processing and MAGE scripts are available through GitHub. 
(https://github.com/Biobix/MAGE_preprocessing and 
https://github.com/Biobix/MAGE, respectively). A Conda environment file is enable 
easy (pre-)processing. 
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Conclusions & perspectives 
Humans and other complex diploid organisms inherit two copies of DNA, one from 
their father and one from their mother. The DNA present is thus basically the same in 
virtually each cell of a human being, yet a wide variety of cell types, all with their own 
phenotype, exist. Therefore, aside genetics, also epigenetics is important in normal 
functioning of cells. Epigenetics establish which genes are (in)active in specific cell 
types. For the majority of genes, both copies are regulated in the same way, leading 
to a balanced expression or suppression of both alleles. However, for a subset of 
genes, expression of one allele is higher than the other, called allele-specific 
expression. The main focus of this thesis was imprinting, yet also other types of ASE 
exist and were studied in this doctoral study. If ASE originates from a parent-of-origin-
specific, monoallelic expression, it is called imprinting. As a consequence, either the 
paternal allele or the maternal one is expressed in a cell. As paternally expressed 
genes are often growth-promoting and maternally expressed ones growth-
suppressing, balanced expression of imprinted genes is crucial for a healthy 
regulation of cells. Indeed, imprinted genes have important roles in growth and 
development, with more imprinting in placental tissue and brain, and their 
deregulation is deemed a crucial factor in a number of imprinting disorders and 
cancers. 
The advent of sequencing technologies enabled studying genetics and epigenetics 
on a genome-wide level. Next-generation sequencing has had a major impact on our 
knowledge on cell regulation and functioning. The massive decrease in sequencing 
cost has transferred the bottleneck to accurate analysis of the sequencing data and 
development of the proper computational methods. However, research on imprinting 
and other ASE effects was still hampered by the limited availability of cost-efficient 
methods, particularly when the affordable procedure of crossing divergent inbred 
strains (as is done in mice) is not feasible due to ethical or practical reasons. 
Imprinting and cis-eQTLs, for example, were often studied by combining genotyping 
data with RNA-seq data to identify heterozygous samples (DNA) that only express a 
single allele (RNA). The combination of both data types, however, make these 
experiments extremely expensive, and the resolution depends on the quality and 
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genome-wide character of the genotyping data. Similarly, monoallelic methylation can 
be used as an indication for imprinting, methylation status and genotypes can (at least 
in theory) both be inferred from bisulphite sequencing data. However, the latter is very 
expensive, while the use of enrichment-based sequencing methods as cost-efficient 
alternative does not provide single-base resolution nor information on the 
unmethylated allele. Nevertheless, in 2014, a methodological framework for the 
detection of monoallelic methylation in MBD-seq data was developed at the BIOBIX 
lab.196 In this thesis, the rationale of this framework was employed to develop an 
improved and enhanced methodology for identifying not merely imprinted genes but 
also other ASE genes using distinct models. Another major focus of this thesis was 
the deregulation of these ASE genes in cancer and several methods were created to 
this end. Figure 25 gives an overview of the main results obtained in this research. 
Imprinting in healthy tissue 
The first proof-of-concept was an imprinting study on solely RNA-seq data from 
healthy and cancerous breast tissue from TCGA. A mixture model detected 121 
imprinted SNPs in control data, corresponding to 30 genes such as IGF2, H19 and 
MEG3. Validation of these putatively imprinted genes was possible in healthy breast 
GTEx data. Instead of comparing DNA genotypes with expressed genotypes for 
single samples, population genetics were applied to identify imprinting in multiple 
samples by exploring deviation from HWE. More precisely, RNA-based genotypes of 
imprinted genes can never be heterozygous, as only a single allele is expressed. 
Therefore, in RNA-seq data, only homozygous samples will be observed. As a 
comparison to previously developed methods, we also validated the imprinted SNPs 
by means of whole exome sequencing data, yet often the coverage was too low, 
highlighting the advantage of only using RNA-seq. Our method is based on HWE and 
thus also on its assumptions, such as absence of inbreeding. In an improved version 
of the methodology, incorporated in the MAGE (Modeller of Allelic Gene Expression) 
package, we also adjusted for possible inbreeding. As most loci are not featured by 
imprinting regulation, the degree of inbreeding can be estimated from the population 
as median degree of deviation from HWE over all SNPs. This adapted version was 
applied on healthy kidney tissue, again from TCGA, in a second case study. In kidney, 
we identified 105 SNPs, corresponding to 42 genes, putatively featured by imprinting. 
Other unpublished studies also showed the feasibility of the developed framework by 
detecting imprinted genes in prostate, blood, brain as well as a mixture of tissues. As 
for most methods available now, one important remark is that our method does not 
allow distinction between imprinting and random monoallelic expression, though the 
latter is anticipated to be far less consistent between all cells of a sample. Further 
validation is thus necessary to clarify if the identified genes are indeed imprinted. Trio 
family data were, however, not available for our studies, so we were not able to 
perform accurate validation. 
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The SNP-based character of our method made correct gene annotation extremely 
difficult, especially because imprinted genes are mostly located in gene clusters with 
many overlapping genes. However, analysing SNPs instead of whole genes allowed 
to evaluate if genes are imprinted in an isoform-specific manner. Studies found that 
imprinting can vary between isoforms and that the expression (regulation) depends 
on the promoter used. GRB10 and IGF2 are, for example, differently regulated for 
various isoforms.286,287 We here speculate that several genes, such as ZNF331 and 
GNAS, are regulated in the same way in breast tissue. Recently, independent 
evidence for isoform-specific imprinting of ZNF331 has become available, supporting 
our finding.187 As correct gene annotation was a difficult aspect of our analysis, some 
known imprinted genes were not identified. In breast, solely SNPs in the overlapping 
regions of SNRPN and SNURF were detected and we decided to only retain the 
SNRPN annotation. Data quality, such as low coverage, also hampered detection of 
some genes, which could explain why we did not always detect all known imprinted 
genes. However, contrary to many imprinting studies, we analyse imprinting in a 
tissue-specific manner. We therefore hypothesise that the largest part of known 
imprinted genes that we could not detect, are not imprinted in the analysed tissues. 
An important remark that should be made is that we analyse healthy control data from 
TCGA, which are actually matched normal samples adjacent to the tumour. Aberrant 
methylation has already been described in tissue neighbouring many tumour types, 
such as colon and prostate cancer, and we cannot rule out that this might disturb 
imprinting regulation in our analysed “healthy” samples.288,289 Yet healthy breast data 
in GTEx (not adjacent to tumours) allowed validation of most imprinted genes. 
Model-based, alignment bias-aware genotyping 
Similar to imprinting studies, most eQTL scanning experiments rely on both 
genotyping and transcriptomics data. However, in principle, genotypes can also be 
inferred from RNA-seq data, leading to a more limited (transcriptome only) yet far 
more cost-efficient methodology. Moreover, the presence of cis-eQTLs should in 
principle be detectable at the SNP level, as one allele will be expressed to a higher 
extent than the other (due to linkage with the causal cis-eQTL SNP). Nevertheless, 
also alignment bias will lead to higher expression of one allele (the reference allele) 
than the other. Therefore, we implemented an improved RNA-seq-based genotyping 
method, that relies on HWE and an expectation-maximisation procedure. Upon 
comparison with Affymetrix SNP array data for the renal control data, this led to 
genotyping error rates that were consistently better than those obtained from SeqEM. 
Moreover, the genotyping error rate approached 1%, implying that thus obtained 
genotypes are accurate for cis-eQTL studies using standard software such as Matrix 
eQTL, which can take into account the probabilistic nature of the genotype calls 
obtained by MAGE.272 
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Deregulated allelic expression in breast and renal cancer 
In breast cancer, apparent loss of imprinting was found for 24 SNPs in tumour data 
from various breast cancer subtypes (HER2, BL, LumA and LumB), yet only SNPs in 
HM13 showed LOI with expression upregulation. Most genes were featured by 
expression downregulation and residual expression of the silenced allele, which is 
perceived as LOI. To enable a clear distinction between different types of imprinting 
deregulation, we coined general imprinting deregulation “differential imprinting” (DI), 
and reserved the term LOI for the case where imprinting deregulation is associated 
with re-expression. DI was also often associated with CNVs and methylation 
differences. 
The rationale for detection of DI is that for imprinted SNPs, RNA-seq data would again 
show heterozygous individuals in cancer tissue. In the breast cancer study, the allelic 
ratio (lowest allele count over highest allele count) was employed as a measure for 
DI. Yet coverage was here not taken into account. In the study on kidney cancer, DI 
was evaluated using a logistic regression model, in which the lowest allele count per 
sample is the number of successes and the highest the number of failures, thereby 
incorporating coverage information of the loci. In stage 1 clear cell renal cell 
carcinoma, seven genes showed deregulated imprinting, again mostly combined with 
downregulation of gene expression. The exception, in line with canonical LOI, was 
again HM13. One important difficulty in both approaches of DI detection was the 
power. For homozygous samples, DI cannot be observed as biallelic expression 
because RNA-seq data will still be homozygous. If the number of DI samples is low, 
its accurate detection will therefore be challenging. This power issue is also present 
for imprinting detection, yet here sample numbers are usually sufficiently high. 
Four known imprinted genes featuring DI overlapped between breast and kidney 
cancer: MEST, ZNF331, ZDBF2, and HM13. For all genes the same deregulation 
directionality was found in both tumour types. In breast cancer, also DI of H19 and 
MEG3 was observed, both well-described imprinted genes that are frequently 
deregulated in cancer, such as in gastric, bladder, colorectal and liver cancer as well 
as in breast and renal cancer.224,229,290–301 We found imbalanced expression of both 
in renal cancer, yet no differential expression was observed. Importantly, we cannot 
exclude that the TCGA normal samples adjacent to the tumour hampered DE 
detection in renal cancer as methylation aberrations might have already been present 
in the normal-appearing controls. However, as DI detection of other imprinted genes 
was possible and we detected H19 and MEG3 deregulation in breast cancer, we 
hypothesise that this will only slightly impact our results. Also deregulation of MEST 
has already been extensively studied in cancer. Loss of imprinting with biallelic 
expression, independent of differential expression, was found in many cancers, such 
as lung, cervical and breast cancer.221,222,227,302 Possibly, deregulated methylation is 
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causing LOI.227 Other studies discovered that isoform-specific imprinting of MEST 
occurred, implying that the deregulated imprinting could be caused by promoter and 
isoform switching.303–305 This promoter switching was, for example, already described 
for IGF2.306 The IGF2/H19 locus also showed heavy deregulation in breast cancer, 
yet we were not able to clarify the cause of the deregulation. In kidney cancer, only 
H19 deregulation was found as IGF2 was not sufficiently expressed in the control 
data. ZDBF2 and ZNF331 deregulation is less well studied, yet our study as well as 
others found indications of isoform-specific ZNF331 imprinting that could again cause 
easy imprinting deregulation.307 HM13 was the only gene that showed consistent 
biallelic expression and upregulation in breast as well as kidney cancer. A recent 
study indicated that HM13 was also involved in tumour progression in glioblastoma.308 
In mice, HM13 is expressed from five different transcripts, two of which are paternally 
expressed and three maternally.218 Recently, the distinct imprinting status of various 
transcripts was also independently confirmed in humans.187 Possibly, transcript-
specific regulation of HM13 explains why detection of HM13 imprinting was rather 
dubious in previous studies and, moreover, why it is that easily deregulated in 
cancer.189 
In the last study on kidney tissue, our focus was not only on deregulation of imprinting, 
but also on disrupted allelic balance of other genes. The developed methodology was 
extended to allow detection of induced allelic imbalance, which we found to heavily 
occur in stage 1 clear cell renal cell cancer. Most iAI was observed on chromosome 
3, supporting the loss of the 3p arm, known to be of major importance in renal 
cancer.263 Aside 3p loss, we also identified many TSGs deregulated by iAI, such as 
SERPINA5 and WT1, with strong iAI and DE. Yet some important TSGs, such as 
VHL, were identified with only low levels of AI, as complete loss of a gene, instead of 
downregulation or loss of a specific allele, is not readily detected by our methodology. 
Furthermore, it is here important to note that finding an accurate measure for the 
effect size of iAI challenged its proper detection. We have implemented ΔAI as 
measure for iAI, yet this will more easily detect loci showing allelic losses than gains. 
Interestingly, many transmembrane transporter genes showed heavy allelic 
deregulation in renal cancer, mostly combined with downregulation, yet also 
upregulated transporters were observed. We hypothesise that induced allelic 
imbalance of transporters helps tumour development through remodelling the tumour 
metabolism, known as the Warburg effect, which is particularly important in renal 
cancer.274 We were also able to link iAI in tumour cells to copy number alterations and 
methylation differences, both possible sources of iAI. Studying allelic imbalance in 
tumour samples thus provided us with an extensive insight into cancer deregulation 
by not only identifying many imbalanced TSGs, but also by discovering an altered 
metabolism. 
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Opportunities and challenges 
By searching for and explicit modelling of different ASE effects on a population level, 
we circumvented the need for genotyping data. Nevertheless, the sole use of RNA-
seq and the assumptions our models entail, do imply a few limitations. Additionally, 
we only focussed on imprinting (deregulation) and iAI in human tissue using RNA-seq 
data, yet studying other expression patterns, data types or organisms could also 
provide interesting new biological insights. 
Limitations to RNA-seq data 
A difficulty of only using RNA-seq data is the possibility that random monoallelic 
expression was actually detected instead of the desired ASE effect. For detection of 
imprinting, we partially prevented this bias by applying a goodness-of-fit test on 
(symmetry of) the model. Random monoallelic expression generally still results in 
mixed expression of both alleles as various cells might silence different alleles and 
this will cancel each other out. We can assume that detection of random monoallelic 
expression instead of imprinting will thus only rarely be the case On the other hand, 
loci featuring random monoallelic expression in control tissue may lead to aberrant 
iAI detection in cancer. Whereas normal tissue would be a mixture of cells randomly 
expressing one allele (i.e. both are observed in the bulk RNA-seq data), clonal 
expansion of a single cell may lead to the expression of only a single allele in cancer. 
This would, however, not result in DE and therefore we only retained loci also showing 
DE. Yet in all analyses random monoallelic expression can never be fully ruled out 
without further validation. Parental data, or, where possible, reciprocal crosses of 
inbred strains, are necessary to make a distinction between all types of ASE.184,186 
Another limitation of our RNA-seq-based method is the mapping bias present in RNA-
seq data. As alignment of sequencing data is normally done on a reference genome 
with only one nucleotide, it was found that lower mapping rates were obtained for non-
reference alleles.309 It might thus seem as if reference alleles are expressed to a 
higher extent at heterozygous SNPs. Especially for short-read sequencing the bias 
caused problems, however when read depth increased, the bias decreased.309 For 
the detection of cis-eQTLs, this distinction in expression is exactly what we are 
looking for and hence the mapping bias hindered its accurate detection. Indeed, we 
observed a bias towards the reference allele for the major part of our putative cis-
eQTLs. Although a recent study described that the bias was less of a problem than 
originally thought for eQTL studies in general (where the bias may affect the 
expression estimates themselves), our results show that RNA-seq-based genotyping 
is particularly prone to alignment bias.170 Further analyses into the effect of this 
mapping bias on our cis-eQTL model and how to tackle it are necessary, yet the bias-
aware EM algorithm for genotyping was very successful. Many different techniques 
to take the bias into account were already described and a combination of such a 
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technique with our improved genotyping method could allow subsequent cis-eQTL 
detection that is not impeded by the mapping bias. It is also important to note that for 
cis-eQTLs, the causal variant itself is often not expressed and we can hence not 
compare expression levels to the variant itself. Previous studies therefore mostly 
compare expression data with genotyping data to search for causal variation in the 
neighbourhood of the expressed genes and this cannot be done solely using RNA-
seq. Nevertheless, we anticipate that linkage of the studied (i.e. expressed) SNPs 
with the causal SNP will still lead to the identification of (cis-)eQTLs. 
The mixture models described in this thesis were all developed as mixtures of 
binomial distributions with homozygous and heterozygous weights according to HWE. 
However, as sequencing includes an amplification step, errors made in the beginning 
of the process are amplified in the sequencing data. Indeed, often very broad 
heterozygous peaks were observed that hindered easy fit of the model. When more 
variance is present in the data, a beta-binomial distribution may be better suited. The 
probability of obtaining a specific allele is here not a constant, yet follows a beta 
distribution, allowing for more variance in the model. Another possible origin of 
variance in the data is that often a mixture of cell types (for example, a mix of imprinted 
and non-imprinted cells) is analysed, called heterogeneous data. For imprinting 
detection, we already took this into account by allowing partial imprinting. However, 
when a locus was featured by a large amount of variance, its broad heterozygous 
peak was sometimes incorrectly identified as partially imprinted. The use of a beta-
binomial distribution would again enable a better fit of the data, avoiding inaccurate 
modelling. Yet we did not implement the beta-binomial mixture model so far, as this 
would increase computational load and may compromise the stability of our methods 
(for example by overfitting to artefacts in the data). Interestingly, for analysis of iAI, 
the dispersion parameter modelled by the beta distribution could also be used an 
estimate for the amount of iAI. 
Limitations to the Hardy-Weinberg equilibrium 
The major assumption made in the developed methodologies is that the studied 
population is under HWE. The theorem states that a panmictic population is being 
studied. In the improved version of the methods, the most important source of 
deviation from HWE was already taken into account, i.e. inbreeding. Here, the amount 
of inbreeding in the population is estimated and the genotype frequency estimates 
were corrected afterwards. Still, deviation from HWE can occur, e.g. due to selection 
against deleterious homozygous genotypes, and it would be interesting to further 
develop our method independent of the HWE assumption. For example, besides 
estimation of allele frequencies in SeqEM, also genotype frequencies can be 
estimated with or without the assumption of HWE.156 The estimated genotype 
frequencies from SeqEM without HWE could thus be used as weights in our model 
instead of calculating those with HWE from the estimated allele frequencies. Also 
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here, increased flexibility of the models may lead to increased computational load and 
overfitting to artefacts. Alternatively, prior genotype probabilities from, for example, 
dbSNP could also serve as weights in the model. This eliminates the need of empirical 
estimation, but will only lead to valid results when estimates are present for exactly 
the population under study.155 A major disadvantage of using SeqEM for genotyping 
is that it can only handle two alleles at a SNP position. We implemented a Bayes’ 
approach to filter out two alleles and developed our model to only take into account 
two alleles as well. This is rather inconvenient and time consuming, applying another 
genotyping method, such as the popular GATK, would definitely be interesting.157 
GATK was not yet tested in our pipeline, because genotyping over multiple RNA-seq 
samples was initially not available. Recently, a workflow for joint genotyping of RNA-
seq data was however tested and proved successful.310 When a method is used able 
to determine the genotype from four possible alleles, our mixture model could easily 
be modified for four alleles. A mixture of multinomial distributions, instead of binomial 
distributions, would here allow to model the count data. Furthermore, we recently 
developed our own genotyping method able to deal with the mapping bias present in 
RNA-seq data, which SeqEM nor the GATK pipeline take into account. As our method 
proved more accurate than SeqEM, we could eliminate the use of SeqEM completely 
and only use our own genotyping method. Interestingly, it can estimate genotypes 
when four alleles are present and also works without assuming HWE. Yet thorough 
validation of this far more complex model would be necessary to eliminate possible 
artefacts and increase computational efficiency. 
Future applications 
The development of single-cell and third-generation sequencing currently enables 
sequencing of single cells and single molecules. As imprinting and other forms of ASE 
may occur in a tissue- and cell-type-specific manner, it would be very interesting to 
use single-cell sequencing (scRNA-seq) to analyse ASE with our method. Several 
methods were already developed, mostly by combining scRNA-seq data with 
genotyping data or by using reciprocal crosses in mice.258,311–313 However, a recent 
study showed that many of the discovered ASE loci were actually detected due to 
technical noise and this has to be taken into account.314 Furthermore, when genes 
are switched between active and non-active transcription (i.e. are not constitutively 
expressed), this typically happens through transcriptional bursting. It was observed 
that activation of the two alleles does not always occur simultaneously and this can 
hence be mistaken as allele-specific expression.311,312 Other methods use long-read 
third-generation RNA sequencing combined with next-generation RNA-seq data to 
detect ASE on the isoform level.315 NGS data were here still necessary because TGS 
data are featured by high sequencing error rates. Hence, when applying our method 
on TGS data, a beta-binomial mixture distribution would again be more suited, 
whereas for single-cell data transcriptional bursting should be taken into account. 
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Furthermore, scRNA-seq might be interesting for iAI analyses. As we described for 
VHL in KIRC, tumour impurity hindered accurate iAI detection. Indeed, high tumour 
impurity has already been observed in renal cancer.264 In our kidney study, iAI thus 
appeared less strong for many genes as a mix of non-tumour and tumour cells, with 
balanced and imbalanced expression respectively, was actually studied. scRNA-seq 
of tumour cells would thus provide a more accurate estimate of allelic imbalance in 
cancer. 
Imprinting does not only occur in humans, but also in other mammals, insects as well 
as in plants.316–318 Analysis of imprinting in other species with our method would be 
very interesting, however some problems will have to be tackled. Our method is based 
on detection of SNPs present in dbSNP.155 When studying other organisms such a 
database might not be present resulting in extra noise, particularly when also 
alignment is compromised due to a subpar genome (annotation) quality. Extra filtering 
and stricter goodness-of-fit might be necessary and should definitely be considered 
in advance. Furthermore, as the method was developed for only two alleles, the 
reference and variant alleles are also determined from dbSNP. The Bayes’ approach 
to only retain two alleles, i.e. the reference and variant allele, can be applied to obtain 
the two standard alleles from four possible alleles. However, this will often also cause 
extra noise and the use of alternatives to dbSNP would definitely be recommended. 
Another important aspect to take into account is that many species are polyploid, they 
inherit more than one copy from a specific or both parents. When analysing ASE 
effects in plants, different mixture models will thus be necessary, with more than three 
(beta-)binomial distributions. Also here the HWE-derived weights will have to reflect 
polyploidy. Note that SNPs present in homologous regions of alloploid species will be 
extremely hard to analyse without full length transcript information (e.g. obtained with 
TGS). 
Finally, we would like to point out that with the increased throughput and decreased 
cost of next-generation sequencing, we have entered the era of big data analysis. 
Large datasets containing numerous samples and multiple datatypes are now 
available, for example TCGA and GTEx, to study various (epi)genomic features. 
Instead of common statistical interference approaches where one merely focusses 
on deviation from the null hypothesis, we demonstrated that it is also possible to 
explicitly model the data under the alternative hypothesis and search for those loci 
that significantly adhere to the latter. Large populations enable the use of population 
genetics and the conversion of biological and molecular knowledge into such 
statistical models. In this work, we demonstrated that explicit statistical modelling of 
the effect under study allows for a more robust approach than common statistical 
interference. Moreover, the progress made through this work shows that this principle 
is far more applicable than originally thought, and can most likely also be applied to 
study other genetic features, given sufficient insight in the underlying biology and 
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technical aspects. Alternatively, with the increasing size of datasets also machine 
learning approaches are frequently used. However, the latter are typically black or 
grey box models that lead to accurate prediction and may even identify relevant 
technical and biological factors, yet do not provide us with an interpretable model. In 
contrast, loci that do not comply with knowledge-based statistical models can give 
new insights into biological features or technical artefacts. In other words, explicit 
statistical modelling of biological effects not solely serves to increase our knowledge 
regarding specific genes of interest, but also to evaluate to which extent we actually 




Figure 25 Overview of the results obtained throughout this research with the developed methods to study allele-specific 
expression (ASE) with typical examples. In breast tissue, 30 imprinted genes, including the well-known H19 gene, were identified 
of which 8 showed differential imprinting (DI) in breast cancer. Only one gene, namely HM13, showed DI together with expression 
upregulation, called loss of imprinting (LOI), while most DI genes were downregulated in cancer samples. In a kidney study, 42 
genes were significantly imprinted, such as MEG3 and H19. DI was observed for 7 genes in stages 1 clear cell renal cell 
carcinoma. Again, only HM13 showed canonical LOI. Induced allelic imbalance (iAI) of non-ASE SNPs was found for the large 
majority of SNPs, with a major enrichment of SNPs located on chromosome 3p. The latter reflects the loss of chromosome 3p 
that characterises renal cancer. Furthermore, many transmembrane ion transporters, such as AQP2, showed iAI providing a 
possible explanation for the Warburg effect observed in renal cancer. Finally, also an improved genotyping method was 








Allele-specific expression of genes is the imbalanced expression of the two parental 
copies of a gene. In humans, an autosomal gene is present in two copies, one 
maternally and one paternally inherited, called alleles. For the largest part of genes, 
both alleles are expressed at similar levels, yet for a subset of genes one allele is 
substantially less expressed or even not expressed at all. The former phenomenon is 
called allele-specific expression, while the latter is termed monoallelic expression. 
The silenced allele in monoallelic expression can be determined randomly, which 
occurs in X chromosome inactivation and autosomal random monoallelic expression, 
or can be based on the parental origin of the allele, called imprinting. For imprinted 
genes, only the maternal or paternal allele is thus expressed. Imprinting and allele-
specific expression are regulated by epigenetics, signatures on the DNA sequence 
that determine if genes are expressed or not. The most important epigenetic mark for 
imprinting is DNA methylation. The maternal and paternal DNA strand are 
differentially methylated, resulting in expression of only one allele. Yet, also other 
epigenetic mechanisms, such as histone modifications and non-coding RNAs, are 
important for imprinting and allele-specific expression regulation. Although the first 
imprinted and allele-specifically expressed genes have been detected decades ago, 
their exact characterisation in humans is lacking due to insufficient experimental and 
computational detection methods. We therefore developed new methodologies for 
the genome-wide detection of (the deregulation of) imprinting and allele-specific 
expression in health and disease. 
Most methods for detection of allele-specific expression available now combine 
genome and transcriptome data, genotyping-free methods are scarce to date. Our 
method models distinct expression patterns in populations instead of single samples 
and hence eliminates the need for prior genotyping. It is based on a principle of 
population genetics, the Hardy-Weinberg theorem, which estimates the number of 
heterozygotes and homozygotes in a population as the allele and genotype 
frequencies remain constant over generations. The Hardy-Weinberg equilibrium only 
holds true for large, random mating populations. When studying allele-specific 
expression in expression data, however, deviation from HWE will be observed. For 
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imprinting, for example, only a single allele is expressed and hence no heterozygous 
samples will occur in RNA-seq data. We used a mixture model of binomial 
distributions with HWE-based weights to screen for these deviations from HWE. 
Sequencing error rates, degree of imprinting and (in a second version) inbreeding are 
taken into account in the model. In 113 healthy breast samples from TCGA, we 
detected 30 putatively imprinted genes that could also be validated in GTEx data. 
Known imprinted genes, such as IGF2, H19 and MEST, were identified as well as 
novel candidate genes. Also from TCGA, we studied 128 healthy kidney samples and 
found 42 imprinted genes, of which many of the same known imprinted genes. In 
breast tissue, indications of transcript-specific imprinting were observed and 
imprinting was associated with monoallelically methylated sited. Our new method 
solely using RNA-seq data thus proved successful for the detection of imprinting in 
several tissues. A similar HWE-based model allowed to improve genotyping-based 
on RNA-seq data, which can subsequently be used for the detection of eQTLs. 
As imprinting is strictly regulated in healthy tissues and imprinted genes have 
important functions in development and growth, its deregulation easily results in many 
diseases, including cancer. Until now, most studies have only studied a limited 
number of imprinted genes instead of evaluating (virtually) all imprinted genes at 
once. We hence developed a new method to analyse genome-wide imprinting 
deregulation based on the idea that in RNA-seq data more heterozygotes will be 
observed compared to healthy tissue when loss of imprinting occurred. A first 
methodology observed differential imprinting of three genes, MEST, H19 and HM13, 
in 506 breast cancer samples from TCGA, furthermore eight genes showed 
deregulation when studying the various breast cancer subtypes. We here confirmed 
incorrect imprinting of the H19/IGF2 locus that was already discovered before in many 
cancer types. Most imprinting aberrations were associated with expression 
downregulation, possibly implying the presence of an imprinted gene network, yet 
loss of HM13 imprinting led to expression upregulation. For the former type of 
deregulation, we hypothesise that downregulation of the active allele and residual 
expression of the inactive allele is perceived as loss of imprinting. For both HM13 as 
well as the other deregulated genes, we were able to associate the differential 
imprinting to copy number alterations and methylation differences. The method was 
later improved and enabled detection of flawed imprinting of seven genes in 256 stage 
1 clear cell renal cell carcinoma samples from TCGA, including ZDBF2 and MEST. 
Imprinting was thus found to be heavily deregulated in breast cancer as well as kidney 
cancer. 
Allelic imbalance of non-allele-specific genes also has vital consequences in cell 
regulation, indeed imbalanced expression of tumour suppressor genes has been 
found in a myriad of cancer types. We can apply the same rationale to study induced 
allelic imbalance in stage 1 clear cell renal cell carcinoma. Here, however, we expect 
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an equal number of heterozygotes as derived from HWE in healthy tissue and a 
significant decrease in number of heterozygous samples in cancer tissue. We found 
numerous loci with iAI and also confirmed loss of the short arm of chromosome 3 in 
renal cancer. Furthermore, some of the most imbalanced loci were tumour suppressor 
genes and many transmembrane transporters were deregulated. We hypothesise 
that the latter may be an important contributor to the Warburg effect observed in clear 
cell renal cell carcinoma. Studying allelic imbalance is thus not only interesting for 
imprinted genes or eQTLs, but also to identify genes relevant in disease. Our 
developed method enhanced knowledge on imprinting and allele-specific expression 
in a more comprehensive manner and also showed massive allelic imbalance of 





Allelspecifieke genexpressie is de ongelijke expressie van de parentale kopieën van 
een gen. In het menselijk lichaam bevat een autosomaal gen normaalgezien twee 
kopieën: een maternaal en paternaal geërfde kopie. Deze kopieën worden allelen 
genoemd. De expressie van beide allelen is ongeveer gelijk voor de meeste genen, 
maar voor een aantal genen wordt één allel veel minder of helemaal niet 
geëxpresseerd, wat respectievelijk allelspecifieke en monoallellische expressie 
genoemd wordt. In monoallelische expressie kan het actieve allel willekeurig bepaald 
zijn, o.a. in X-chromosoominactivatie en in autosomale random monoallelische 
expressie, of parentaal bepaald, namelijk bij imprinting. Imprinted genen brengen dus 
enkel het maternale of het paternale allel tot expressie. Imprinting en allelspecifieke 
expressie worden epigenetisch gereguleerd: modificaties op de DNA-sequentie 
bepalen of een gen geëxpresseerd wordt of niet. Het belangrijkste epigenetische 
mechanisme voor imprinting is methylatie van DNA. De paternale en maternale DNA-
streng worden hierbij differentieel gemethyleerd en zo wordt slechts één allel tot 
expressie gebracht. Daarnaast zijn andere epigenetische mechanismen, zoals 
histonmodificaties en niet-coderend RNA, ook belangrijk voor de regulatie van 
imprinting en allelspecifieke expressie. Hoewel imprinting en allelspecificiteit lang 
geleden ontdekt werden, ontbreekt de genoomwijde beschrijving ervan in mensen 
door een gebrek aan goede en betaalbare detectiemethodes. Wij hebben daarom 
een nieuwe methode ontwikkeld voor de genoomwijde detectie van imprinting en 
allelspecifieke expressie in verschillende weefsels. 
De meeste methodes die nu beschikbaar zijn voor de detectie van allelspecifieke 
expressie maken gebruik van zowel genoom- als transcriptoomdata. Methodes die 
geen genotyperingsdata nodig hebben, zijn nog steeds zeldzaam. Onze methode 
modelleert verschillende expressiepatronen in populaties in plaats van in 
afzonderlijke stalen en elimineert zo de vereiste om eerst te genotyperen. De 
methode is gebaseerd op een principe van de populatiegenetica, namelijk de wet van 
Hardy-Weinberg. Hierin worden het aantal heterozygoten en homozygoten in een 
populatie berekend, uitgaande van constante allel- en genotypefrequenties over 
verschillende generaties. Het Hardy-Weinberg evenwicht geldt enkel voor grote, 
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panmictische populaties. In expressiedata zullen echter afwijkingen van het HWE 
waargenomen worden bij allelspecifieke expressie. Zo komt voor imprinting 
bijvoorbeeld maar één allel tot expressie en zullen er dus geen heterozygoten te zien 
zijn in RNA-seq data. Een mixture model van binomiale distributies met gewichten 
bepaald via HWE werd gebruikt om afwijking van HWE te detecteren. 
Sequeneringsfouten, graad van imprinting en (in een tweede versie) inteelt werden in 
het model in rekening gebracht. In 113 gezonde borstweefsel stalen van TCGA 
konden we 30 genen met hoogstwaarschijnlijke imprinting detecteren. Deze werden 
ook gevalideerd in borstdata van GTEx. Zowel gekende imprinted genen, zoals IGF2, 
H19 en MEST, als mogelijks nieuwe kandidaten werden geïdentificeerd. In gezond 
nierweefsel werden 42 imprinted genen gedetecteerd in 128 stalen van TCGA, 
waaronder veelal dezelfde gekende genen als in borstweefsel. In borstweefsel 
vonden we indicaties voor transcriptspecifieke imprinting en associaties met 
monoallelische methylatie. Onze nieuwe methode bleek dus succesvol voor de 
detectie van imprinting enkel gebruikmakend van RNA-seq data in verschillende 
weefsels. Een gelijkaardig HWE-gebaseerd model liet toe om genotypering 
gebaseerd op enkel RNA-seq data uit te voeren, wat op zijn beurt kan gebruikt worden 
om eQTLs op te sporen. 
Aangezien imprinting nauwkeurig gereguleerd wordt in gezond weefsel en imprinted 
genen een belangrijke rol spelen in ontwikkeling en groei, leidt deregulatie van 
imprinting tot veel ziektes, waaronder kanker. De meeste studies tot nu bestudeerden 
slechts een klein aantal imprinted genen eerder dan deregulatie van imprinting in het 
geheel te bekijken. Daarom hebben wij een nieuwe methode ontwikkeld voor de 
genoomwijde analyse van imprinting deregulatie. Vergeleken met gezond weefsel 
zullen in RNA-seq data opnieuw (meer) heterozygoten waargenomen worden 
wanneer verlies van imprinting optrad. Onze eerste methode detecteerde differentiële 
imprinting van drie genen, namelijk MEST, H19 en HM13, in 506 borstkanker stalen 
van TCGA. In de verschillende borstkanker subtypes vertoonden acht genen 
deregulatie. We konden de incorrecte imprinting van het H19/IGF2 locus, dat reeds 
ontdekt werd in veel andere kankertypes, bevestigen. De meeste afwijkingen van 
imprinting waren gelinkt met downregulatie van expressie, een imprinted gennetwerk 
is dus mogelijks aanwezig. We veronderstellen hier dat downregulatie van het actieve 
allel en residuele expressie van het inactieve allel waargenomen wordt als verlies van 
imprinting. Enkel HM13 vertoonde verlies van imprinting resulterend in opregulatie 
van expressie. We konden de differentiële imprinting van HM13 en de andere genen 
linken aan kopie-aantalvariaties en methylatieverschillen. Later werd de methode 
verbeterd en zo vonden we gedereguleerde imprinting van zeven genen, waaronder 
ZDBF2 en MEST, in 256 stadium 1 niercelkanker stalen van TCGA. Imprinting is dus 
sterk gedereguleerd in borst- en nierkanker. 
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Ongebalanceerde expressie van allelen in genen zonder allelspecifieke expressie 
heeft ook vitale gevolgen in celregulatie en we kunnen dezelfde methode toepassen 
om geïnduceerd allelisch onevenwicht te bestuderen in stadium 1 niercelkanker. 
Ongebalanceerde expressie van tumorsuppressorgenen werd inderdaad reeds in 
talrijke kankertypes gevonden. Hier verwachten we echter een aantal heterozygoten 
volgens HWE in gezond weefsel en een beduidend lager aantal in kankerweefsel. 
Talloze loci met geïnduceerd allelisch onevenwicht werden gevonden en we konden 
het verlies van de korte arm van chromosoom 3 in nierkanker bevestigen. 
Daarenboven detecteerden we zeer veel tumorsuppressorgenen onder de genen met 
het duidelijkste onevenwicht en werden bijzonder veel transmembraan 
transportergenen gedereguleerd. We stellen de hypothese voor dat dit laatste een 
verklaring biedt voor het Warburg-effect in niercelkanker. Ongebalanceerde 
expressie bestuderen is dus niet enkel interessant voor imprinted genen en eQTLs, 
maar ook om gedereguleerde genen in ziekte op te sporen. De ontwikkelde methode 
bevorderde de algemene kennis over imprinting en allelspecifieke expressie en 
toonde het belang aan van ongebalanceerde expressie van veel imprinted en niet-
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S.1.  A comprehensive overview of 
imprinting in breast tissue and 
its deregulation in breast cancer 
S.1.1. SNP tracing & data filtering 
After SNP calling and filtering of SNP sites not included in dbSNP, a total of 337,120 
SNPs were retained for the 113 normal breast samples. Additional filtering on model 
fit, FDR-adjusted p-value and median imprinting (see Methods, Section 2) led to a 
remaining 23,190, 16,214 and 148 SNPS, respectively. The number of SNPs per 
chromosome and in total are shown in Supplementary Table 6 for these different 
filtering steps. 140 SNPs (including various HLA, HLA-DR and HLA-DQ genes) were 
detected as putatively imprinted. Note that sex chromosomes were not taken into 
account in our analysis. After GTEx validation, 121 SNPs (with annotation) remained. 
For putatively imprinted SNPs located in overlapping genes, a rule of thumb was 
applied to determine the corresponding imprinted gene. As we are assessing RNA-
seq data, the most likely imprinted gene is the one in which the SNP is located in an 
exonic region. However, some loci were not situated in an exon, forcing us to evaluate 
other regions as well. We hence used the following rule to determine the matching 
gene for a SNP: exon (coding) > UTR > intron > upstream gene variant/downstream. 
Applying this rule on the Ensembl annotation of the 121 putatively imprinted SNPs 












Supplementary Table 6 Number of SNP positions found after SNP calling that 
overlapped with SNV positions of dbSNP (Overlap dbSNP), the number of retained 
loci after prior filtering (fSNPs), additional filtering on (i) FDR-adjusted p-value (adjP 
SNPs) and (ii) median imprinting (miSNPs) as well as the number of significantly 
imprinted SNPs (iSNPs). The final set of (annotated) imprinted SNPs (viSNP, 







miSNPs iSNPs viSNP 
1 38,200 2,290 1653 5 2 2 
2 26,873 1,588 1079 6 6 6 
3 23,093 1,505 1064 2 2 1 
4 16,806 977 682 4 3 2 
5 17,778 1,166 845 1 1 1 
6 24,094 1,338 913 20 20 7 
7 19,472 1,268 898 6 5 5 
8 13,816 871 660 0 0 0 
9 17,025 998 642 1 1 0 
10 16,627 981 683 1 0 0 
11 20,130 1,210 860 13 13 13 
12 18,417 1,221 874 1 1 0 
13 7,104 426 312 0 0 0 
14 13,828 840 551 26 26 26 
15 12,239 819 538 29 29 29 
16 15,537 967 687 7 6 5 
17 20,071 1,286 921 5 5 5 
18 6,091 455 315 0 0 0 
19 23,714 1,377 888 13 12 12 
20 9,983 656 445 7 7 6 
21 5,948 374 277 0 0 0 
22 10,274 577 427 1 1 1 
TOTAL 377,120 23,190 16,214 148 140 121 
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S.1.2. Mixture distributions of putatively imprinted genes (TCGA) 
 
Supplementary Figure 1 Mixture distributions of significantly imprinted SNPs. (a) 
rs112232512 (MTCO1P12, adj. p-value = 1.42E-75, candidate imprinted) (b) rs61746209 
(LINC01139, adj. p-value = 6.14E-29) (c) rs7582864 (ZDBF2, adj. p-value = 1.02E-21) (d) 
rs3732084 (ZDBF2, adj. p-value = 6.54E-26) (e) rs1975597 (ZDBF2, adj. p-value = 7.97E-30) 
(f) rs1448902 (ZDBF2, adj. p-value =2.02E-17) (g) rs4673350 (ZDBF2, adj. p-value = 2.56E-
23) (h) rs7585510 (PAX8-AS1, adj.p-value = 0.0068) (i) rs73158510 (PTX3, adj. p-value = 
5.44E-07, candidate imprinted) (j) rs12497062 (CPHL1P, adj. p-value = 0.00027, filtered – not 
validated in GTEx) (k) rs11940243 (ATP8A1, adj. p-value = 3.21E-08, filtered – not validated 
in GTEx) (l) rs8605 (NAP1L5, adj. p-value = 3.77E-22) 
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Supplementary Figure 2 Mixture distributions of significantly imprinted SNPs. (a) rs710834 
(NAP1L5, adj. p-value = 9.10E-21) (b) rs17800987 (ZNF300P1, adj. p-value = 4.87E-11) (c) 
rs2328535 (PLAGL1, adj. p-value = 3.09E-10) (d) rs9373409 (PLAGL1, adj. p-value = 1.40E-
27) (e) rs73006222 (PLAGL1, adj. p-value = 2.41E-15) (f) rs17615967 (PLAGL1, adj. p-value 
= 1.76E-14) (g) rs77203559 (PLAGL1, adj. p-value = 3.76E-15) (h) rs9321953 (PLAGL1, adj. 
p-value = 1.48E-21) (i) rs241407 (LOC100294145, adj. p-value = 2.71E-07) (j) rs35237090 
(PEG10, adj. p-value = 1.69E-17) (k) rs13073 (PEG10, adj. p-value = 3.35E-13) (l) rs7810469 
(PEG10, adj. p-value = 6.18E-29) 
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Supplementary Figure 3 Mixture distributions of significantly imprinted SNPs. (a) rs10863 
(MEST, adj. p-value = <detection limit) (b) rs706018 (HOTAIRM1, adj. p-value = 5.67E-36) (c) 
rs2075745 (H19, adj. p-value = 6.63E-34) (d) rs2075744 (H19, adj. p-value = 3.21E-27) (e) 
rs2839698 (H19, adj. p-value = 3.18E-57) (f) rs2067051 (H19, adj. p-value = 1.94E-57) (g) 
rs2839701 (H19, adj. p-value = 3.29E-61) (h) rs2839704 (H19, adj. p-value = 1.40E-44) (i) 
rs2839702 (H19, adj. p-value = 2.94E-50) (j) rs2839703 (H19, adj. p-value = 1.10E-46) (k) 
rs10840159 (H19, adj. p-value = 2.28E-50) (l) rs3741219 (H19, adj. p-value = 1.01E-107) 
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Supplementary Figure 4 Mixture distributions of significantly imprinted SNPs. (a) 
rs201284359 (RP11-109L13.1, adj. p-value = 4.97E-10, candidate imprinted) (b) rs7873 
(IGF2, adj. p-value = 1.08E-268) (c) rs1056905 (GLIPR1/KRR1, adj. p-value = 1.20E-06, 
filtered – not validated in GTEx) (d) rs1802710 (DLK1, adj. p-value = 2.68E-28) (e) 
rs78793760 (MEG3, adj. p-value = 4.16E-21) (f) rs35458454 (MEG3, adj. p-value = 5.16E-
21) (g) rs35431412 (MEG3, adj. p-value = 1.62E-29) (h) rs10147988 (MEG3, adj. p-value = 
1.07E-26) (i) rs3087918 (MEG3, adj. p-value = 5.47E-27) (j) rs3087917 (MEG3, adj. p-value 
= 1.64E-30) (k) rs3742391 (MEG3, adj. p-value = 2.13E-19) (l) rs12897172 (MEG3, adj. p-
value = 2.31E-17) 
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Supplementary Figure 5 Mixture distributions of significantly imprinted SNPs. (a) rs1884540 
(MEG3, adj. p-value = 1.78E-26) (b) rs2400941 (MEG3, adj. p-value = 1.64E-29) (c) 
rs77658190 (MEG3, adj. p-value = 2.45E-17) (d) rs10132552 (MEG3, adj. p-value = 4.26E-
17) (e) rs3194464 (MEG3, adj. p-value = 1.43E-23) (f) rs11160606 (MEG3, adj. p-value = 
1.53E-23) (g) rs1950628 (MEG3, adj. p-value = 1.01E-26) (h) rs1053900 (MEG3, adj. p-value 
= 4.91E-34) (i) rs1054000 (MEG3, adj. p-value = 7.58E-27) (j) rs8013873 (MEG3, adj. p-value 
= 6.63E-27) (k) rs11859 (MEG3, adj. p-value = 2.17E-25) (l) rs74080162 (MEG3, adj. p-value 
= 1.15E-24) 
S.1 Imprinting in breast and its deregulation in breast cancer 156 
 
Supplementary Figure 6 Mixture distributions of significantly imprinted SNPs. (a) rs4378559 
(MEG3, adj. p-value = 8.76E-25) (b) rs12890215 (MEG3, adj. p-value = 8.74E-25) (c) 
rs55996894 (MEG3, adj. p-value = 5.63E-21) (d) rs3742390 (MEG3, adj. p-value = 6.24E-31) 
(e) rs4906022 (MEG3, adj. p-value = 8.42E-204) (f) rs2554426 (SNRPN, adj. p-value = 9.39E-
16) (g) rs2732028 (SNHG14, adj. p-value = 3.33E-15) (h) rs74335291 (SNHG14, adj. p-value 
= 5.12E-24) (i) rs2732029 (SNHG14, adj. p-value = 6.71E-28) (j) rs765438 (SNHG14, adj. p-
value = 1.96E-28) (k) rs2732030 (SNHG14, adj. p-value = 9.43E-12) (l) rs10451029 
(SNHG14, adj. p-value = 6.14E-22) 
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Supplementary Figure 7 Mixture distributions of significantly imprinted SNPs. (a) rs2052723 
(SNHG14, adj. p-value = 1.14E-25) (b) rs2554419 (SNHG14, adj. p-value = 7.96E-31) (c) 
rs719704 (SNHG14, adj. p-value = 3.32E-22) (d) rs34316840 (SNHG14, adj. p-value = 1.13E-
25) (e) rs2732031 (SNHG14, adj. p-value = 1.23E-26) (f) rs2732041 (PWAR6, adj. p-value = 
1.60E-12) (g) rs2732043 (PWAR6, adj. p-value = 1.78E-13) (h) rs2732044 (PWAR6, adj. p-
value = 1.42E-26) (i) rs1030389 (PWAR6, adj. p-value = 1.68E-28) (j) rs62001981 (PWAR6, 
adj. p-value = 1.41E-26) (k) rs62001982 (PWAR6, adj. p-value = 1.09E-19) (l) rs1045935 
(PWAR6, adj. p-value = 6.76E-29) 
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Supplementary Figure 8 Mixture distributions of significantly imprinted SNPs. (a) 
rs11637436 (SNHG14, adj. p-value = 1.44E-11) (b) rs4344720 (SNHG14, adj. p-value = 
7.48E-20) (c) rs3863396 (SNHG14, adj. p-value = 2.68E-19) (d) rs62002013 (SNHG14, adj. 
p-value = 3.83E-12) (e) rs2356294 (SNHG14, adj. p-value = 4.96E-24) (f) rs1043164 
(SNHG14, adj. p-value = 6.41E-12) (g) rs691 (SNHG14, adj. p-value = 6.11E-33) (h) rs13526 
(SNHG14, adj. p-value = 3.74E-29) (i) rs4578621 (PLIN1, adj. p-value = 3.29E-06, candidate 
imprinted) (j) rs37822 (ZNF597, adj. p-value = 1.47E-18) (k) rs37823 (ZNF597, adj. p-value = 
3.08E-18) (l) rs11639510 (ZNF597, adj. p-value = 3.42E-25) 
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Supplementary Figure 9 Mixture distributions of significantly imprinted SNPs. (a) rs37824 
(ZNF597, adj. p-value = 3.21E-18) (b) rs12737 (ZNF597, adj. p-value = 1.01E-21) (c) 
rs77309587 (TPSB2, adj. p-value = 1.52E-08, filtered – not validated in GTEx) (d) 
rs141915702 (USP32P2, adj. p-value = 9.30E-03, candidate imprinted) (e) rs3931649 
(MTRNR2L1, adj. p-value = 3.16E-28, candidate imprinted) (f) rs113014658 (MTRNR2L1, adj. 
p-value = 6.82E-09, candidate imprinted) (g) rs113626706 (MTRNR2L1, adj. p-value = 5.74E-
12, candidate imprinted) (h) rs3931650 (MTRNR2L1, adj. p-value = 7.67E-29, candidate 
imprinted) (i) rs113983639 (ZNF331, adj. p-value = 1.99E-13) (j) rs8110350 (ZNF331, adj. p-
value = 4.12E-106) (k) rs8110538 (ZNF331, adj. p-value = 1.74E-109) (l) rs8109631 (ZNF331, 
adj. p-value = 8.52E-175) 
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Supplementary Figure 10 Mixture distributions of significantly imprinted SNPs. (a) 
rs4801386 (PEG3, adj. p-value = 1.10E-04) (b) rs1558355 (PEG3, adj. p-value = 2.70E-04) 
(c) rs723082 (PEG3, adj. p-value = 1.62E-31) (d) rs3143 (PEG3, adj. p-value = 7.86E-06) (e) 
rs1055359 (PEG3, adj. p-value = 9.07E-20) (f) rs11666110 (PEG3, adj. p-value = 8.06E-28) 
(g) rs1860565 (PEG3, adj. p-value = 1.02E-21) (h) rs33931963 (PEG3, adj. p-value = 6.73E-
28) (i) rs6058058 (HM13, adj. p-value = 1.33E-10) (j) rs6059869 (HM13, adj. p-value = 4.04E-
14) (k) rs6059873 (HM13, adj. p-value = 1.29E-19) (l) rs6059874 (HM13, adj. p-value = 4.88E-
14) 
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Supplementary Figure 11 Mixture distributions of significantly 
imprinted SNPs. (a) rs1115713 (HM13, adj. p-value = 7.94E-09) 
(b) rs2269621 (adj. p-value = 1.84E-18, filtered (no dbSNP 
annotation, though likely L3MBTL1)) (c) rs1800900 
(GNAS/GNAS-AS1, adj. p-value = 5.02E-16) (d) rs550197 (BCR, 
adj. p-value = 7.93E-50) 
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S.1.3. Validation of putatively imprinted regions 
a. Comparison with external references  
To independently validate our methodology, we compared these loci with the results 
found by Baran et al.189 By using RNA-seq data combined with genotype data from 
27 primary breast tissue samples (GTEx project), they were able to establish (partial) 
imprinting in breast tissue in 15 genes, including both novel and previously identified 
genes (Supplementary Data5, see189). They also detected several HLA genes, but as 
already stated in the Results section, these are not taken into account. In summary, 
13 genes were also found to be imprinted in breast tissue by our methodology, 
whereas 1 (= PPIEL) was not detected due to too low coverage in our samples (i.e. 
was filtered out prior to statistical analysis). For a second gene, SNURF, intronic 
SNPs were detected to be imprinted in TCGA as well. Yet, based on manual curation, 
it was deemed more likely that SNRPN was the imprinted gene rather than SNURF. 
Of the 23 genes not identified by Baran et al. as imprinted, 5 have been identified as 
imprinted in blood by Joshi et al.219 More genes concurred between the latter method 
and ours, however, many were curated due to annotation difficulties. Also, several 
genes were located near known imprinted regions. For example, PWAR6 is a gene 
lying in the Prader-Willi/Angelman region (PWAR), a region on chromosome 15 for 
which deregulation of the imprinting pattern is known to result in imprinting disorders, 
i.e. Prader-Willi and Angelman syndromes. Also SNHG14 is found in this region. 
An additional comparison was made with Geneimprint - a species-specific database 
containing already known imprinted or predicted imprinted genes with some 
(preliminary) evidence over all tissues – and the Imprinted Genes Catalogue – a 
database containing genes showing parent-of-origin effects.319,320 Our methodology 
successfully detected 17 of these genes (with 2 genes found in only one of the 
databases) to be monoallelically expressed in the 113 normal breast tissue samples 
(coloured in green or orange in Supplementary Table 7). Though 19 genes were not 
yet included in Geneimprint, it should be noted that for several genes, alternative 
independent evidence for imprinting is available. 
Supplementary Table 7 Overlap between our detected imprinted SNPs and the Geneimprint319 
and Imprinted Genes Cataloque320. The genes found in both databases and detected by our method 
are coloured in green. In red imprinted genes are shown which are not found in either of the 
databases. Genes found in one of the databases are coloured orange.  
MTCO1P12** LINC01139 ZDBF2 PAX8-AS1 PTX3** CPHL1P* 
ATP8A1* NAP1L5 ZNF300P1 PLAGL1 LOC100294145 PEG10 
MEST HOTAIRM1 H19 RP11-109L13.1** IGF2 GLIPR1* 
KRR1* DLK1 MEG3 SNRPN SNHG14 PWAR6 
PLIN1** ZNF597 TPSB2* USP32P2** MTRNR2L1** ZNF331 
PEG3 HM13 L3MBTL1 GNAS-AS1 GNAS BCR 
Genes eliminated after GTEx validation are indicated with * and candidate imprinted genes with **. 
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b. Comparison with previously found monoallelically methylated loci 
In 2014, our lab created a data-analytical framework based on the Hardy-Weinberg 
theorem that - using enrichment-based sequencing data (e.g. MethylCap-seq) - 
screens for regions featured by monoallelic DNA methylation in a genome-wide 
manner.196 Applied on 334 MethylCap-seq samples of diverse origin, 80 genomic 
regions were identified that featured significant monoallelic methylation, of which 49 
were located in genic regions. As an additional evaluation, these results were 
combined with the here reported monoallelically expressed genes (Supplementary 
Table 8). 
Supplementary Table 8 Overlap between monoallelically methylated regions found by Steyaert 
et al. and the imprinted genes identified by the current methodology196. Shown are the genes 
found by the former method. Genes also identified as monoallelically expressed by our framework 
are coloured in green, whereas genes not detected as imprinted by our method are coloured in 
red. Genes which were not (sufficiently) covered in our dataset - and thus were not analysed by 
our framework - are shown in grey. 
DUSP5P RN5S6 ZDBF2 ANTXR1 CDC27P1 
MFI2 SORCS2 HERC3 NAP1L5 ADAMTS2 
FAM50B RP11-420L9.4.1 WDR27 AC007091.1.1 PTPRN2 
SEC31 NDUFB8 KCNQ1 KCNQ10T1 MIR675 
H19 C13ORF33 LINC00351 RP11-1152H15.1.1 SNURF 
SNRPN NAA60 ZNF597 RMI2 AC136932.1 
ACCN1 PEG3 ZIM2 NOTCH3 AC092279.1 
ZNF331 GNAS-AS1 GNAS TMPRSS3 WRB 
MX2 FAM19A5 NHP2L1   
The presence of genes overlapping between both datasets suggests that monoallelic 
methylation of these loci is associated with - and is possibly involved in the 
mechanism of - the imprinted expression pattern. Here, 8 overlapping genes were 
found featuring both monoallelic methylation as well as monoallelic expression. 
c. Methodological validation using whole exome sequencing data 
The reliability of using RNA-seq data without corresponding DNA sequencing inferred 
genotypes for detection of imprinting was tested by comparing RNA-seq-based 
genotypes with WES-based genotypes (both SeqEM inferred) on the control data. 
Basically, it was evaluated whether for imprinted SNPs, heterozygous samples (as 
identified by WES) were indeed featured by monoallelic expression (RNA-seq). As 
already mentioned, inclusion of whole exome sequencing data for validation of 
imprinted SNPs led to massive loss of data. The WES data often showed too low 
coverage for accurate genotyping. Increasing the minimal reads threshold resulted in 
loss of many of the called genotypes (Supplementary Figure 12). Many of our 
detected SNPs are located in intronic regions or UTR’s, which could explain the low 
coverage or absence of the SNPs in WES data. As the minimal coverage imposed 
for genotyping increases, however, the concordance between the genotypes called 
by RNA-seq and WES reaches a plateau phase. Although only a limited set of 
genotypes remained after enforcing a minimal reads threshold, we were able to 
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confirm imprinting in the control data for virtually all heterozygous SNPs 
(Supplementary Figure 13 and Supplementary Table 4). We can hence conclude that 




Supplementary Table 4 Validation of imprinting by comparison of RNA “genotype” with whole 
exome sequencing (WES) data. Concordance is shown between the heterozygous DNA 
samples that were indeed apparently homozygous on the RNA level. Varying minimal 
coverages are shown. 
Min coverage Heterozygote DNA Homozygote RNA Concordance (%) 
5 467 447 95.7 
10 275 258 93.8 
15 206 191 92.7 
20 163 151 92.6 
Supplementary Figure 12 Correspondence between RNA-seq and whole exome 
sequencing data for the putatively imprinted SNPs of the control samples. As the 
minimal number of reads increases, the number of SNPs and samples available in 
whole exome sequencing data decreases and often too few data are available for 
accurate methodological validation. 
Supplementary Figure 13 Concordance between the RNA-seq genotypes and 
whole exome sequencing (WES) genotypes in control samples. As the reads 
threshold increases (for both RNA-seq and WES), the concordance also increases, 
but the absolute number of heterozygous loci decreases. 
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Subsequently, we analysed how accurate the allelic ratio is for determining 
heterozygous samples featured by biallelic expression in RNA-seq data of the tumour 
samples. By increasing the minimal allelic ratio for calling a sample biallelically 
expressing (and thus heterozygous), the concordance between RNA-seq and WES 
increased as well (Supplementary Figure 14). Low allelic ratios probably represent 
sequencing errors in the RNA-seq data, yet some SNPs remained discordant even 
after raising the reads threshold for both WES and RNA-seq. After looking into more 
detail in those SNPs, we found that – next to some remaining sequencing errors/low 
coverage artefacts – these discordances were probably due to too low minor allele 
frequencies deluding the SeqEM statistical methodology, though in some rare 
occasions, software errors may provide a likely alternative explanation. 
d. Candidate imprinted loci and transcript-specific imprinting 
GTEx healthy breast data was used to validate putatively imprinted genes. Validation 
led to elimination of four genes from our set of imprinted genes that could not be 
verified in GTEx data. Furthermore, four other genes were denoted as candidate 
imprinted. We were able to validate these genes in GTEx, but they showed a mixed 
imprinting pattern in TCGA that could not be explained by transcript-specific 
imprinting as no consistent results between exons were found (Supplementary Figure 
15). On the other hand, the more complex imprinting patterns of ZNF300P1, 
LOC100294145, ZNF331 and GNAS/GNAS-AS1 in TCGA showed consistent 
differences between exons and transcripts (Supplementary Figure 16), while for 
HOTAIRM1 evidence was less clear (Supplementary Figure 17). 
Supplementary Figure 14 Concordance of determining heterozygous samples in 
tumour RNA-seq data by allelic ratio with genotypes determined by whole exome 
sequencing data for varying allelic ratios and minimal reads thresholds. Only few loci 
had an allelic ratio approximately equal to 1, yet with one error, explaining the sudden 
drop at the right part of the figure. 
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To further evaluate whether inconsistencies for SNPs within a single gene are actually 
due to technical/power associated causes, or due to re-expression of overlapping 
non-imprinted isoforms, we analysed all (significant and non-significant) SNPs in 
some additional genes with known overlapping non-imprinted transcripts not 
discussed higher (GRB10, MEST, INPP5F/INPP5Fv2, NAPIL5/HERC3, PPIEL, 
ZNF597/NAA60/MIR6126, WRB, SNU13 and C22orf46). Most genes for which we 
did not observe any imprinting (GRB10, INPP5F, NAA60, WRB, SNU13 and 
C22orf46, Supplementary Figure 18(c) and (e) and Supplementary Figure 19, 
respectively) were clearly not imprinted independent of overlapping transcripts. Only 
PPIEL was missed due to technical issues, mainly low coverage for putatively 
imprinted SNPs. Note that this was also the locus found by Baran et al. that we 
missed.189 Supplementary Figure 18(a) illustrates that overlapping transcripts may 
disguise imprinting, yet the evidence/coverage was too poor to call this an imprinting 
candidate in our data. For NAP1L5 and MEST imprinting was clear in the actual genes 
(non-significant SNPs only due to technical issues, Supplementary Figure 18(b) and 
(d), respectively), whereas the overlapping genes were certainly not imprinted. 
In summary, visual evaluation of loci featured by complex imprinting patterns verifies 
that we extracted the large majority of (complex) imprinting events clearly present in 
the data, i.e. the current bottleneck for further improvement is the short-read RNA-
seq data rather than the proposed methodology. 
Supplementary Figure 15 Gene structure from candidate imprinted genes. Transcript 
maps of four genes denoted as candidate imprinted: (a) PLIN1, (b) USP32P2, (c) PTX3 
and (d) RP11-109L13.1. The red arrow indicates the SNP that was detected as imprinted 
in TCGA data. The other SNPs were either not detected due to technical issues or were 
clearly not imprinted. 
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Supplementary Figure 16 Gene structure from putative imprinted genes with transcript-
specific imprinting patterns. Transcript maps of four genes: (a) ZNF300P1, (b) 
LOC100294145, (c) ZNF331 and (d) GNAS/GNAS-AS1. The red arrow/circle indicates the 
SNPs that were clearly imprinted in TCGA data. The other SNPs were either not detected due 
to technical issues or were clearly not imprinted. Differences between imprinting patterns 
could here be attributed to transcript-specific effects. 
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e. Validation of imprinted pseudogenes 
In the set of imprinted genes, some pseudogenes were detected: CPHL1P, 
MTCO1P12, MTRNR2L1, USP32P2 and ZNF300P1. To verify that the pseudogene 
is imprinted rather than the original gene, additional validation was required. Reads 
containing the putatively imprinted SNPs were extracted from the BAM files. Next, a 
consensus sequence for each gene was constructed with multiple sequence 
alignment. Similar nucleotide sequences were then detected with BLAST 
(https://blast.ncbi.nlm.nih.gov/) against the human genome (blastn, “Human genomic 
+ transcript”). For CPHL1P, ZNF300P1 and USP32P2 we indeed found high similarity 
with the pseudogenes and not with the original gene. However, for MTCO1P12 and 
MTRNR2L1 evidence was contradictory: though aligning to both pseudogenes and 
original mitochondrial genes (even better to the latter for MTRNR2L1), imprinting of 
pseudogenes rather than mitochondrial artefacts is supported by (i) the observation 
of heterozygous samples (partial imprinting) for both genes (MTCO1P12, 
Supplementary Fig. 1(a); MTRNR2L1, Supplementary Fig. 9(e)-(h)) which is 
incompatible with mitochondrial genes; (ii) the perfect match between observed 
alleles and pseudogene dbSNP alleles; (iii) varying allele fractions for MTRNR2L1 
between SNPs (Supplementary Fig. 9(e)-(h)), incompatible with mitochondrial 
inheritance. Nevertheless, as the possibility of mitochondrial artefacts cannot be 
excluded, these loci are designated as candidate imprinted. 
Supplementary Figure 17 Gene structure of HOTAIRM1. The red arrow indicates the SNP 
that was clearly imprinted in TCGA data. The other SNPs were either not detected due to 
technical issues or were clearly not imprinted. Differences between imprinting patterns could 
here be attributed to transcript-specific effects. 
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Supplementary Figure 18 Isoform-specific maps and mixture distribution plots of (non-
)significant SNPs located in the corresponding gene(s). (a) PPIEL/BMP8A: more complex 
patterns of imprinting are observed here which could be explained by overlapping transcripts. 
(b) NAP1L5/HERC3: an imprinted SNP located in NAP1L5 and a non-imprinted one located 
in HERC3, indicating that only NAP1L5 is imprinted. (c) GRB10: clearly not imprinted. (d) 
MEST/MESTIT1: SNP that looks (partially) imprinted, but was missed due to technical issues. 
(e) INPP5F: clearly not imprinted. On the transcript map SNPs that were filtered for technical 
reasons are marked with #, filtered imprinted SNPs that could be imprinted with *, non-
imprinted SNP with ° and imprinted SNPs with “i”. The SNP corresponding to the mixture 
distribution is indicated with a red arrow. 
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Supplementary Figure 19 Isoform-specific maps and mixture distribution plots of (non-
)significant SNPs located in the corresponding gene(s). (a) ZNF597/NAA60/MIR6126: the 
transcript map shows that indeed only ZNF597 is imprinted. (b) WRB: clearly not imprinted. 
(c) SNU13: clearly not imprinted. (d) C22orf46: clearly not imprinted. On the transcript map 
SNPs that were filtered for technical reasons are marked with #, filtered imprinted SNPs that 
could be imprinted with *, non-imprinted SNP with ° and imprinted SNPs with “i”. The SNP 
corresponding to the mixture distribution is indicated with a red arrow. 
171 SUPPLEMENTARY INFORMATION 
 
S.1.4. Differential imprinting 
a. Differentially imprinted SNPs per subtype 
 
Supplementary Figure 20 Mixture distributions of SNP positions with differential 
imprinting between control samples and cancer subtypes. The significant subtypes are 
here shown. (a) rs1053900 (MEG3) (b) rs4378559 (MEG3) (c) rs12890215 (MEG3) (d) 
rs3741219 (H19) (e) rs2839703 (H19) 
S.1 Imprinting in breast and its deregulation in breast cancer 172 
 
Supplementary Figure 21 Mixture distributions of SNP 
positions with differential imprinting between control 
samples and cancer subtypes. The significant subtypes 
are here shown. (a) rs10840159 (H19) (b) rs2839702 
(H19) (c) rs2839701 (H19) (d) rs2067051 (H19) 
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Supplementary Figure 22 Mixture distributions of SNP positions with differential 
imprinting between control samples and cancer subtypes. The significant subtypes are 
here shown. (a) rs2075745 (H19) (b) rs2075744 (H19) (c) rs2839698 (H19) (d) 
rs7582864 (ZDBF2) (e) rs3732084 (ZDBF2) (f) rs1975597 (ZDBF2) (g) rs2585 (IGF2) 
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Supplementary Figure 23 Mixture distributions of SNP positions with differential 
imprinting between control samples and cancer subtypes. The significant subtypes are 
here shown. (a) rs7873 (IGF2) (b) rs6059869 (HM13) (c) rs8110350 (ZNF331) (d) 
rs8110538 (ZNF331) (e) rs7810469 (PEG10) 
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b. Biallelically expressing sample identification by RNA genotyping 
Validation of heterozygosity of biallelically expressing samples in WES data was 
limited due to low coverage, hence identification of such samples was also performed 
using RNA-seq data. To avoid the introduction of bias by imposing allelic-ratio-based 
cut-offs, genotypes were called in all samples for the DI SNPs with SeqEM. To avoid 
that samples with low fractions of the silenced allele were automatically called 
homozygous, the HWE option of SeqEM was used. The estimated number of 
heterozygous samples (based on HWE, 2PAPT*total#samples) was used to provide 




Supplementary Table 5 Number of observed and expected heterozygous samples in RNA-seq data for SNPs with DI for control, tumour and different 
breast cancer subtypes. Genotyping was done with SeqEM assuming Hardy Weinberg equilibrium to estimate the observed number of heterozygous 
samples. The expected number, on the other hand, is calculated by HWE as 2PAPT*total#samples. Significant DI SNPs per subtype are shown in bold. 
SNP  Gene 
Observed/Expected Heterozygous Samples % Observed/Expected Heterozygous Samples 
Control Tumour LumA LumB HER2 BL Control Tumour LumA LumB HER2 BL 
rs1053900 MEG3 0/56 11/245 2/112 3/59 5/27 1/43 0 4.5 1.8 5.1 18.3 2.3 
rs4378559 MEG3 0/37 27/147 8/69 10/34 5/17 4/24 0 18.4 11.6 29.7 29.5 16.3 
rs12890215 MEG3 1/38 30/150 7/71 13/34 4/17 6/25 2.6 20 9.9 38.1 23.4 23.6 
rs10863 MEST 8/31 101/137 41/62 36/33 16/15 7/25 26.1 73.6 66.5 109.5 103.3 28 
rs3741219 H19 0/56 15/251 2/113 1/60 6/28 6/46 0 6 1.8 1.7 21.3 13.2 
rs2839704 H19 0/53 14/239 1/107 3/57 4/27 6/43 0 5.9 0.9 5.3 14.9 13.8 
rs2839703 H19 0/53 13/239 1/107 3/57 3/27 6/43 0 5.4 0.9 5.3 11.2 13.8 
rs10840159 H19 0/56 16/251 1/113 3/60 6/28 6/46 0 6.4 0.9 5.0 21.3 13.2 
rs2839702 H19 0/56 16/251 2/113 4/60 3/28 7/46 0 6.4 1.8 6.7 10.6 15.4 
rs2839701 H19 0/56 16/251 2/113 4/60 3/28 7/46 0 6.4 1.8 6.7 10.6 15.4 
rs2067051 H19 1/56 16/252 0/114 2/60 4/28 10/45 1.8 6.4 0 3.3 14.1 22 
rs2075745 H19 1/56 16/252 2/114 2/60 5/28 7/45 1.8 6.4 1.8 3.3 17.6 15.4 
rs2075744 H19 1/50 18/243 2/109 4/58 2/28 10/43 2 7.4 1.8 6.9 7.1 23 
rs2839698 H19 0/56 14/251 0/113 3/60 4/28 7/46 0 5.6 0 5 14.1 15.3 
rs7582864 ZDBF2 5/44 58/145 30/72 11/33 5/11 12/28 11.3 40 41.6 33.8 45.5 42.6 
rs3732084 ZDBF2 5/47 48/162 23/80 7/35 7/16 11/28 10.6 29.7 28.7 19.7 44.4 39.2 
rs1975597 ZDBF2 1/48 69/182 25/84 22/42 13/21 8/33 2.1 37.9 29.9 52.3 62.4 24.6 
rs2585 IGF2 0/46 18/205 4/93 5/49 3/23 6/37 0 8.8 4.3 10.2 13 16.1 
rs7873 IGF2 0/21 5/96 0/43 1/23 3/11 1/17 0 5.2 0 4.4 28.2 5.7 
rs6059869 HM13 8/34 66/150 25/68 16/37 10/16 15/27 23.7 44 36.6 43.8 64.4 55.3 
rs6059873 HM13 4/33 42/147 10/67 13/36 6/16 12/27 12.2 28.6 15 36.6 37.9 44.9 
rs8110538 ZNF331 4/50 49/222 11/100 18/53 6/25 13/40 8 22.1 11 33.8 24.4 32.1 
rs8110350 ZNF331 6/48 53/216 14/97 15/51 8/24 15/39 12.4 24.5 14.4 29.2 32.8 38.1 
rs7810469 PEG10 1/22 22/97 5/44 10/22 5/11 1/18 4.5 22.7 11.4 45 45 5.5 
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c. Degree of imprinting linked to survival and age 
It was evaluated whether DI was associated with survival in tumour samples. Based 
on a Cox proportional hazard model (see Methods, Section 5), adjusting for age, and 
considering allelic ratio (AR = allele count least expressed allele/allele count most 
expressed allele) as measure for degree of imprinting, the ZDBF2 AR was 
significantly associated with poorer survival (for two of the three SNPs with significant 
DI in ZDBF2; FDR-adjusted p = 0.027 and 0.086 for rs3732084 and rs1975597, 
respectively). Also when survival analysis was performed solely on the putative 
heterozygous samples (see Supplementary Methods), ZDBF2 AR was associated 
with significant lower survival. The degree of imprinting (AR) was not correlated to 
age for tumour or control data (Supplementary Table 6). 
The logCPM-value of the least expressed allele count was also linked to survival 
using an age adjusted Cox proportional hazard model. However, here too little events 
occurred to accurately draw conclusion from this analysis. Both the allelic ratio as well 
as the logCPM-value of the least expressed allele count were also correlated to age 
(Pearson’s correlation test), but no significant correlations were found 
(Supplementary Table 6). The same conclusions were obtained when only taking the 
putative heterozygous samples into account. 
Supplementary Table 6 Correlation of imprinting degree with age. Pearson’s r (r) and FDR-adjusted p-
values (p) of tumour and control subsets are shown for all DI SNPs. The degree of imprinting was once 




Tumour Control Tumour Control 
r p r p r p r p 
rs3741219 H19 -0.02 0.79 -0.04 0.77 -0.09 0.29 0.11 0.69 
rs2839704 H19 -0.03 0.79 -0.06 0.72 -0.04 0.57 0.14 0.69 
rs2839703 H19 -0.02 0.79 -0.12 0.62 0 0.94 0.09 0.69 
rs10840159 H19 -0.02 0.79 -0.07 0.72 -0.10 0.28 0.14 0.69 
rs2839702 H19 -0.04 0.68 0.02 0.87 -0.10 0.28 0.10 0.69 
rs2839701 H19 -0.04 0.68 0.04 0.77 -0.04 0.57 0.06 0.71 
rs2067051 H19 -0.05 0.68 -0.08 0.72 -0.06 0.57 -0.04 0.71 
rs2075745 H19 -0.05 0.68 -0.06 0.72 -0.04 0.57 -0.05 0.71 
rs2075744 H19 -0.07 0.68 -0.20 0.62 -0.04 0.57 -0.09 0.69 
rs2839698 H19 -0.06 0.68 -0.15 0.62 -0.07 0.57 -0.06 0.71 
rs2585 IGF2 0.02 0.79 0.07 0.72 -0.05 0.57 0.12 0.69 
rs7873 IGF2 -0.04 0.68 0.11 0.62 -0.12 0.26 0.29 0.07 
rs6059869 HM13 -0.06 0.68 0.04 0.77 -0.06 0.57 0.08 0.69 
rs6059873 HM13 -0.07 0.68 0.08 0.72 -0.05 0.57 0.09 0.69 
rs8110538 ZNF331 0 1 0.07 0.72 0.02 0.66 0.04 0.71 
rs8110350 ZNF331 0.01 0.88 0.06 0.72 0.04 0.57 0.07 0.71 
rs7810469 PEG10 0.01 0.93 -0.12 0.62 0.03 0.66 -0.08 0.70 
rs1053900 MEG3 -0.05 0.68 -0.02 0.87 -0.03 0.66 0.04 0.71 
rs4378559 MEG3 -0.04 0.68 0.12 0.62 -0.04 0.57 0.13 0.69 
rs12890215 MEG3 -0.02 0.86 0.01 0.88 -0.04 0.57 0.03 0.79 
rs10863 MEST 0.06 0.68 -0.16 0.62 0.04 0.57 -0.09 0.69 
rs3732084 ZDBF2 0.03 0.79 0.13 0.62 0.05 0.57 0.14 0.69 
rs1975597 ZDBF2 0.04 0.68 -0.11 0.62 0.01 0.81 -0.11 0.69 
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S.1.5. Differential expression 
Significant DE was found in 92% of the imprinted SNPs (111 out of 121) for all tumour 
samples. In the different subtypes 90% (109 SNPs), 89% (108 SNPs), 89% (108 
SNPs) and 92% (111 SNPs) showed significant DE for HER2, BL, LumA and LumB 
respectively (Supplementary Table 7). In this set of differentially expressed SNPs 
most loci were downregulated. 87% (97 out of 111 SNPs) were detected with a 
negative log fold change for the tumour samples. 95% (104 out of 1109 SNPs), 86% 
(93 out of 108 SNPs), 93% (100 out of 108 SNPs) and 85% (94 out of 1141 SNPs) of 
the deregulated loci were downregulated for HER2, BL, LumA and LumB respectively 
(Supplementary Table 7). The FDR-adjusted p-values and log fold changes for all 
SNPs can be found in Supplementary Data 5. 
Supplementary Table 7 Number of significant differentially expressed 
imprinted SNPs in control versus tumour data and control versus the different 
breast cancer subtypes. The number of SNPs with an FDR-adjusted p-value ≤ 
0.05 are shown in column “# DE” with the percentage between brackets. The 
number and percentage of upregulated (positive log fold change) and 
downregulated (negative log fold change) SNPs are shown in the other 
columns. 
Control vs # DE (%) # Up (%) # Down (%) 
Tumour 111 (92) 14 (13) 97 (87) 
HER2 109 (90) 5 (5) 104 (95) 
BL 108 (89) 15 (14) 93 (86) 
LumA 108 (89) 8 (7) 100 (93) 
LumB 111 (92) 17 (15) 94 (85) 
Afterwards, we also examined differential expression for the detected imprinted genes 
by taking the sum of the CPM-values of the SNPs corresponding to an imprinted gene. 
Again this analysis was done for tumour samples as well as the different subtypes. 
FDR-adjusted p-values are shown in Supplementary Table 8. As two SNPs 
(rs1056905 and rs1800900) were located in the exonic region of two genes, these 
genes (GLIPR1/KRR1 and GNAS/GNAS-AS1) were here analysed as one. Hence, in 
this analysis only 29 imprinted genes were studied. The results again confirm that 
imprinting is heavily deregulated in breast cancer and the different subtypes. We 
found 100% DE in the aggregated tumour data and 93% (27 out of 29 genes), 86% 
(25 out of 29 genes), 90% (26 out of 29 genes) and 97% (28 out of 29 genes) in 
HER2, BL, LumA and LumB respectively (Supplementary Table 9). In the tumour 
samples all genes were differentially expressed, 24 downregulated (76%) and 7 
(24%) upregulated. Also in the varying subtypes most genes were differentially 
expressed. Only for 9 genes no DE was found in some of the subtypes, namely H19, 
HM13 (borderline in HER2, significant in other subtypes), LINC01139, 
LOC100294145, PEG10, PTX3, USP32P2 (borderline in BL, significant in other 
subtypes) and ZNF597. Again, most genes were downregulated with around 26 
downregulated genes for all subtypes. 
 
 
Supplementary Table 8 FDR-adjusted p-values (p) and log fold changes (logFC) of differential expression analysis. CPM-values of the 
corresponding SNPs per gene were used to compare control versus diseased samples. Differential expression between control and tumour was 
analysed with a Wilcoxon Rank Sum test, while analysis per subtype was done with a Kruskal-Wallis test and Dunn’s post-hoc test.* 
Gene 
Tumour HER2 BL LumA LumB 
logFC p logFC p logFC p logFC p logFC p 
BCR -0.83 4.07E-06 -0.88 1.24E-03 -0.72 2.92E-05 -0.96 2.35E-05 -0.66 3.70E-04 
DLK1 1.15 9.54E-31 2.82 6.02E-10 2.46 5.72E-19 -4.16 4.01E-25 0.61 1.46E-25 
GNAS-AS1/GNAS -2.06 9.33E-19 -1.70 3.92E-08 -0.86 2.64E-04 -3.83 5.51E-19 -2.01 5.03E-19 
H19 -0.75 4.27E-02 -1.09 4.44E-03 -0.67 7.12E-04 -0.58 4.32E-01 -1.07 2.17E-03 
HM13 0.47 1.53E-05 0.27 5.43E-02 0.59 2.38E-05 0.37 9.09E-04 0.64 1.05E-06 
HOTAIRM1 -1.79 5.43E-26 -2.46 1.08E-17 -0.59 3.88E-06 -2.13 2.28E-22 -2.57 5.66E-24 
IGF2 -1.15 2.10E-33 -2.37 2.22E-22 0.14 3.50E-36 -1.38 2.59E-15 -2.31 7.52E-29 
LINC01139 0.20 7.32E-04 -0.49 1.23E-03 1.27 1.66E-01 -0.34 2.58E-04 0.16 5.37E-03 
LOC100294145 0.58 9.12E-04 0.76 2.60E-04 1.01 6.98E-06 0.13 2.51E-01 0.84 4.30E-06 
MEG3 -2.41 1.08E-45 -2.15 1.87E-16 -3.06 3.13E-41 -2.16 1.67E-29 -2.73 1.06E-36 
MEST -1.59 1.23E-31 -1.68 3.23E-13 -0.94 6.47E-15 -1.86 6.30E-31 -1.74 2.53E-19 
MTCO1P12 0.14 4.09E-04 -0.53 3.86E-02 0.86 2.10E-04 0.17 2.17E-03 -0.47 9.45E-04 
MTRNR2L1 -1.56 1.84E-27 -1.16 2.25E-07 -1.58 2.43E-16 -1.61 2.53E-23 -1.85 4.93E-24 
NAP1L5 -1.13 1.60E-33 -1.58 1.06E-24 -1.15 1.22E-21 -1.00 4.60E-22 -1.25 2.88E-25 
PAX8-AS1 -0.60 3.00E-06 -0.83 9.19E-04 -0.38 1.67E-04 -0.56 9.74E-05 -0.74 1.46E-05 
PEG10 0.77 1.32E-03 0.85 5.51E-02 0.87 2.96E-01 0.78 5.59E-05 0.70 3.56E-04 
PEG3 0.01 1.79E-21 -0.70 3.82E-12 0.74 6.52E-12 -0.40 5.64E-17 0.28 6.85E-16 
PLAGL1 -2.54 3.03E-41 -3.02 1.98E-21 -1.34 1.19E-08 -2.84 1.25E-35 -3.61 3.12E-42 
PLIN1** -5.53 1.31E-42 -5.95 1.11E-21 -7.24 3.36E-36 -5.32 5.96E-30 -5.17 5.17E-26 
PTX3** -1.45 5.53E-25 -3.83 1.68E-19 0.11 1.30E-01 -1.62 8.37E-22 -4.47 2.57E-33 
PWAR6 -1.33 1.41E-32 -1.73 5.23E-19 -2.22 6.45E-35 -1.15 3.00E-19 -1.03 7.94E-20 
RP11-109L13.1** -1.75 9.62E-07 -1.20 3.09E-02 -1.80 2.38E-05 -1.68 3.24E-06 -2.20 1.48E-05 
SNHG14 -1.20 9.54E-31 -1.19 5.90E-14 -1.90 4.27E-32 -1.16 1.22E-21 -0.88 1.87E-16 
SNRPN -0.55 1.20E-13 -0.57 4.51E-07 -1.22 1.06E-22 -0.42 2.25E-07 -0.41 2.59E-07 
USP32P2** -0.57 6.38E-04 -1.12 2.09E-03 -0.20 5.51E-02 -0.46 1.18E-03 -0.93 4.12E-04 
ZDBF2 -1.34 2.49E-33 -2.12 4.93E-24 -1.28 1.14E-18 -1.28 2.81E-24 -1.25 5.11E-23 
ZNF300P1 -2.87 1.32E-36 -2.45 3.90E-14 -3.49 3.67E-27 -2.75 6.73E-28 -3.11 2.62E-26 
ZNF331 -0.91 2.76E-28 -1.00 1.36E-18 -1.02 4.04E-18 -0.93 4.60E-22 -0.75 3.01E-16 
ZNF597 -0.09 1.68E-02 -0.13 3.88E-02 -0.84 6.04E-12 0.07 2.79E-01 0.08 4.01E-01 
*Significant DE is shown in bold. **Candidate imprinted genes. 
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Supplementary Table 9 Number of significant differentially expressed imprinted 
genes in control versus tumour data and control versus the different breast cancer 
subtypes. The number of genes with an FDR-adjusted p-value ≤ 0.05 are shown 
in column “# DE” with the percentage between brackets. The number and 
percentage of upregulated (positive log fold change) and downregulated 
(negative log fold change) genes are shown in the other columns. 
Control vs # DE (%) # Up (%) # Down (%) 
Tumour 29 (100) 7 (24) 22 (76) 
HER2 27 (93) 2 (7) 25 (93) 
BL 25 (86) 6 (24) 19 (76) 
LumA 26 (90) 3 (12) 23 (88) 
LumB 28 (97) 6 (21) 22 (79) 
Verification of DI associated DE  
Whole exome sequencing data were used to verify the impact of DI on differential 
expression. Biallelically expressing samples were here conservatively defined as 
samples with a heterozygous WES-based genotype and an AR of 0.2 or more (cf. 
Supplementary Figure 14). Not-biallelically expressing heterozygotes, conversely, 
were samples with a heterozygous WES genotype and an AR of 0.2 or less. A raw 
count threshold of 6 per SNP was used to limit loss of data. The combination of 
genotyping data and an AR-threshold was used to make the identification of 
biallelically expressing samples less sensitive to sequencing errors. When no 
biallelically expressing heterozygotes were found amongst the control samples, we 
assumed that biallelic expression did not occur in control tissue and all control 
samples were considered to be monoallelically expressing. Expression values were 
the same as the ones used for the SNP subtype analysis. The data were thus split 
into biallelically expressing tumour, monoallelically expressing tumour, biallelically 
expressing control and monoallelically expressing control samples (Supplementary 
Table 10). Overall differential expression between all subgroups was tested with a 
Kruskal-Wallis test. When FDR-corrected Kruskal-Wallis p-values were smaller than 
0.1, enough evidence for differential expression among subgroups was assumed to 
further explore the changes between the subgroups with a Dunn’s test. Dunn’s test 
p-values were not further FDR-corrected as the remaining number of tests performed 






Supplementary Table 10 Number of biallelically expressing (BA) and monoallelically expressing (MA) samples in tumour and control samples based on the allelic ratio and 
whole exome sequencing genotype. Mean CPM-values per subgroup and their confidence interval are also shown. 
Gene SNP # BA tumour # MA tumour # BA control # MA control CPM BA tumour CPM MA tumour CPM BA control CPM MA control 
ZNF331 rs8109631 46 126 3 30 0.23 [0.14-0.39] 0.32 [0.24-0.49] 0.31 [0.26-0.53] 0.70 [0.54-0.83] 
HM13 rs1115713 17 63 3 13 0.30 [0.25-0.56] 0.17 [0.12-0.28] 0.29 [0.24-0.32] 0.17 [0.14-0.18] 
USP32P2* rs141915702 9 6 5 0 0.12 [0.11-0.19] 0.18 [0.15-0.31] 0.38 [0.22-0.39] NA 
ZDBF2 rs3732084 6 51 0 83** 0.15 [0.07-0.22] 0.09 [0.07-0.12] NA 0.12 [0.07-0.18] 
H19 rs2839701 5 46 0 83** 2.72 [2.08-3.16] 5.15 [2.60-7.55] NA 4.31 [2.44-9.41] 
*Candidate imprinted genes. **When no heterozygote BA samples were observed, all control samples were considered to be MA 
 
 
Supplementary Table 11 Differential expression analysis between biallelically expressing (BA) and monoallelically expressing (MA) 
samples in control and tumour tissue. Differential expression between the subgroups with a Dunn’s test was only tested when the FDR-
adjusted p-value of the Kruskal-Wallis test was significant with a significance threshold of 0.1.*  
Gene SNP p Kruskal-Wallis 
p BA tumour 
vs  
MA control 
p BA tumour 
vs  
MA tumour 
p BA control 
vs  
MA control 
p BA control 
vs 
 BA tumour 
p MA control  
vs 
 MA tumour 
ZNF331 rs8109631 3.287E-09 9.089E-12 0.003544 0.05928 0.1445 2.133E-08 
HM13 rs1115713 0.003314 0.0003734 0.0001473 0.06941 0.3192 0.2032 
USP32P2** rs141915702 0.1215 NA NA NA NA NA 
ZDBF2 rs3732084 0.1896 NA NA NA NA NA 
H19 rs2839701 0.2658 NA NA NA NA NA 
*Significant results are shown in bold. **Candidate imprinted genes. 
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S.1.6. DE and DI linked to copy number variation 
LogCPM-values of all genes (counts obtained from firebrowse.org and normalised 
with EdgeR) were compared with CNV data with a linear model in tumour samples. A 
second linear model was constructed including the breast cancer subtypes. For 17 of 
the 23 imprinted genes a significant link between expression and CNV was found 
(Supplementary Table 12). For each gene, a contingency table was made comparing 
CNV with DE. A sample was called up- or downregulated when featured by a 
normalised logCPM-value outside of the 95% confidence interval of the control data 
(Supplementary Data 6). Results are graphically summarised in Supplementary 
Figure 24. 
Supplementary Table 12 Degrees of freedom (df), F-values (F) and FDR-adjusted p-values (p) for 
imprinted genes of linear models for expression (dependent variable) and copy number variation (model 1; 
2 degrees of freedom) and also expression, copy number variations and breast cancer subtype (model 2; 
2 and 4 degrees of freedom respectively).* 
Gene 
CNV (model 1) CNV (model 2) Subtypes (model 2) 
df F p df F p df F p 
LINC01139 464 1.39 2.74E-01 460 1.41 2.69E-01 460 2.43 5.79E-02 
PLAGL1 464 7.10 1.76E-03 460 10.08 1.19E-04 460 49.75 9.95E-34 
SNRPN 464 65.38 7.42E-25 460 71.72 5.92E-27 460 2.26 5.09E-09 
PEG10 464 3.80 3.19E-02 460 3.91 2.80E-02 460 4.35 2.82E-03 
ZNF300P1 464 4.54 1.71E-02 460 4.91 1.19E-02 460 10.47 8.37E-08 
PTX3 464 5.93 4.70E-03 460 9.54 1.83E-04 460 71.52 1.02E-45 
PAX8-AS1 464 0.10 9.09E-01 460 0.10 9.09E-01 460 1.06 3.93E-01 
PEG3 464 7.23 1.69E-03 460 7.21 1.36E-03 460 0.62 6.49E-01 
DLK1 464 2.57 9.91E-02 460 2.68 8.92E-02 460 5.83 2.47E-04 
MEST 464 3.98 3.67E-06 460 14.06 3.40E-06 460 1.69 1.66E-01 
BCR 464 166.63 6.63E-54 460 182.50 1.03E-57 460 12.05 6.52E-09 
GNAS 464 43.50 2.22E-17 460 49.86 1.45E-19 460 17.95 4.78E-13 
PLIN1 464 6.82 2.14E-03 460 7.90 7.52E-04 460 19.39 5.35E-14 
USP32P2 443 11.54 3.32E-05 439 11.69 2.89E-05 439 2.42 5.79E-02 
NAP1L5 464 18.06 9.23E-08 460 18.71 5.05E-08 460 5.23 6.57E-04 
ZNF331 464 48.73 3.54E-19 460 49.58 1.45E-19 460 3.02 2.38E-02 
H19 465 0.11 9.09E-01 460 0.12 9.09E-01 460 0.35 3.18E-06 
MEG3 464 0.19 1.37E-01 460 2.39 1.12E-01 460 11.55 1.39E-08 
IGF2 463 3.78 3.19E-02 459 4.53 1.62E-02 459 24.06 3.36E-17 
ZNF597 463 126.32 1.92E-43 459 138.86 7.94E-47 459 12.50 3.83E-09 
GNAS-AS1 464 2.11 1.41E-01 460 2.13 1.38E-01 460 2.26 7.06E-02 
HM13 464 34.05 6.11E-14 460 37.88 2.26E-15 460 14.05 3.04E-10 
ZDBF2 464 7.92 9.55E-04 460 8.07 6.90E-04 460 3.18 1.96E-02 
*Significant p-values are shown in bold. 
For HM13, overexpression in tumour samples was compared to CNV data to 
ascertain that LOI was not associated with gain of the locus (given the observed re-
expression of the previously silenced allele, DI here corresponds to LOI). Genotypes 
of the SNPs were called with SeqEM (assuming HWE) on the RNA-seq data to 
identify heterozygous, and thus LOI, samples. CNV data was downloaded from 
TCGA, a segment mean < -0.2 was called a loss, > 0.2 a gain, and in between 
neutral.243 A χ² test compared LOI status with CNV (notLOI-gain vs notLOI-
neutral/loss vs LOI-gain vs LOI-neutral/loss). No significant p-values were obtained 
showing that LOI occurs independently from CNV for HM13 (Supplementary Table 
13). 
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Supplementary Table 13 Contingency table for LOI vs CNV of each imprinted HM13 SNP in 
tumour data. The p-values of the χ² test (p) comparing notLOI-gain vs notLOI-neutral/loss vs 
LOI-gain vs LOI-neutral/loss is also denoted in the table. 
Position 
30127392 30128553 30129046 30129099 30135990 
LOI nLOI LOI nLOI LOI nLOI LOI nLOI LOI nLOI 
Gain 14 124 20 115 13 125 13 128 11 128 
Neutral 25 282 40 268 24 290 28 284 18 297 
Loss 0 9 3 7 1 9 0 10 0 10 
p 0.55 0.83 0.67 1 0.45 
 
Supplementary Figure 24 Overview of copy number variation and differential expression of the imprinted loci. For each SNP and all samples, the colour 
scale indicates significant DE and/or CNV. A samples is called up- or downregulated when the normalised logCPM-value outside of the 95%-confidence 
interval of control data. A loss was defined as a segment with mean < -0.2, a gain when it is > 0.2.  
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S.1.7. Preliminary gene network analysis 
As many of the imprinted genes were downregulated in breast tumour data, we 
hypothesise that an imprinted gene network may be present in breast. The counts of 
all genes from the breast RNA-seq expression count file (obtained from 
firebrowse.org) were normalised with EdgeR and log-transformed to obtain logCPM-
values. Differential expression analysis between tumour and control data was 
subsequently done with a Wilcoxon Rank Sum test. Spearman correlation was 
performed for all DE loci, yet as differential expression between tumours and controls 
was prominent and would thus affect correlation measures, we only considered 
tumour data. Many positive correlations were found between the downregulated 
genes and also the upregulated (HM13 and GNAS) genes were positively correlated 
(Supplementary Figure 25). DE genes that showed downregulation in cancer were 
also used for PCA (tumour data only) to evaluate potential co-expression. Also here, 
the first principal component suggests concerted action, given that virtually all 
loadings are negative, compatible with imprinted gene networks. Moreover, these 
analyses put forward PLAGL1, MEG3 and ZNF300P1 as candidate regulators, of 
which at least MEG3 deregulation is independent of CNV but possibly methylation 
driven (cf. Results, Supplementary Figure 26). Nevertheless, advanced co-
expression analysis is required (also taking into account the impact of CNV and 
aberrant DNA methylation) to formally assess whether an imprinted gene network is 
indeed present and responsible for imprinted gene downregulation in breast cancer. 
S.1.8. Infiltrating lymphocytes 
We evaluated lymphocyte infiltration in tumour tissue as possible explanation of DI of 
MEST and HM13, given prior evidence for biallelic MEST expression (isoform 2) in 
blood, and the relevant results for HM13 in breast cancer in this study.321 
No significant correlation (p-value of 0.9 and R of 0.0006 with a correlation 
permutation test if only the 2PAPT highest fraction is taken into account) was found 
between the percentage of infiltrating lymphocytes and biallelic expression of MEST 
(estimated as the allelic ratio). Furthermore, MEST was downregulated in tumour 
samples, decreasing the probability that infiltrating lymphocytes may be relevant in 
MEST DI. 
Only for the last HM13 SNP (rs1115713), a significant correlation between the 
percentage of infiltrating lymphocytes and biallelic expression was found (p-value of 
0.01 and R of 0.15), though here no DI was detected. Note that this SNP is exonic in 
MCTS2P and the correlation could be hence rather due to biallelic MCTS2P 
expression than HM13 expression. 
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Supplementary Figure 25 Correlation plot of imprinted genes in tumour data. Spearman 
correlation was used on the normalised expression counts. Significant correlations are 
indicated with a circle of which the colour, colour intensity and size are proportional to the 
correlation coefficient. Significantly downregulated genes are denoted with * and upregulated 
ones with **. 





S.1.9. Supplementary Figures 
 
Supplementary Figure 26 Principal component analysis biplot of the downregulated genes 
in tumour data. The arrows and their colour indicate the influence of each gene on the principal 
components (PC). The first PC accounts for 17.9% of the variance and the second for 9.9%. 
Supplementary Figure 27 Structure of HM13/MCTS2P. Varying transcripts of the HM13 and 
MCTS2P locus with the imprinted SNPs are shown. Differential expression and LOI 
information for each SNP in breast cancer (subtypes) is also provided. 
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Supplementary Figure 28 Methylation levels for all probes in TCGA data, probes of interest 
are denoted with their probe name.  
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S.1.10. Supplementary Tables 
Other Supplementary Tables 
Supplementary Table 14 P-values and FDR-adjusted p-values of DI 
based on the logCPM-value of the least expressed allele count.*  
SNP Gene p-value FDR-adjusted p-value 
rs3741219 H19 0.96627 1 
rs2839704 H19 0.47665 1 
rs2839703 H19 0.77801 1 
rs10840159 H19 0.86182 1 
rs2839702 H19 0.58448 1 
rs2839701 H19 0.62859 1 
rs2067051 H19 0.3955 1 
rs2075745 H19 0.40713 1 
rs2075744 H19 0.45442 1 
rs2839698 H19 0.50549 1 
rs2585 IGF2 0.99998 1 
rs7873 IGF2 1 1 
rs6059869 HM13 0.18073 1 
rs6059873 HM13 0.01283 0.30792 
rs8110538 ZNF331 0.9785 1 
rs8110350 ZNF331 0.99327 1 
rs7810469 PEG10 0.14197 1 
rs1053900 MEG3 0.99965 1 
rs4378559 MEG3 0.87254 1 
rs12890215 MEG3 0.78843 1 
rs10863 MEST 0.63443 1 
rs7582864 ZDBF2 0.67573 1 
rs3732084 ZDBF2 0.42571 1 
rs1975597 ZDBF2 0.82632 1 
*Significant results are shown in bold. 
 
Supplementary Table 15 Differential expression of varying exons in HM13. A Wilcoxon Rank Sum test was used to obtain the FDR-adjusted p-values (adjusted p) between 
tumour and control samples (mean logCPM-values are given in columns mean tumour and mean control and for the breast cancer subtypes). The adjusted p-values for the 
different subtypes were obtained with a Kruskal-Wallis test (KW) and post-hoc Dunn’s test (adjusted p per subtype). 

















30102241-30102537 15.30 8.35 4.12E-17 5.71E-20 12.56 1.54E-05 19.77 9.58E-15 13.80 2.79E-12 18.30 1.03E-17 
30115287-30115385 14.24 7.87 1.07E-23 6.96E-28 12.31 1.92E-09 18.38 3.32E-21 12.67 9.14E-15 16.81 2.43E-23 
30125982-30127596 22.58 14.31 5.29E-17 4.72E-22 19.72 2.37E-06 27.72 1.33E-16 20.35 5.34E-10 26.75 2.05E-19 
30132750-30132838 22.65 12.87 2.66E-21 2.17E-26 19.84 5.61E-09 30.00 2.96E-21 19.89 2.11E-12 26.64 2.83E-21 
30135185-30136017 4.32 2.83 1.66E-06 4.06E-19 6.61 9.58E-15 4.20 3.47E-05 3.26 9.26E-02 4.78 1.05E-08 
30135249-30136917 32.66 18.69 2.47E-24 2.19E-33 36.26 9.34E-21 39.60 1.48E-21 27.15 1.28E-10 37.41 6.73E-24 
30137010-30137135 32.51 18.17 2.47E-24 7.29E-30 30.37 2.25E-13 42.07 1.45E-22 28.09 6.52E-13 38.08 5.89E-24 
30137867-30137924 17.32 9.38 2.05E-26 2.79E-32 16.55 6.80E-16 22.47 5.89E-24 14.85 7.63E-14 20.18 5.81E-25 
30142549-30142632 22.63 12.15 1.24E-26 2.86E-32 22.04 1.12E-16 29.63 6.89E-25 19.36 3.71E-14 25.84 7.51E-24 
30147414-30147450 16.79 8.81 2.51E-28 6.12E-34 16.55 2.53E-18 21.99 1.12E-25 14.37 3.37E-15 18.99 1.36E-24 
30149437-30149539 34.14 17.37 1.33E-29 3.34E-35 33.96 3.36E-19 44.92 9.93E-27 29.25 3.18E-16 38.11 6.89E-25 
30154013-30154098 29.75 14.39 9.88E-33 8.09E-38 29.58 8.52E-21 39.33 2.24E-28 25.71 7.33E-19 32.54 2.20E-26 
30155881-30156083 1.76 1.35 1.71E-04 4.72E-11 2.00 7.08E-06 2.13 6.97E-07 1.45 2.28E-01 1.99 2.67E-06 
30156923-30157368 75.09 33.83 9.88E-33 3.07E-38 78.64 1.94E-22 99.45 2.18E-28 64.20 1.25E-18 79.09 1.34E-25 
 
Supplementary Table 16 Differential expression of methylation probes in HM13/MCTSP2 DMR (and exhibiting probable allele-specific methylation) and average 
methylation over all probes. A Wilcoxon Rank Sum test was used to obtain the FDR-adjusted p-values (adjusted p) between tumour and control samples (mean β-
values are given in columns mean tumour and mean control and for the breast cancer subtypes). The adjusted p-values for the different subtypes were obtained with a 
Kruskal-Wallis test (KW) and post-hoc Dunn’s test (adjusted p per subtype).*  

















cg02146091 0.43 0.42 0.37 7.24E-06 0.328 9.14E-04 0.42 0.43 0.45 0.01 0.42 0.29 
cg06000530 0.42 0.41 0.51 1.25E-05 0.304 6.41E-04 0.40 0.36 0.44 0.03 0.41 0.29 
cg15815607 0.45 0.44 0.37 4.81E-06 0.335 1.60E-03 0.44 0.43 0.48 0.01 0.44 0.29 
cg17840843 0.31 0.29 0.37 6.11E-05 0.217 3.99E-05 0.28 0.20 0.31 0.36 0.29 0.34 
cg18471488 0.56 0.42 4.93E-13 7.40E-15 0.494 1.08E-02 0.34 3.3E-07 0.41 3.76E-13 0.43 1.67E-06 
cg19617948 0.44 0.44 0.37 3.23E-06 0.330 1.18E-03 0.43 0.43 0.47 0.01 0.43 0.29 
cg20129782 0.31 0.27 0.31 6.47E-02 0.245 2.51E-03 0.27 0.36 0.28 0.28 0.26 0.25 
cg24607140 0.64 0.58 0.02 6.24E-07 0.464 1.22E-07 0.58 0.06 0.61 0.16 0.58 0.25 
cg25359645 0.43 0.42 0.37 1.16E-06 0.312 4.55E-04 0.44 0.36 0.45 0.01 0.42 0.29 
cg25645178 0.34 0.32 0.37 2.23E-05 0.236 3.59E-05 0.32 0.22 0.35 0.30 0.33 0.34 
Mean(probes) 0.42 0.40 0.74 2.98E-05 0.31 4.87E-05 0.40 0.13 0.44 0.10 0.40 0.50 







Supplementary Table 17 Spearman correlation between methylation probes and logCPM-values of exon 30125982-30127596 and HM13 (full length 
gene).* 
probeID** 























cg02146091 1 1 1 -0.04 0.02 0.05 1 1 1 0.04 -0.07 0.02 
cg06000530 1 1 1 0.13 -0.01 0.03 1 1 1 0.15 -0.10 -0.02 
cg15815607 1 1 1 0.07 0.00 0.05 1 1 1 0.15 -0.07 0.04 
cg17840843 1 1 1 0.18 0.05 0.04 1 1 0.85 0.00 -0.08 -0.09 
cg18471488 1 0.19 6.1E-05 -0.04 -0.17 -0.28 1 0.04 1.7E-11 -0.02 -0.21 -0.42 
cg19617948 1 1 1 -0.05 0.01 0.05 1 1 1 0.04 -0.09 0.02 
cg20129782 1 1 1 0.11 -0.01 -0.05 1 0.92 0.06 0.11 -0.12 -0.17 
cg24607140 0.44 1 1 0.24 0.03 0.01 1 1 0.19 0.16 -0.08 -0.14 
cg25359645 1 1 1 0.16 0.06 0.09 1 1 1 0.02 -0.11 -0.01 
cg25645178 1 1 1 0.01 0.04 0.01 1 1 0.61 -0.05 -0.09 -0.11 
Mean(probes) 0.12 0.85 0.72 0.19 -0.01 -0.02 0.21 0.04 0.02 0.15 -0.15 -0.14 
*Significant results are shown in bold. **No data was available for probe cg14175568 in TCGA 
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S.1.11. Supplementary Methods 
a. Samples & data pre-processing 
A total of 113 human healthy control and 506 diseased RNA-seq samples of the 
TCGA breast invasive carcinoma dataset were downloaded from the TCGA data 
portal. Downloaded data were already mapped. For all cancer samples, additional 
expression subtypes based on the PAM50 classifier were obtained from the UCSC 
cancer genome browser (8 normal-like samples, 92 basal-like, 228 luminal A, 121 
luminal B and 57 HER2-enriched). Also, 92 healthy breast samples were download 
from GTEx and preprocessed in the same way.  
After downloading the data, in all samples, variants were called for the non-duplicate 
uniquely mapped reads with Samtools mpileup/bcftools (v0.1.19) whereby variant 
sites with a raw read depth lower than 10 in all samples were filtered out. Next, only 
SNP positions called by Samtools mpileup and present in the public NCBI SNP-
archive dbSNP (version 137) were kept. Additionally, loci with only one reference 
allele in dbSNP (deletions and insertions) and/or loci corresponding with mutations 
from the Human Gene Mutation Database were filtered out as well.322 Afterwards, the 
found SNP positions for all samples were merged and the corresponding nucleotide 
sequences were determined. 
b. Assumptions 
It is important to note that several assumptions are made for the methodology 
described in Methods, Section 4 and 5: 
(i) The basic assumption for the detection of imprinting using the proposed 
methodology is that under the null hypothesis SNP loci are in HWE, which only 
holds for a panmictic population and for variants that are not under selection, i.e. 
a single population that is long-term mating. 
(ii) In the model developed to screen for imprinted loci, it is assumed that the 
degree of imprinting is equal in all samples. This translates in the assumption that 
the cell type composition of each sample is similar. 
For the robust measure of imprinting as well as the detection of differential imprinting, 
samples with the lowest and highest fractions of the alleles with least expression are 
considered as putatively homozygous resp. heterozygous. Yet, particularly in the 
case of 100% imprinting, homozygous and heterozygous samples cannot be 
discriminated using this approach. However, this will not bias the results as (i) in case 
of 100% imprinting, the robust imprinting criterion will have no practical impact on 
detection, (ii) to detect differential imprinting, both sample groups are treated equally, 
implying no bias as long as the genotype frequencies are not associated with the 
case-control status. 
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S.1.12. Supplementary Data 
Supplementary Data files can be found on https://www.nature.com/articles/s41467-
018-06566-7#Sec19 
Supplementary Data 1  
Parameters of all SNPs in gene HM13. The dbSNP IDs (dbSNP), likelihood ratio test 
statistic (LRT), estimated degrees of imprinting (i), p-values of the LRT (p), allele 
frequencies (pA), estimated sequencing error rates (SE), mean coverage (cov), the 
number of samples (nr_samples), the GOF-likelihood value (GOF; eliminates 
artefacts, but may also exclude transcripts with mixed imprinting patterns), the χ² p-
value for the symmetry test (sym; eliminates loci featured by allele-specific 
expression), the median imprinting value (med. imp.; retains robustly imprinted 
results), the genomic annotation (annotation) and the reason why a SNP was filtered 
(filtered) are shown for all SNPs. Green indicates the values that passed our filters 
and in red the SNPs detected as imprinted by our method are shown. 
Supplementary Data 2 
Parameters of all SNPs in genes for which no consistent imprinting results were 
found. The dbSNP IDs (dbSNP), likelihood ratio test statistic (LRT), estimated 
degrees of imprinting (i), pvalues of the LRT (p), allele frequencies (pA), estimated 
sequencing error rates (SE), mean coverage (cov), the number of samples 
(nr_samples), the GOF-likelihood value (GOF; eliminates artefacts, but also indicates 
transcripts with mixed imprinting patterns), the χ² p-value for the symmetry test (sym; 
eliminates loci featured by allele-specific expression), the median imprinting value 
(med. imp.; retains robustly imprinted results) and the reason why a SNP was filtered 
(filtered) are shown for all SNPs. The last column (imprinting status/annotation/…) 
indicates the genomic annotation and whether or not it was filtered/imprinted. Green 
indicates the values that passed the filters and in red the SNPs detected as imprinted 
by our method are shown. 
Supplementary Data 3 
DNA methylation in TCGA breast samples. Probe id (ID), the gene in which it is 
located (Gene), if it was linked with a SNP (dbSNP), number of control and tumour 
samples (nr_control and nr_tumour, respectively), the median methylation levels 
(Median control and Median tumour) and whether or not the probe is located in a 
DMR (DMR?) are given. The FDR-adjusted p-values of the Wilcoxon Rank Sum Test 
to compare methylation levels of control data with tumour data are shown in the last 
column (adjusted p). Significant results are shown in red and hemimethylated probes 
(methylation between 0.33 and 0.66) are coloured light red. 
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Supplementary Data 4 
FDR-adjusted p-values of DI analysis for all SNPs. Tumour samples as well as the 
varying subtypes were compared to the normal samples. Significant results are 
shown in red. 
Supplementary Data 5 
FDR-adjusted p-values and log fold changes of differential expression (DE) analysis. 
CPM-values of the SNPs were used to compare control versus diseased samples. 
Differential expression between control and tumour was analysed with a Wilcoxon 
Rank Sum test, while analysis per subtype was done with a Kruskal-Wallis test and 
Dunn’s post-hoc test. Significant DE is coloured in red.  
Supplementary Data 6 
Contingency tables for differential expression (DE) vs copy number variation (CNV) 
of each imprinted gene in tumour data. FDR-adjusted p-values for imprinted genes of 
linear models for expression (dependent variable) and copy number variation are also 
provided in column “p linear model”. 
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S.2.  Modeller of Allelic Gene 
Expression (MAGE) unlocks the 
RNA-seq-based study of allele-
specific expression mechanisms 
in health and disease 
S.2.1. Supplementary Tables 
Supplementary Table 18 FDR-adjusted harmonic p-values (from the logistic regression model) for 
imprinted genes indicating if they are featured by differential imprinting in all clear cell renal cell cancer 
samples (p_DI). p_DE shows the FDR-adjusted harmonic p-values of the differential expression Welch’s t-
test and logFC the mean base 2 logarithmic fold change between cases and controls. In bold significant p-
values (≤ 0.05) and thus significant DI/DE is shown.* 
Gene p_DI p_DE logFC Gene p_DI p_DE logFC 
CYP4A11 4.09E-19 2.36E-03 -1.80 SNRPN 1.74E-06 6.89E-36 -1.59 
LOC107985522 2.17E-03 5.10E-01 -0.17 SNHG14 0.11 3.04E-29 -1.25 
ADORA2BP1* 0.81 2.08E-08 -1.77 PWAR6 0.74 1.36E-27 -1.11 
ZDBF2 8.52E-02 2.21E-24 -0.73 IPW 0.27 1.56E-12 -0.51 
NDUFC1* 0.98 7.04E-05 -0.69 SCAMP5* 0.43 2.25E-03 -0.47 
CYP4V2* 0.30 6.81E-01 0.02 ZNF597 0.16 3.26E-01 -0.02 
PCBD2 8.99E-03 5.10E-01 -0.75 ACSM1 0.98 1.03E-01 0.54 
SLC25A48* 1.00 7.04E-05 -2.16 FANCA* 3.4E-04 1.05E-12 1.34 
ZNF107 4.35E-02 2.78E-03 0.56 RPH3AL 2.7E-03 1.61E-01 -0.29 
TYW1B 0.98 8.60E-02 -0.56 MTRNR2L1* 1.00 8.16E-01 0.25 
PEG10 0.98 5.43E-19 -0.57 ZNF506* 6.8E-06 4.03E-02 -0.84 
MEST 3.45E-04 3.39E-29 -1.04 MTDHP3 5.92E-11 3.19E-04 -0.34 
COPG2 0.41 2.03E-12 -1.57 ZNF331 4.09E-19 1.62E-20 -1.48 
COPG2IT1 0.41 3.01E-15 -1.50 PEG3 4.99E-02 1.33E-37 -2.21 
TUBBP5 0.17 1.77E-06 -1.25 FRG1BP* 4.13E-01 1.01E-01 -0.32 
H19 4.10E-07 4.90E-01 1.53 HM13 6.03E-02 3.35E-03 0.26 
LOC105369972 3.83E-02 3.66E-01 -0.31 L3MBTL1 0.91 2.07E-15 1.34 
MDM2* 0.26 6.43E-05 1.15 GNAS 4.99E-02 5.10E-01 2.86 
MEG3 1.55E-11 4.03E-02 0.68 BCR* 9.09E-02 1.92E-06 -1.10 
NDN 0.41 7.04E-05 0.07 CRYBB2P1* 0.81 3.95E-03 0.51 
HLA-A** 1.11E-03 3.75E-24 1.98 HLA-DQA1** 6.42E-05 1.01E-05 1.23 
HLA-DRB5** 8.74E-16 5.65E-05 1.13 HLA-DQA2** 7.63E-11 2.10E-07 2.16 
*Candidate imprinted genes **Likely random monoallelically expressed genes 
 




Supplementary Table 19 Results of induced allelic imbalance (iAI) analysis on both tumour stage 1 and 
all tumour samples for the detected significantly mutated genes (SMGs) in stage 1 samples and all samples. 
Significantly mutated genes, i.e. the union of all genes significant in at least one of the two MutSigCV 
analyses (SMG), q-value outputted by MutSigCV analysis (q), gene level mean of median allelic ratio 
difference per SNP level (ΔAI), harmonic p-value of iAI on the gene level (harmonic p) are shown. Significant 




All Stages Stage I 
q ΔAI harmonic 
p 
q ΔAI harmonic 
p 
VHL 3p25.3 <9.4E-12 2.90E-01 7.75E-28 3.1E-12 2.95E-01 1.77E-26 
SETD2 3p21.31 <9.4E-12 3.25E-01 7.55E-12 1.3E-06 2.94E-01 2.49E-09 
PBRM1 3p21.1 <9.4E-12 2.91E-01 1.57E-96 <9.4E-12 2.72E-01 5.75E-79 
PTEN 10q23.31 <9.4E-12 7.46E-02 2.78E-14 1 6.20E-02 2.97E-10 
MAX 14q23.3 <9.4E-12 1.24E-01 1.64E-40 1 9.41E-02 1.14E-73 
CYB5B 16q22.1 <9.4E-12 9.17E-02 3.13E-35 1 7.68E-02 3.92E-18 
BAP1 3p21.1 <9.4E-12 na na 2.6E-04 na na 
ARID1A 1p36.11 8.2E-02 na na 2.5E-02 na na 
XCL1 1q24.2 <9.4E-12 na na 1 na na 
KDM5C Xp11.22 3.4E-10 na na 2.6E-04 na na 
ZNF800 7q31.33 6.1E-04 na na 4.5E-01 na na 




Supplementary Table 20 Overview of analysed loci from genome-wide association studies (GWAS). 
The risk loci (Locus), the corresponding dbSNP id (refSNP), corresponding gene (Gene) and its 
reference study (Reference). 
Locus refSNP  Gene Reference  
1p32.3 rs4381241 FAF1 Scelo et al. 2017323 
3p22.1 rs67311347 RPL14 Scelo et al. 2017323 
3q26.2 rs10936602 LRRIQ4 Scelo et al. 2017323 
8p21.3 rs2241261 RHOBTB2, TNFRSF10B Scelo et al. 2017323 
10q24.33-q25.1 rs11813268 SH3PXD2A, STN1 (OBFC1), SLK Scelo et al. 2017323 
11q22.3 rs74911261 KDELC2 Scelo et al. 2017323 
14q24.2 rs4903064 DPF3 Scelo et al. 2017323 
2p21 rs7579899 EPAS1 Purdue et al. 2011324 
2p21 rs6706003 EPAS1 Purdue et al. 2011324 
2q22.3 rs12105918 ZEB2 Henrion et al. 2013325 
8q24.21 rs35252396 flanks MYC and PVT1 Gudmundsson et al. 326 
11q13.3 rs7105934 flanks MYEOV and CCND1  Purdue et al. 2011324 
12p11.23 rs718314 ITPR2 Wu et al. 2012327 
12p11.23 rs1049380 ITPR2 Wu et al. 2012327 
12q24.31 rs4765623 SCARB1 Purdue et al. 2011324 
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Supplementary Table 21 Overlap between genome-wide association studies 
(GWAS) and induced allelic imbalance (iAI). The locus (Locus), the dbSNP id 
(refSNP), gene name (Gene) and whether or not it occurred in the iAI results (Overlap 
iAI) are denoted. The latter indicates if information was available for the same SNP 
(SNP level), for the gene corresponding to the GWAS detected risk loci (gene level) 
or if information was missing due to filtering of genes with low coverage or allele 
frequency before iAI analysis. 
Locus refSNP  Gene Overlap iAI  
1p32.3 rs4381241 FAF1 not in results 
3p22.1 rs67311347 RPL14 gene level 
3q26.2 rs10936602 LRRIQ4 not in results 
8p21.3 rs2241261 RHOBTB2, TNFRSF10B SNP level 
10q24.33-q25.1 rs11813268 SH3PXD2A, STN1, SLK gene level 
11q22.3 rs74911261 KDELC2 gene level 
14q24.2 rs4903064 DPF3 not in results 
2p21 rs7579899 EPAS1 not in results 
2p21 rs6706003 EPAS1 not in results 
2q22.3 rs12105918 ZEB2 gene level 
8q24.21 rs35252396 flanks MYC and PVT1 not in results 
11q13.3 rs7105934 flanks MYEOV and 
CCND1  
gene level 
12p11.23 rs718314 ITPR2 gene level 
12p11.23 rs1049380 ITPR2 SNP level 
12q24.31 rs4765623 SCARB1 gene level 
 
Supplementary Table 22 Results of induced allelic imbalance (iAI) for two 
specific genome-wide association study (GWAS) SNPs. Results of analysis 
on stage 1 tumour samples and samples from all tumour stages: dbSNP id 
(refSNP), median allelic ratio difference (ΔAI), logistic p-value (p-value). 
Significant values (p-value ≤ 0.05) are shown in bold. 
refSNP 
Stage 1 All Stages 
ΔAI p-value ΔAI p-value 
rs2241261 4.43E-02 6.95E-01 4.43E-02 4.65E-01 
rs1049380 1.26E-01 1.21E-07 1.45E-01 8.19E-22 
 
Supplementary Table 23 Induced allelic imbalance (iAI) results for the known genome-
wide association study (GWAS) genes. Only genes also represented in the iAI results on 
stage 1 and all tumour samples, respectively. The number of SNPs (#SNPs) present in 
the specific gene is shown with their median allelic ratio difference (ΔAI) and logistic p-
value (p-value, significant values, ≤ 0.05, in bold).* 
Gene #SNPs 
Stage I All Stages 
ΔAI p-value ΔAI p-value 
RPL14 1 6.47E-01 5.97E-179 6.63E-01 2.01E-246 
TNFRSF10B 1 8.36E-03 4.20E-11 3.08E-02 1.85E-14 
SH3PXD2A 3 1.14E-01* 3.45E-08* 1.40E-01* 2.03E-06* 
STN1 (OBFC1) 4 1.91E-01* 3.21E-13* 2.10E-01* 7.73E-22* 
SLK 5 5.37E-02* 3.66E-11* 7.02E-02* 5.44E-12* 
KDELC2 1 3.57E-02 3.17E-32 3.54E-02 3.78E-19 
ZEB2 1 2.56E-02 9.33E-02 3.85E-02 8.01E-01 
CCND1 2 1.62E-02* 7.41E-03* 2.75E-02* 1.07E-02* 
ITPR2 12 1.60E-01* 1.26E-35 * 1.77E-01* 1.47E-34* 
SCARB1 1 1.48E-01 9.70E-50 1.32E-01 2.00E-38 
*values represent the summarised iAI results per gene. ΔAI is the mean of the ΔAIs 
for each SNP, the p-value is the harmonic mean of the p-values for each SNP. 
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S.2.2. Supplementary Data 
All Supplementary Data files can be found in SupplementaryData.zip 
Supplementary Data 7 
Parameters of all SNPs with significant variant bias. The chromosome, position, gene 
annotation (gene), dbSNP ID (dbSNP), estimated allelic shift (shift), likelihood ratio 
test statistic (LRT), p-value of the LRT (p), sample quality (quality), estimated allele 
frequencies (pA), estimated sequencing error rates (SE), mean coverage (cov), 
number of samples (nr_samples), GOF-likelihood value (GOF), median shift 
(median_shift; retains robustly cis-eQTL results), estimated degree of inbreeding 
(est_inbreeding), degree of inbreeding per chromosome (tot_inbreeding), number of 
EM replications (nrep) and the estimated genotype frequencies (homo_ref, homo_var 
and hetero for homozygous reference, homozygous variant and heterozygous, 
respectively) are shown for all SNPs. 
Supplementary Data 8 
Parameters of all significant imprinted SNPs in healthy kidney tissue and their 
differential imprinting in stage 1 kidney tumour samples. The chromosome, position, 
gene annotation (gene), dbSNP ID (dbSNP), likelihood ratio test statistic (LRT), p-
value of the LRT (p), FDR-adjusted p-value (adj_p), estimated degree of imprinting 
(i), estimated allele frequencies (pA), reference allele (reference), variant allele 
(variant), estimated sequencing error rates (SE), mean coverage (coverage), number 
of control samples (nr_samples), GOF-likelihood value (GOF), symmetry GOF 
(symmetry), median degree of imprinting (med_impr; retains robust imprinting 
results), estimated degree of inbreeding (est_inbreeding), degree of inbreeding per 
chromosome (tot_inbreeding) and p_value of DI logistic regression (p_DI), 
FDR_adjusted p-value of DI analysis (adj_p_DI), differential expression p-value 
(DE_p), FDR_adjusted p-value of DE analysis (adj_p_DE), mean coverage of control 
samples (mean_c) and mean coverage of tumour samples (mean_t) are shown for 
all SNPs. na values indicate that the SNP was not present in tumour data and hence 
no DI analysis was done. 
Supplementary Data 9 
Parameters of all significant imprinted SNPs in healthy kidney tissue and their 
differential imprinting in all kidney tumour samples. The chromosome, position, gene 
annotation (gene), dbSNP ID (dbSNP), likelihood ratio test statistic (LRT), p-value of 
the LRT (p), FDR-adjusted p-value (adj_p), estimated degree of imprinting (i), 
estimated allele frequencies (pA), reference allele (reference), variant allele (variant), 
estimated sequencing error rates (SE), mean coverage (coverage), number of control 
samples (nr_samples), GOF-likelihood value (GOF), symmetry GOF (symmetry), 
median degree of imprinting (med_impr; retains robust imprinting results), estimated 
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degree of inbreeding (est_inbreeding), degree of inbreeding per chromosome 
(tot_inbreeding) and p_value of DI logistic regression (p_DI), FDR_adjusted p-value 
of DI analysis (adj_p_DI), differential expression p-value (DE_p), FDR_adjusted p-
value of DE analysis (adj_p_DE), mean coverage of control samples (mean_c) and 
mean coverage of tumour samples (mean_t) are shown for all SNPs. na values 
indicate that the SNP was not present in tumour data and hence no DI analysis was 
done. 
Supplementary Data 10 
Parameters of genes with induced allelic imbalance (iAI) in stage 1 tumour samples 
compared to healthy kidney tissue. For each gene the chromosome, the amount of 
SNPs in the gene (nr_SNPs), mean of median allelic ratio difference over all SNPs 
(mean_AI), harmonic p-value for iAI (AI_harm_pval), FDR-adjusted harmonic p-value 
for iAI (AI_harm_FDR), mean logarithmic fold change over all SNPs (mean_logFC), 
differential expression harmonic p-value (DE_harm_pval), differential expression 
FDR-adjusted harmonic p-value (DE_harm_FDR), maximal number of 
hypermethylated tumour samples for a CpG in the promoter region 
(nr_hypermeth_prom_t) CpG id with hypermethylation (selected_id_prom), number 
of tumour samples with Infinium HumanMethylation450k data (n_t), maximal number 
of hypermethylated control samples for a CpG in the promoter region 
(nr_hypermeth_prom_c), number of control samples with Infinium 
HumanMethylation450k data (n_c), percentage of tumour samples showing 
hypermethylation, subtracted with the percentage of control samples showing 
hypermethylation (perc_hypermeth_prom_tvsc), amount of losses divided by the 
number of samples (nr_cnv_loss_av) and amount of gains divided by the amount of 
samples (nr_cnv_gain_av) are shown. 
Supplementary Data 11 
Parameters of genes with induced allelic imbalance (iAI) in all tumour samples 
compared to healthy kidney tissue. For each gene the chromosome, the amount of 
SNPs in the gene (nr_SNPs), mean of median allelic ratio difference over all 
(mean_AI), harmonic p-value for iAI (AI_harm_pval), FDR-adjusted harmonic p-value 
for iAI (AI_harm_FDR), mean logarithmic fold change over all SNPs (mean_logFC), 
differential expression harmonic p-value (DE_harm_pval), differential expression 
FDR-adjusted harmonic p-value (DE_harm_FDR), maximal number of 
hypermethylated tumour samples for a CpG in the promoter region 
(nr_hypermeth_prom_t) CpG id with hypermeth (selected_id_prom), number of 
tumour samples with Infinium HumanMethylation450k data (n_t), maximal number of 
hypermethylated control samples for a CpG in the promoter region 
(nr_hypermeth_prom_c), number of control samples with Infinium 
HumanMethylation450k data (n_c), percentage of tumour samples showing 
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hypermethylation, subtracted with the percentage of control samples showing 
hypermethylation (perc_hypermeth_prom_tvsc), amount of losses divided by the 
number of samples (nr_cnv_loss_av) and amount of gains divided by the amount of 
samples (nr_cnv_gain_av) are shown. 
Supplementary Data 12 
Gene set analysis of genes with induced allelic imbalance (iAI) in stage 1 kidney 
tumour samples. WebGestalt gene set analysis results (overrepresentation analysis; 
ΔAI ≥ 0.25 as cut-off for iAI) for Gene Ontology (Biological Process; Cellular 
Component; Molecular Function), Chromosomal Location and Reactome Pathway 
Analysis. For each class of gene sets, the top 10 of most significant results are 
presented. 
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S.2.3. Supplementary Figures 
Supplementary Figure 29 Allele frequency plots of significantly imprinted SNPs. (a) 
rs113317316 (CROCCP2, adj. p-value = 4.22E-10, candidate imprinted), (b) rs12735774 
(CYP4A11, adj. p-value < detection limit), (c) rs141018108 (LOC107985522, adj. p-value = 
1.18E-28), (d) rs7532324 (ADORA2BP1, adj. p-value = 0.000259, candidate imprinted), (e) 
rs10932150 (ZDBF2, adj. p-value = 1.23E-20), (f) rs7582864 (ZDBF2, adj. p-value = 7.83E-
26), (g) rs3732084 (ZDBF2, adj. p-value = 4.56E-27), (h) rs1975597 (ZDBF2, adj. p-value = 
1.42E-22), (i) rs1448902 (ZDBF2, adj. p-value = 1.66E-29), (j) rs4673350 (ZDBF2, adj. p-
value = 6.97E-38), (k) rs6851954 (NDUFC1, adj. p-value = 9.23E-19, candidate imprinted), (l) 
rs10033577 (CYP4V2, adj. p-value = 7.17E-46, candidate imprinted). 
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Supplementary Figure 30 Allele frequency plots of significantly imprinted SNPs. (a) 
rs10033581 (CYP4V2, adj. p-value = 5.29E-61 , candidate imprinted), (b) rs878896752 
(PCBD2, adj. p-value = 5.86E-16), (c) rs113201302 (PCBD2, adj. p-value = 1.20E-23), (d) 
rs4312874 (SLC25A48, adj. p-value = 1.21E-25, candidate imprinted), (e) rs10263594 
(ZNF107, adj. p-value = 3.87E-19), (f) rs117110249 (TYW1B, adj. p-value = 1.68E-16), (g) 
rs13073 (PEG10, adj. p-value = 2.36E-49), (h) rs1050582 (MEST, adj. p-value = 9.39E-96), 
(i) rs10863 (MEST, adj. p-value = 4.12E-175), (j) rs974384588 (COPG2, adj. p-value = 3.81E-
12), (k) rs36165261 (COPG2, adj. p-value = 8.52E-10), (l) rs1044074180 (COPG2IT1, adj. p-
value = 9.73E-13). 
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Supplementary Figure 31 Allele frequency plots of significantly imprinted SNPs. (a) 
rs11538696 (COPG2IT1, adj. p-value = 8.64E-16), (b) rs975058179 (COPG2IT1, adj. p-value 
= 7.41E-17), (c) rs36183797 (COPG2IT1, adj. p-value = 2.29E-16), (d) rs1127302 
(COPG2IT1, adj. p-value = 6.01E-12), (e) rs4088486 (TUBBP5, adj. p-value = 0.00222), (f) 
rs2839702 (H19, adj. p-value = 3.73E-153), (g) rs2839701 (H19, adj. p-value = 1.58E-129), 
(h) rs368092436 (LOC105369972, adj. p-value = 0.000519), (i) rs2870821 (MDM2, adj. p-
value = 1.66E-102, candidate imprinted), (j) rs3742390 (MEG3, adj. p-value = 3.95E-10), (k) 
rs12878222 (MEG3, adj. p-value = 1.46E-05), (l) rs1884540 (MEG3, adj. p-value = 2.99E-07). 
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Supplementary Figure 32 Allele frequency plots of significantly imprinted SNPs. (a) 
rs10132552 (MEG3, adj. p-value = 3.39E-07), (b) rs3194464 (MEG3, adj. p-value = 1.59E-
21), (c) rs11160606 (MEG3, adj. p-value = 8.08E-08), (d) rs1950628 (MEG3, adj. p-value = 
3.37E-08), (e) rs1053900 (MEG3, adj. p-value = 2.40E-08), (f) rs1054000 (MEG3, adj. p-value 
= 6.66E-10), (g) rs4906022 (MEG3, adj. p-value = 1.67E-08), (h) rs8013873 (MEG3, adj. p-
value = 1.01E-17), (i) rs11859 (MEG3, adj. p-value = 5.17E-12), (j) rs2192206 (NDN, adj. p-
value = 6.79E-25), (k) rs705 (SNRPN, adj. p-value< detection limit), (l) rs74335291 (SNHG14, 
adj. p-value = 3.81E-27). 
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Supplementary Figure 33 Allele frequency plots of significantly imprinted SNPs. (a) 
rs6576398 (SNHG14, adj. p-value = 3.09E-29), (b) rs2732029 (SNHG14, adj. p-value = 
2.24E-30), (c) rs765438 (SNHG14, adj. p-value = 1.10E-32), (d) rs10451029 (SNHG14, adj. 
p-value = 2.04E-33), (e) rs2052723 (SNHG14, adj. p-value = 8.87E-28), (f) rs2554419 
(SNHG14, adj. p-value = 1.57E-35), (g) rs719704 (SNHG14, adj. p-value = 2.30E-39), (h) 
rs34316840 (SNHG14, adj. p-value = 5.52E-42), (i) rs2732031 (SNHG14, adj. p-value = 
1.12E-38), (j) rs2732040 (SNHG14, adj. p-value = 3.05E-21), (k) rs1541759 (SNHG14, adj. 
p-value = 8.42E-25), (l) rs2554441 (SNHG14, adj. p-value = 1.38E-26). 
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Supplementary Figure 34 Allele frequency plots of significantly imprinted SNPs. (a) 
rs2732044 (PWAR6, adj. p-value = 1.99E-34), (b) rs1030389 (PWAR6, adj. p-value = 1.65E-
33), (c) rs62001981 (PWAR6, adj. p-value = 5.39E-43), (d) rs1045935 (PWAR6, adj. p-value 
= 1.09E-44), (e) rs4344720 (SNHG14, adj. p-value = 1.67E-31), (f) rs3863396 (SNHG14, adj. 
p-value = 2.06E-27), (g) rs691 (IPW, adj. p-value = 1.52E-49), (h) rs13526 (IPW, adj. p-value 
= 6.93E-42), (i) rs61300393 (SLC28A2, adj. p-value = 5.96E-05), (j) rs8034149 (SCAMP5, 
adj. p-value = 9.75E-49, candidate imprinted), (k) rs2301672 (ACSM1, adj. p-value = 7.14E-
07), (l) rs37823 (ZNF597, adj. p-value = 3.74E-20). 
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Supplementary Figure 35 Allele frequency plots of significantly imprinted SNPs. (a) 
rs11639510 (ZNF597, adj. p-value = 2.31E-26), (b) rs37824 (ZNF597, adj. p-value = 6.32E-
17), (c) rs12737 (ZNF597, adj. p-value = 2.86E-32), (d) rs2270494 (ZNF597, adj. p-value = 
1.98E-17), (e) rs1800358 (FANCA, adj. p-value = 4.30E-22, candidate imprinted), (f) 
rs62057050 (RPH3AL, adj. p-value = 1.66E-20), (g) rs1363029012 (MTRNR2L1 (upstream), 
adj. p-value = 1.82E-06), (h) rs72620574 (ZNF506, adj. p-value = 1.05E-70, candidate 
imprinted), (i) rs12461329 (MTDHP3, adj. p-value = 2.16E-12), (j) rs12973337 (MTDHP3, adj. 
p-value = 2.16E-21), (k) rs12973147 (MTDHP3, adj. p-value = 8.52E-09), (l) rs12975447 
(MTDHP3, adj. p-value = 1.31E-05). 
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Supplementary Figure 36 Allele frequency plots of significantly imprinted SNPs. (a) 
rs16998334 (MTDHP3, adj. p-value = 0.0131), (b) rs8109631 (ZNF331, adj. p-value = 1.08E-
79), (c) rs8110538 (ZNF331, adj. p-value = 7.90E-74), (d) rs8110350 (ZNF331, adj. p-value = 
3.03E-69), (e) rs4801386 (PEG3, adj. p-value = 5.25E-19), (f) rs1558355 (PEG3, adj. p-value 
= 4.23E-06), (g) rs723082 (PEG3, adj. p-value = 2.04E-33), (h) rs3143 (PEG3, adj. p-value = 
1.37E-19), (i) rs34051133 (PEG3, adj. p-value = 8.03E-09), (j) rs33931963 (PEG3, adj. p-
value = 1.48E-21), (k) rs1860565 (PEG3, adj. p-value = 1.87E-32), (l) rs2302376 (PEG3, adj. 
p-value = 4.57E-17). 
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Supplementary Figure 37 Allele frequency plots of significantly imprinted SNPs. (a) 
rs564196523 (FRG1BP, adj. p-value = 8.62E-19, candidate imprinted), (b) rs532953935 
(FRG1BP, adj. p-value = 1.56E-21, candidate imprinted), (c) rs6059873 (HM13, adj. p-value 
= 2.85E-44), (d) rs6059874 (HM13, adj. p-value = 4.32E-34), (e) rs1115713 (HM13, adj. p-
value = 6.69E-16), (f) rs2269621 (L3MBTL1, adj. p-value = 1.60E-09), (g) rs1800900 (GNAS, 
adj. p-value = 5.58E-20), (h) rs712967 (BCR, adj. p-value = 2.77E-34, candidate imprinted), 
(i) rs7288843 (CRYBB2P1, adj. p-value = 4.81E-92). 
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Supplementary Figure 38 Allele frequency plots of imprinted SNPs in stage 1 clear cell renal 
cell carcinoma samples. A significant p-value indicates LOI in diseased samples compared to 
healthy control data. (a) rs141018108 (LOC107985522, p-value = 0.016), (b) rs7532324 
(ADORA2BP1, p-value = 0.360, candidate imprinted), (c) rs12735774 (CYP4A11, p-value = 
2.29E-30), (d) rs10932150 (ZDBF2, p-value = 0.235), (e) rs7582864 (ZDBF2, p-value = 
0.808), (f) rs3732084 (ZDBF2, p-value = 0.104), (g) rs1975597 (ZDBF2, p-value = 0.297), (h) 
rs1448902 (ZDBF2, p-value = 1.73E-03), (i) rs4673350 (ZDBF2, p-value = 0.039), (j) 
rs6851954 (NDUFC1, p-value = 0.931, candidate imprinted), (k) rs10033577 (CYP4V2, p-
value = 0.392, candidate imprinted), (l) rs10033581 (CYP4V2, p-value = 0.099, candidate 
imprinted). 
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Supplementary Figure 39 Allele frequency plots of imprinted SNPs in clear cell renal cell 
carcinoma samples. A significant p-value indicates LOI in diseased samples compared to 
healthy control data. (a) rs878896752 (PCBD2, p-value = 5.94E-04), (b) rs113201302 
(PCBD2, p-value = 1.46E-03), (c) rs4312874 (SLC25A48, p-value = 0.997, candidate 
imprinted), (d) rs1050582 (MEST, p-value = 1.56E-10), (e) rs10863 (MEST, p-value = 0.010), 
(f) rs974384588 (COPG2, p-value = 0.232), (g) rs36165261 (COPG2, p-value = 0.460), (h) 
rs1044074180 (COPG2IT1, p-value = 0.885), (i) rs11538696 (COPG2IT1, p-value = 0.944), 
(j) rs975058179 (COPG2IT1, p-value = 0.815), (k) rs36183797 (COPG2IT1, p-value = 0.843), 
(l) rs1127302 (COPG2IT1, p-value = 0.051). 
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Supplementary Figure 40 Allele frequency plots of imprinted SNPs in clear cell renal cell 
carcinoma samples. A significant p-value indicates LOI in diseased samples compared to 
healthy control data. (a) rs10263594 (ZNF107, p-value = 0.070), (b) rs117110249 (TYW1B, 
p-value = 1), (c) rs13073 (PEG10, p-value = 0.776), (d) rs4088486 (TUBBP5, p-value = 
0.069), (e) rs2839702 (H19, p-value = 1.83E-04), (f) rs2839701 (H19, p-value = 1.77E-09), 
(g) rs368092436 (LOC105369972, p-value = 0.099), (h) rs2870821 (MDM2, p-value = 0.151, 
candidate imprinted), (i) rs3742390 (MEG3, p-value = 0.580), (j) rs12878222 (MEG3, p-value 
= 1.03E-06), (k) rs1884540 (MEG3, p-value = 8.95E-07), (l) rs10132552 (MEG3, p-value = 
1.22E-08).  
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Supplementary Figure 41 Allele frequency plots of imprinted SNPs in clear cell renal cell 
carcinoma samples. A significant p-value indicates LOI in diseased samples compared to 
healthy control data. (a) rs3194464 (MEG3, p-value = 0.030), (b) rs11160606 (MEG3, p-value 
= 1.49E-04), (c) rs1950628 (MEG3, p-value = 1.94E-03), (d) rs1053900 (MEG3, p-value = 
7.09E-07), (e) rs1054000 (MEG3, p-value = 3.87E-03), (f) rs4906022 (MEG3, p-value = 
7.00E-04), (g) rs8013873 (MEG3, p-value = 0.014), (h) rs11859 (MEG3, p-value = 4.90E-06), 
(i) rs2192206 (NDN, p-value = 0.123), (j) rs705 (SNRPN, p-value = 2.39E-16), (k) rs74335291 
(SNHG14, p-value = 0.576), (l) rs6576398 (SNHG14, p-value = 0.521). 
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Supplementary Figure 42 Allele frequency plots of imprinted SNPs in clear cell renal cell 
carcinoma samples. A significant p-value indicates LOI in diseased samples compared to 
healthy control data. (a) rs2732029 (SNHG14, p-value = 0.658), (b) rs765438 (SNHG14, p-
value = 0.453), (c) rs10451029 (SNHG14, p-value = 0.572), (d) rs2052723 (SNHG14, p-value 
= 0.559), (e) rs2554419 (SNHG14, p-value = 0.204), (f) rs719704 (SNHG14, p-value = 0.074), 
(g) rs34316840 (SNHG14, p-value = 0.322), (h) rs2732031 (SNHG14, p-value = 0.882), (i) 
rs2732040 (SNHG14, p-value = 0.997), (j) rs1541759 (SNHG14, p-value = 0.996), (k) 
rs2554441 (SNHG14, p-value = 0.148), (l) rs4344720 (SNHG14, p-value = 0.520). 
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Supplementary Figure 43 Allele frequency plots of imprinted SNPs in clear cell renal cell 
carcinoma samples. A significant p-value indicates LOI in diseased samples compared to 
healthy control data. (a) rs3863396 (SNHG14, p-value = 0.037), (b) rs2732044 (PWAR6, p-
value = 0.947), (c) rs1030389 (PWAR6, p-value = 0.678), (d) rs62001981 (PWAR6, p-value 
= 0.591), (e) rs1045935 (PWAR6, p-value = 0.930), (f) rs691 (IPW, p-value = 0.211), (g) 
rs13526 (IPW, p-value = 0.221), (h) rs8034149 (SCAMP5, p-value = 0.774, candidate 
imprinted), (i) rs2301672 (ACSM1, p-value = 0.223), (j) rs37823 (ZNF597, p-value = 0.954), 
(k) rs11639510 (ZNF597, p-value = 0.048), (l) rs37824 (ZNF597, p-value = 0.932). 
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Supplementary Figure 44 Allele frequency plots of imprinted SNPs in clear cell renal cell 
carcinoma samples. A significant p-value indicates LOI in diseased samples compared to 
healthy control data. (a) rs12737 (ZNF597, p-value = 0.098), (b) rs2270494 (ZNF597, p-value 
= 0.633), (c) rs1800358 (FANCA, p-value = 5.32E-05, candidate imprinted), (d) rs62057050 
(RPH3AL, p-value = 1.11E-03), (e) rs1363029012 (MTRNR2L1, p-value = 0.997), (f) 
rs72620574 (ZNF506, p-value = 1.51E-07, candidate imprinted), (g) rs12461329 (MTDHP3, 
p-value = 2.07E-06), (h) rs12973337 (MTDHP3, p-value = 8.74E-07), (i) rs12973147 
(MTDHP3, p-value = 4.53E-04), (j) rs12975447 (MTDHP3, p-value = 3.65E-03), (k) 
rs16998334 (MTDHP3, p-value = 1.84E-03), (l) rs8109631 (ZNF331, p-value = 1.26E-18). 
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Supplementary Figure 45 Allele frequency plots of imprinted SNPs in clear cell renal cell 
carcinoma samples. A significant p-value indicates LOI in diseased samples compared to 
healthy control data. (a) rs8110538 (ZNF331, p-value = 2.68E-12), (b) rs8110350 (ZNF331, 
p-value 5.24E-14), (c) rs4801386 (PEG3, p-value = 0.822), (d) rs1558355 (PEG3, p-value = 
0.750), (e) rs723082 (PEG3, p-value = 0.019), (f) rs3143 (PEG3, p-value = 0.103), (g) 
rs34051133 (PEG3, p-value = 0.266), (h) rs33931963 (PEG3, p-value = 0.022), (i) rs1860565 
(PEG3, p-value = 0.197), (j) rs2302376 (PEG3, p-value = 0.997), (k) rs564196523 (FRG1BP, 
p-value = 0.052, candidate imprinted), (l) rs532953935 (FRG1BP, p-value = 0.037, candidate 
imprinted). 
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Supplementary Figure 46 Allele frequency plots of imprinted SNPs in clear cell renal cell 
carcinoma samples. A significant p-value indicates LOI in diseased samples compared to 
healthy control data. (a) rs6059873 (HM13, p-value = 0.036), (b) rs6059874 (HM13, p-value 
= 5.64E-03), (c) rs1115713 (HM13, p-value = 0.015), (d) rs2269621 (L3MBTL1, p-value = 
0.762), (e) rs1800900 (GNAS, p-value = 0.033), (f) rs712967 (BCR, p-value = 4.33E-03, 
candidate imprinted), (g) rs7288843 (CRYBB2P1, p-value = 0.538). 
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Supplementary Figure 47 Induced allelic imbalance (iAI) versus differential expression (DE) 
between healthy kidney tissue and renal cancer. The median allelic ratio differences (ΔAI) and 
base 2 logarithmic fold changes (logFC) are used as measures for iAI and DE, respectively. 
In (a) the ΔAI and logFC of all SNPs with a normal non-ASE distribution are plotted in grey. 
The SNPs on chromosome 3 are highlighted with SNPs on the short arm in blue and SNPs 
on the long arm in orange. In purple, SNPs in significantly mutated genes with their gene 
names, such as VHL, are marked. In (b) the gene level ΔAI and logFC (mean ΔAI and logFC 
over all SNPs) are plotted in grey. Transmembrane transport genes are highlighted in orange 
and tumour suppressor genes in purple (labelled with their gene names). 
 
 
 
